The Fibroblast Growth Factor signaling pathway.
PDF (2.3M)
Journal: 2016/March - Wiley Interdisciplinary Reviews: Developmental Biology
ISSN: 1759-7692
Abstract:
The signaling component of the mammalian Fibroblast Growth Factor (FGF) family is comprised of eighteen secreted proteins that interact with four signaling tyrosine kinase FGF receptors (FGFRs). Interaction of FGF ligands with their signaling receptors is regulated by protein or proteoglycan cofactors and by extracellular binding proteins. Activated FGFRs phosphorylate specific tyrosine residues that mediate interaction with cytosolic adaptor proteins and the RAS-MAPK, PI3K-AKT, PLCγ, and STAT intracellular signaling pathways. Four structurally related intracellular non-signaling FGFs interact with and regulate the family of voltage gated sodium channels. Members of the FGF family function in the earliest stages of embryonic development and during organogenesis to maintain progenitor cells and mediate their growth, differentiation, survival, and patterning. FGFs also have roles in adult tissues where they mediate metabolic functions, tissue repair, and regeneration, often by reactivating developmental signaling pathways. Consistent with the presence of FGFs in almost all tissues and organs, aberrant activity of the pathway is associated with developmental defects that disrupt organogenesis, impair the response to injury, and result in metabolic disorders, and cancer. For further resources related to this article, please visit the WIREs website.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(258)
References
(748)
Drugs
(1)
Chemicals
(3)
Organisms
(2)
Processes
(8)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Wiley Interdisciplinary Reviews. Developmental Biology. Apr/30/2015; 4(3): 215-266
Published online Mar/12/2015
PMID: 25772309
PMC: 4393358

The Fibroblast Growth Factor signaling pathway

Abstract

Introduction

The Fibroblast Growth Factor (FGF) family is comprised of secreted signaling proteins (secreted FGFs) that signal to receptor tyrosine kinases and intracellular non-signaling proteins (intracellular FGFs (iFGFs)) that serve as cofactors for voltage gated sodium channels and other molecules (Table1(a) and Figure 1(a)). Additionally, secreted FGFs and iFGFs may have direct functions in the nucleus and functional interactions with other cellular proteins. Members of both branches of the FGF family are related by core sequence conservation and structure and are found in vertebrates and invertebrates.1,2 Secreted FGFs are expressed in nearly all tissues and they serve essential roles in the earliest stages of embryonic development, during organogenesis, and in the adult, where they function as homeostatic factors that are important for tissue maintenance, repair, regeneration, and metabolism (Table2(a)). In general, secreted FGFs function as autocrine or paracrine factors (canonical FGFs; also called paracrine FGFs), however, three members of the secreted FGFs have evolved to function as endocrine factors (endocrine FGFs) with essential roles in the adult where they regulate phosphate, bile acid, carbohydrate and lipid metabolism in addition to the canonical FGF functions that control cell proliferation, differentiation and survival.75–77,98,149–163

Table 1

Nomenclature of the Mammalian Fgf and Fgfr family

HUGO/MGI SymbolNameAlternative SymbolName, Comments
(a) Fgf
FGF1/Fgf1Fibroblast Growth Factor 1aFgfAcidic Fgf
Hbgf1Heparin-binding growth factor 1
EcgrEndothelial cell growth factor
FGF2/Fgf2Fibroblast Growth Factor 2bFgfBasic Fgf
Hbgf2Heparin-binding growth factor 2
FGF3/Fgf3Fibroblast Growth Factor 3Int-2Int-2 oncogene
V-Int-2MMTV integration site 2
FGF4/Fgf4Fibroblast Growth Factor 4Hst1Human stomach tumor oncogene
Hstf1Heparin secretory transforming protein 1
K-Fgf, KfgfKaposi sarcoma Fgf
FGF5/Fgf5Fibroblast Growth Factor 5
FGF6/Fgf6Fibroblast Growth Factor 6Hst2Hst2 oncogene
FGF7/Fgf7Fibroblast Growth Factor 7KgfKeratinocyte growth factor
FGF8/Fgf8Fibroblast Growth Factor 8AigfAndrogen induced growth factor
Kal6
FGF9/Fgf9Fibroblast Growth Factor 9GafGlia activating factor
EksElbow knee synostosis
FGF10/Fgf10Fibroblast Growth Factor 10Kgf-2Keratinocyte growth factor 2
FGF11/Fgf11Fibroblast Growth Factor 11Fhf3Fibroblast Growth Factor homologous factor 3
FGF12/Fgf12Fibroblast Growth Factor 12Fhf1Fibroblast Growth Factor homologous factor 1
FGF13/Fgf13Fibroblast Growth Factor 13Fhf2Fibroblast Growth Factor homologous factor 2
FGF14/Fgf14Fibroblast Growth Factor 14Fhf4Fibroblast Growth Factor homologous factor 4 spinocerebellar ataxia 27
Sca27
Fgf15Fibroblast Growth Factor 15Rodent ortholog of vertebrate Fgf19
FGF16/Fgf16Fibroblast Growth Factor 16
FGF17/Fgf17Fibroblast Growth Factor 17Called FGF-13 in some older literature
FGF18/Fgf18Fibroblast Growth Factor 18
FGF19Fibroblast Growth Factor 19Human ortholog of rodent Fgf15
FGF20/Fgf20Fibroblast Growth Factor 20
FGF21/Fgf21Fibroblast Growth Factor 21
FGF22/Fgf22Fibroblast Growth Factor 22
FGF23/Fgf23Fibroblast Growth Factor 23
(b) Fgfr
FGFR1/Fgfr1Fgf receptor 1FlgFms-like gene
Flt2Fms-like tyrosine kinase 2
CekChicken embryo kinase 1
KAL2Kallman syndrome 2
K-samKATO-III cell-derived stomach cancer amplified gene
FGFR2/Fgfr2Fgf Receptor 2BekBacterial expressed kinase
Cek3Chicken embryo kinase 3
KgfrKGF receptor
FGFR3/Fgfr3Fgf Receptor 3Cek2Chicken embryo kinases 2
AchAchondroplasia
FGFR4/Fgfr4Fgf Receptor 4TkfTyrosine kinase related to Fibroblast Growth Factor receptor
FGFRL1/Fgfrl1Fgf receptor like 1Fgfr5Fgf receptor 5
Figure 1

FGF and FGFR families. (a) Phylogenetic analysis suggests that 22 Fgf genes can be arranged into seven subfamilies containing two to four members each. Branch lengths are proportional to the evolutionary distance between each gene. The Fgf1, Fgf4, Fgf7, Fgf8, and Fgf9 subfamily genes encode secreted canonical FGFs, which bind to and activate FGFRs with heparin/HS as a cofactor. The Fgf15/19 subfamily members encode endocrine FGFs, which bind to and activate FGFRs with the Klotho family protein as a cofactor. The Fgf11 subfamily genes encode intracellular FGFs, which are non-signaling proteins serving as cofactors for voltage gated sodium channels and other molecules. (b) Schematic representations of FGFR protein structures are shown. FGFR is a receptor tyrosine kinase of ∼800 amino acids with several domains including three extracellular immunoglobulin-like domains (I, II, and III), a transmembrane domain (TM), and two intracellular tyrosine kinase domains (TK1 and TK2). SP indicates a cleavable secreted signal sequence. The Fgfr gene family is comprised of four members, Fgfr1-Fgfr4. Among them, Fgfr1–Fgfr3 generate two major splice variants of immunoglobulin-like domain III, referred to as IIIb and IIIc, which are essential determinants of ligand-binding specificity. (c) The schematic representation of FGFRL1/FGFR5 protein structure is shown. FGFRL1, with structural similarity to FGFRs, is a membrane protein of ∼500 amino acids with three extracellular immunoglobulin-like domains (I, II, and III), a transmembrane domain (TM), and a short intracellular tail with no tyrosine kinase domain. SP indicates a cleavable secreted signal sequence.

Table 2

Phenotypes of Null and Tissue-Specific Fgf Mutations

Gene NameViability /Age at Death of Null MutantNull Phenotype (Organ, Structure, or Cell Type Affected)Tissue-Specific (Conditional) Phenotypes, Redundant Phenotypes, Phenotypes Induced by Physiological ChallengeSelected References
(a) Phenotypes of germline and conditional loss-of-function Fgf mutations in mice
Fgf1ViableNo apparent phenotypeAn aggressive diabetic phenotype with white adipocyte remodeling on high-fat diet3,4
Fgf2ViableCortical neuron, vascular smooth muscle, blood pressure, skeletal development, and wound healingDecreased cardiac hypertrophy induced by ischemic injury and delayed wound healing; Increased bone mineralization in high molecular weight isoform knockout5–11
Fgf3ViableInner ear and skeletal developmentHeart development (redundant with Fgf10)12,13
Fgf4E4-5Blastocyst inner cell massLimb bud development (redundant with Fgf8)14–17
Fgf5ViableHair follicle development18
Fgf6ViableMuscle developmentMuscle regeneration19–21
Fgf7ViableHair follicle and ureteric bud development and synaptogenesisThymus regeneration (radiation injury) and wound healing22–26
Fgf8E7GastrulationHeart field, limb, somitogenesis, kidney, CNS, inner ear development, spermatogenesis27–39
Fgf9P0Lung, heart, skeletal, gonad, inner ear, and intestine developmentMigration of cerebellar granule neurons and kidney agenesis (redundant with Fgf20)40–53
Fgf10P0Limb bud, lung bud, trachea, thymus, pancreas, pituitary, palate, tongue epithelium, cecum, kidney, submandibular, salivary, lacrimal, and mammary gland, heart, stomach, and white adipose tissueLung branching morphogenesis and inner ear development (redundant with Fgf3)54–68
Fgf11ViableNo identified phenotype(unpublished)
Fgf12ViableNo identified phenotypeSevere ataxia and motor weakness (redundant with Fgf14)69
Fgf13ViableNeuronal migration, learning and memory deficits, and microtubule binding69–73
Fgf14ViableAtaxia, motor weakness, learning and memory deficits, and impaired neuronal excitabilitySevere ataxia and motor weakness (redundant with Fgf12)69,74
Fgf15E13.5-P7Cardiac outflow tract development, neurogenesis, and bile acid metabolismLiver regeneration75–80
Fgf16ViableHeart developmentPromotes cardiac remodeling induced by angiotensin II81–83
Fgf17ViableCerebellum and frontal cortex development31,84
Fgf18P0CNS, skeletal, palate, and lung development40,85–89
Fgf20ViableGuards hair, teeth, cochlea, and kidney developmentKidney agenesis (redundant with Fgf9)40,90–92
Fgf21ViableEnergy/lipid metabolism75,93,94
Fgf22ViableSynaptogenesisDecreased skin papillomas formation following carcinogenesis challenge22,95–97
Fgf23PW4-13Phosphate and vitamin D homeostasis, deafness, middle ear development98–102
(b) Phenotypes of germline and conditional loss-of-function Fgfr mutations in mice
Fgfr1E7.5-9.5Gastrulation, Blastocyst inner cell massHematopoietic cell engraftment39,103–114
Osteoblast maturation
Limb bud development
Hippocampal progenitor cell proliferation
Inner ear sensory epithelium
Deletion of Ig domain 1 (defect in node regression)
Adipocyte metabolism
Endothelial Tgfβ expression and endothelial-mesenchymal transition; Endothelial regulation of CXCR4 in liver regeneration and fibrosis
Spermatogenesis
Fgfr2E10-11Placenta, no limb budsSkeletal, lung, limb bud, CNS, GI tract, skin, and adrenal cortex development in Fgfr2b null mice115–119
Fgfr1/2Myelin sheath thickness in oligodendrocyte120–126
Kidney, metanephric mesenchyme, ureteric bud, ocular gland development
Angiogenesis, vascular integrity
Hepato-cytoprotective through regulation of cytochrome P450 enzymes
Fgfr3ViableSkeletal overgrowth, inner ear, brain, articular cartilage, oligodendrocyte differentiation, pancreatic growth, intestinal crypt cell growth arrestAlveolar septation and elastogenesis (redundant with Fgfr4)10,127–139
Fgfr4ViableCholesterol metabolism and bile acid synthesisIncreased liver injury and fibrosis induced by carbon tetrachloride131,139–146
Alveolar septation and elastogenesis (redundant with Fgfr3)
Vitamin D homeostasis (redundant with Fgfr3)
Phosphate homeostasis (redundant with Fgfr1)
Fgfrl1P0Kidney, diaphragm, skeleton147,148

At the cellular level, secreted FGFs regulate fundamental cellular processes that include positive and negative regulation of proliferation, survival, migration, differentiation, and metabolism. During early development, FGFs regulate differentiation of the inner cell mass into epiblast and primitive endoderm lineages.164–167 Later in development, FGFs have key roles in organogenesis, for example in the regulation of the anterior and secondary heart fields,168,169 induction of limb buds54,55,170 and lung buds,54,55 ventral liver and pancreas,171,172 kidney development,27,40,120,121,147, inner ear development,12,28,41,56,90,103,104,127,173 and brain development.174,175

In the adult, FGFs have important roles in response to injury and tissue repair.176 FGF signaling is cardioprotective following ischemic injury to the heart,177–179 and is important for epithelial repair in the lung and in wound healing.180–182 FGF signaling, however, may also increase or decrease tissue fibrosis.81,183–185 Endocrine FGFs mediate mineral, metabolic, energy, and bile acid homeostasis.75,98,186,187FGF receptor (Fgfr) mutation, amplification, and gene fusions can drive abnormal morphogenesis, the progression of several types of cancer, and provide escape pathways for drugs that target other oncogenic tyrosine kinase receptors.152,188–196

Given the ubiquitous roles for FGF signals in development, homeostasis, and disease, tight regulation of the pathway is essential. Canonical FGFs are tightly bound to heparin/heparan sulfate (HS) proteoglycans (HSPGs), which function to limit diffusion through the extracellular matrix (ECM) and serve as cofactors that regulate specificity and affinity for signaling FGFRs.153,197–201 The endocrine FGFs, evolved with reduced affinity for heparin/HS and the requirement for a protein cofactor, αKlotho, βKlotho, or KLPH for receptor binding.75,202 Additional regulation is provided by a fifth non-tyrosine kinase FGFR (FGFRL1) which can bind FGF ligands and possibly function as a decoy receptor, dimerization-induced inhibitor of tyrosine kinase FGFRs, or modulator of receptor turnover or signaling.203 Downstream of the signaling tyrosine kinase FGFRs, intracellular signaling cascades are also tightly regulated by specialized adaptor proteins such as FGFR substrate 2α (FRS2α) and regulators of the RAS-MAPK and PI3K-AKT pathways such as Sprouty (SPRY) proteins151,204–207 (Figure 3(a)).

iFGFs (also known as FGF homologous factors (FHFs)) are essential regulators of neuronal and myocardial excitability. However, whether iFGFs are required during normal embryonic development is currently not known. Several proteins are known to directly interact with iFGFs. These include members of the voltage gated sodium channel family,154 IB2 (MAPK8IP2, Mitogen-activated protein kinase 8-interacting protein 2),208 β-tubulin,70 and NEMO209 (NF-κB essential modulator). Analysis of evolutionary relationships in the FGF family suggests that iFGFs may be the first members of the family to evolve, followed by the acquisition of a signal peptide for secretion, and affinity for heparin/HS to limit diffusion and regulate receptor binding.210 The most recent evolutionary event led to the endocrine branch of the FGF family, which has reduced affinity for heparin/HS and a requirement for Klotho family cofactors for receptor binding.

In this review we will focus on the roles and regulation of FGF signaling pathways that function during vertebrate organogenesis and on how gain and loss-of-function mutations in the FGF pathway result in developmental or metabolic disease and cancer.

Pathway Components

Fibroblast Growth Factors

Historical Perspective

Embryo extracts and brain extracts were shown to promote the growth of chicken periosteal fibroblast as early as 1939.211 A proteinaceous ‘Fibroblast Growth Factor’ activity was first identified in an extract from bovine pituitary in 1973.212 This activity was shown to be protease sensitive and thermolabile and could stimulate the proliferation of 3 T3 fibroblasts at low (ng/ml) concentrations. This activity was partially purified in 1975213 and purified to homogeneity in 1983214 and would later be referred to as basic FGF (bFGF or FGF2) due the overall basic composition of amino acids and high isoelectric point. Purification of a factor with similar mitogenic activity from bovine brain that was free of myelin basic protein fragments identified a second Fibroblast Growth Factor-like activity with a low isoelectric point that was eventually referred to as acidic FGF215–220 (aFGF or FGF1). This factor was also found to be identical to an activity called endothelial cell growth factor221 (ECGF) and related to FGF2.217 In addition to stimulation of 3 T3 cell proliferation, these growth factors were found to promote proliferation of a wide variety of mesoderm-derived cells such as endothelial cells.217,220–222 cDNA clones for FGF1 were first isolated from a human brain cDNA library in 1986.223 cDNA clones for Fgf1 and Fgf2 were also isolated from bovine pituitary cDNA libraries in 1986.224 Additional members of the FGF family were identified as growth factors for cultured cells, as oncogenes tagged by retroviral insertions, as genes responsible for hereditary diseases, or by homology-based PCR or homology-based searches of DNA databases.152,153,99

The mammalian Fgf family contains 22 genes, 18 of which encode molecules known to signal through FGF tyrosine kinase receptors (Table1(a)). The secreted signaling FGFs can be grouped into subfamilies based on biochemical function, sequence similarities, and evolutionary relationships. The current consensus is that there are 5 subfamilies of paracrine FGFs, one subfamily of endocrine FGFs, and one subfamily of intracellular FGFs150,153,157,158,210,225,226 (Figure 1(a)). Fgf15 and Fgf19 are likely to be orthologs in vertebrates. The orthologs were named Fgf15 in rodents and Fgf19 in other vertebrates. In this review, we refer to these as Fgf15/19.

Canonical (Secreted) FGFs

FGF1 Subfamily

The FGF1 subfamily is comprised of FGF1 and FGF2 (Figure 1(a)). These FGFs lack classical secretory signal peptides but are nevertheless readily exported from cells by direct translocation across the cell membrane.227 The mechanism of translocation is thought to involve a chaperone complex that includes synaptotagmin-1 and the calcium binding protein S100A13.228,229 FGF1 and FGF2 have also been found in the nucleus of some cells. The mechanisms by which FGFs transit through the cell are poorly understood, but are thought to require binding to and activating cell surface tyrosine kinase FGFRs with heparin/HS as a cofactor and interaction with HSP90.230,231 Several studies have shown that extracellular FGF1 passes through the plasma membrane, moves through the cytosol, and enters the nucleus.232,233 Potential functions of nuclear FGF1 include regulation of the cell cycle, cell differentiation, survival, and apoptosis.234,235 FGF1 is the only FGF that can activate all FGFR splice variants (Figure 2; see below).

Figure 2

Receptor specificity of canonical and endocrine FGFs. The six subfamilies of signaling FGFs use either heparin-like molecules or Klotho molecules as cofactors for receptor binding. Data is derived from receptor activation assays using BaF3 cells, L6 myoblasts, or HEK293 cells transfected with individual splice variants of FGFRs or by direct binding studies.140,141,162,237,238,246–254 FGFR4Δ is a two immunoglobulin-like domain form of FGFR4.

FGF4 Subfamily

Phylogenetic analysis suggests that the FGF4 family is comprised of FGF4, FGF5 and FGF6236 (Figure 1(a)). However, there is some controversy as to whether FGF5 should be included in this subfamily, because synteny relationships could be used to place FGF5 in the FGF1 subfamily.210 All members of this subfamily are secreted proteins with cleavable N-terminal signal peptides that mediate biological responses as extracellular proteins by binding to and activating FGFRs.158 These FGFs activate IIIc splice variants of FGFRs 1–3 and FGFR4237,238 (Figure 2; see below).

FGF7 Subfamily

Phylogenetic analysis suggests that the FGF7 family is comprised of FGF3, FGF7, FGF10 and FGF22236 (Figure 1(a)). However, there is some controversy as to whether FGF3 should be included in this subfamily. Sequence homology and biochemical properties support inclusion in the FGF7 subfamily, while chromosomal localization supports inclusion with FGF4 and FGF6.210 One recent study proposed an eighth subfamily composed of only FGF3.226 FGFs, 3, 7, 10, and 22 preferentially activate the IIIb splice variant of FGFR2 and FGF3 and FGF10 also activate the IIIb splice variant of FGFR1237,238 (Figure 2; see below).

FGF8 Subfamily

The FGF8 subfamily is comprised of FGF8, FGF17, and FGF18236 (Figure 1(a)). Members of this subfamily contain an N-terminal cleaved signal peptide. These FGFs activate IIIc splice variants of FGFRs 1–3 and FGFR4237,238 (Figure 2; see below).

FGF9 Subfamily

The FGF9 subfamily is comprised of FGF9, FGF16, and FGF20 (Figure 1(a)). This subfamily does not have a classical N-terminal signal peptide but does have an internal hydrophobic sequence that functions as a non-cleaved signal for transport into the endoplasmic reticulum and secretion from cells.239–241 This subfamily has the unique properties of activation of the IIIb splice variant of FGFR3 in addition to FGFR4 and the IIIc splice variants of FGFRs 1, 2 and 3237,238 (Figure 2; see below).

FGF15/19 Subfamily (Endocrine FGFs)

The FGF15/19 subfamily is comprised of FGF15/19, FGF21, and FGF2375,242 (Figure 1(a)). These FGFs are unique in that they primarily function as endocrine factors and are referred to as endocrine FGFs. In contrast to canonical FGFs, endocrine FGFs bind to heparin/HS with very low affinity.243 The reduced heparin-binding affinity facilitates release from ECM and allows these FGFs to function as endocrine factors. However, endocrine FGFs still mediate their biological responses in an FGFR-dependent manner, but instead of heparin/HS as cofactors for receptor binding and activation, endocrine FGFs require members of the Klotho family, αKlotho (Klotho), βKlotho, and Klotho-LPH related protein (KLPH), which has also been called Lactase-like Klotho (Lctl) or γKlotho. αKlotho and βKlotho are structurally related single-pass transmembrane proteins of ∼1000 amino acids with a short cytoplasmic domain. FGF15/19 and FGF21 signaling requires βKlotho1,75,156,244–246 (see below). In vitro assays for receptor activation using BaF3 cells or L6 myoblasts that co-express FGFR splice variants and βKlotho shows that FGF19 can activate FGFR1c, FGFR2c, FGFR3c, and FGFR4, while FGF21 only activates FGFR1c and FGFR3c162,246 (Figure 2). In vivo studies show that FGF21 directly regulates hepatocyte and adipocyte metabolism through interactions with FGFR1 and βKlotho.162,245,255 By contrast, FGF19, but not FGF21, activates FGFR4, which functions in hepatocytes as a proliferative signal and as a regulator of bile acid synthesis, and has been implicated in the etiology or progression of hepatocellular carcinoma.143,162,256,257 KLPH has been shown to enhance signaling of FGF19 in HEK293 cells,160 however, the in vivo function of KLPH is not known. FGF23 signaling is mediated through the activation of FGFR1c, FGFR3c, and FGFR4, together with the cofactor, αKlotho140,141,247,248,258 (Figure 2; see below).

Intracellular FGFs

FGF11 Subfamily

The FGF11 subfamily (FGF11, FGF12, FGF13, FGF14) is also known as iFGFs259 (Figure 1(a)). iFGFs are not secreted and have no identified interaction with signaling FGFRs.260 iFGFs interact with the cytosolic carboxy terminal tail of voltage gated sodium (Nav) channels. This interaction may help to regulate the subcellular localization of Nav channels at the axon initial segment during development and the ion-gating properties of the channel in mature neurons and other excitable cells such as cardiomyocytes.69,261–264 Additional interacting proteins have been identified for some iFGFs. For example, FGF12 (FHF1) was shown to interact with the MAP kinase scaffolding protein, IB2 (MAPK8IP2),265 and FGF13 (FHF2) was shown to interact with microtubules.70

Fibroblast Growth Factor Receptors

Historical Perspective

Tyrosine kinase activity was first associated with signaling by brain-derived growth factor, an activity with similar properties to FGF1.266 Subsequently, purified FGF1 and FGF2 were shown to cause phosphorylation of a 90 kDa protein in Swiss 3 T3 cells.267 Crosslinking of 125I-FGF2 was used to tag and purify a receptor protein from chicken embryo membrane fractions. Sequence of tryptic peptides from the chicken FGF receptor, were found to match a partial human cDNA clone called FLG (Fms-like gene),268 now referred to as FGF receptor 1 (FGFR1) (Table1(b)). This information was used to clone a full-length cDNA from a chicken library. The cDNA encoded a 91.7 kDa protein with an N-terminal hydrophobic signal sequence, three extracellular immunoglobulin-like domains, and an intracellular tyrosine kinase domain (Figures 1(b) and 3). The chicken cDNA showed high homology to a cDNA isolated from a human library (90–100% in the tyrosine kinase domain) and the partial FLG cDNA clone, and 84% sequence identity to a mouse partial cDNA called Bek (bacterial expressed kinase).269 Bek is now referred to as FGF receptor 2 (FGFR2) (Table1(b)). Homology based cloning was used to identify Fgfr3 and Fgfr4.270–273 A receptor for FGF7/KGF was isolated by functional cloning in NIH3T3 cells that expressed FGF7.274 Sequencing revealed a two immunoglobulin-like domain variant with identity to BEK in the tyrosine kinase domain.

Figure 3

FGF signaling pathways. (a) Binding of canonical FGFs to FGFR with HS (or HSPG) as a cofactor induces the formation of ternary FGF-FGFR-HS complex, which activates the FGFR intracellular tyrosine kinase domain by phosphorylation of specific tyrosine residues. The activated receptor is coupled to intracellular signaling pathways including the RAS-MAPK, PI3K-AKT, PLCγ, and STAT pathways. The RAS-MAPK pathway: The major FGFR kinase substrate, FRS2α, which is constitutively associated with the juxtamembrane region of FGFR (peptide: MAVHKLAKSIPLRRQVTVSADS), interacts with CRKL bound to pY463 and is phosphorylated by the activated FGFR kinase. Phosphorylated FRS2α recruits the adaptor protein GRB2, which then recruits the guanine nucleotide exchange factor SOS. The recruited SOS activates the RAS GTPase, which then activates the MAPK pathway. MAPK activates members of the Ets transcription factor family such as Etv4 (Pea3) and Etv5 (Erm) and negative regulators of the FGF signaling pathways such as SHP2, CBL, SPRY, SEF, and DUSP6. The PI3-AKT pathway: The recruited GRB2 also recruits the adaptor protein GAB1, which then activates the enzyme PI3K, which then phosphorylates the enzyme AKT. AKT has multiple activities including activation of the mTOR complex 1 through inhibition of TSC2 and phosphorylation of the FOXO1 transcription factor causing it to exit the nucleus. The PLCγ pathway: Activated FGFR kinase recruits and activates the enzyme PLCγ, which produces IP3 and DAG by the hydrolysis of PIP2. IP3 induces calcium ion release from intracellular stores and the activation of downstream signaling pathways. DAG activates the enzyme PKC and its downstream signaling pathways. GRB14 inhibits activation of PLCγ. The STAT pathway: FGFR kinase also activates STAT1, 3, and 5. STAT3 interacts with phosphorylated tyrosine 677 (pYxxQ motif). These activated signaling pathways mostly regulate gene expression in the nucleus. SPRY interacts with GRB2 to inhibit the RAS-MAPK pathway and to regulate the PI3K-AKT pathway. GRB2 dimers are docked at the c-terminus of FGFR2 where they inhibit SHP2, allowing low-level receptor kinase activity. Molecules shaded red generally function to inhibit FGFR signaling. (b) Dimerization of the FGFR1 kinase domain leads to sequential phosphorylation of tyrosine residues (1P–6P) leading to increasing activity of the FGFR kinase and phosphorylation of tyrosine substrates for CRKL, STAT, GRB14, and PLCγ binding. In the first phase of activation, Y653 (1P), in the activation loop, is phosphorylated, resulting in a 50- to 100-fold increase in kinase activity. In the third phase of activation, Y654 (6P), in the activation loop, is phosphorylated, resulting in an overall 500–1000 fold increase in kinase activity. Y730 is weakly phosphorylated. Phosphorylation of Y677 allows docking of STAT3 and phosphorylation of Y766 allows docking of either GRB14 or PLCγ. Ligand-induced receptor activation phosphorylates GRB2, leading to its dissociation from the receptor. Tyrosine residues correspond to human FGFR1 (accession NP_075598). (c) Binding of endocrine FGF to FGFR with Klotho as a cofactor induces the formation of ternary FGF-FGFR-Klotho complex, which leads to activation of the FGFR tyrosine kinase. (d) FGFRL1 is a protein containing three extracellular immunoglobulin-like domains with similarity to FGFRs. FGFRL1 has a single transmembrane domain, and a short intracellular tail with no tyrosine kinase domain. The short cytoplasmic domain contains an SH2 binding motif that interacts with SHP1. FGFRL1 is not simply a decoy receptor, but rather a non-tyrosine kinase signaling molecule.

Determinants of Ligand Binding Affinity and Specificity of FGFRs

Immunoglobulin-like domains II and III, and the linker region between these domains regulates the ligand binding specificity of the four FGFR proteins.275–277 Immunoglobulin-like domain I and the acidic amino acid sequence (acidic box) located between immunoglobulin-like domains I and II are thought to inhibit ligand binding.278 Consistent with this, an alternative splicing event that results in receptor variants lacking immunoglobulin-like domain I and the I-II linker have increased affinity for FGF ligands.279,280Fgfr1–Fgfr3 generate two additional major splice variants of immunoglobulin-like domain III, referred to as IIIb and IIIc281–283 (Figure 1(b)). The FGFRb and FGFRc splice variants are essential determinants of ligand-binding specificity (Figure 2).237,238,275,281,282 Alternative splicing of Fgfrs is critical to pathway function as evidenced by the highly conserved intronic control elements in species ranging from sea urchin to mammals.284 Immunoglobulin-like domain III of Fgfr4 is not alternatively spliced.271 Among the other three Fgfrs, alternative splicing of Fgfr2 is functionally the most important. Fgfr1 splicing and ligand binding properties parallels that of Fgfr2, and these two receptors often show functional redundancy during development. Other splice variants of Fgfrs have also been identified. For example, an Fgfr1 cDNA encoding immunoglobulin-like domains II and III generates a secreted FGFR binding domain that can functionally inhibit FGFR signaling.285 An Fgfr3 splice variant in which exons 8–10, which encode the transmembrane domain, are skipped has been identified in both normal epithelial cells and some cancer cell lines. This splice variant produces a secreted protein that can bind FGF ligands and functionally inhibit FGFR signaling.286,287

Ligand binding specificity of the 18 secreted FGFs have been compared using various mitogenic assays and by directly measuring affinity for FGFRs. The BaF3 cell line and L6 myoblasts have been particularly useful, as they have little or no endogenous Fgfr expression. Studies in BaF3 cells identified strong mitogenic response to FGFR1 and FGFR2 and weak responses to FGFR3 and FGFR4, suggesting that the strength or the specific downstream signaling pathways activated by FGFRs may be unique.238,249,288 Using BaF3 cells or L6 myoblasts that express unique extracellular splice variants of Fgfrs (Fgfr1b, 1c, 2b, 2c, 3b, 3c, 4) fused to either the FGFR1 or FGFR2 cytoplasmic domain, the mitogenic activity of all secreted FGFs were compared in the presence of heparin.162,237,238,249–254 Additionally, the mitogenic activity of FGF15/19 and FGF21 were assayed on BaF3 cells or L6 myoblasts that also co-expressed βKlotho and FGF23 was assayed on HEK293 cells that co-expressed αKlotho.162,246,248 This analysis showed that FGF1 was the only ligand that could activate all receptor splice variants (Figure 2). This analysis also showed that members of FGF subfamilies have very similar receptor specificities. Direct binding, using iodinated FGFs and using surface plasmon resonance has also been used to evaluate FGF binding specificity.281,282,289,290 The binding studies are qualitatively in agreement with mitogenic assays.

Expression of alternative splice variants of Fgfr1 and Fgfr2 are regulated in a tissue-specific manner. Mesenchymal tissue expresses IIIc splice variants of Fgfr1 and Fgfr2 and often are activated by FGF ligands that are expressed in epithelial cells, such as members of the Fgf4 and Fgf8 subfamilies.54,55,291,292 By contrast, epithelial tissues express IIIb splice variants of Fgfr1 and Fgfr2 and bind ligands that are normally expressed in mesenchymal tissues, such as members of the Fgf7 subfamily.293,294 This epithelial/mesenchymal expression of alternative splice variants of FGFRs and reciprocal expression of interacting FGF ligands is essential for the development of many organs, particularly those that undergo branching morphogenesis such as the lung or salivary gland, and structures such as the limb bud, and skin (Figure 4).

Figure 4
Mechanisms of FGF signaling during organogenesis. (a–c) Limb bud development uses a classical reciprocal epithelial-mesenchymal FGF signal. The earliest identified event in limb bud development involves an FGF10 signal to coelomic epithelium (a). This induces an epithelial to mesenchymal transition (orange arrow) that increases the amount of mesenchyme (orange hash) at the forming limb bud, resulting in a bulge. As development progresses (b), FGF10 signals to ectoderm to induce the formation of the apical ectodermal ridge (AER). Initially FGF8 (blue hash) is expressed throughout its length of the AER (b) and later FGF4, FGF9, and FGF17 are also expressed in the posterior half of the AER. AER FGFs signal to FGFR1 and FGFR2 in distal mesenchyme. (d, e) Lung development uses a modified reciprocal mesothelial/epithelial-mesenchymal FGF signal. The lung bud is initiated with an FGF10 signal from foregut mesenchyme to FGFR2b in foregut epithelium. Continued FGF10 expression is required for epithelial branching. Reciprocal signals from mesothelial FGF9 regulates mesenchymal proliferation through FGFR1 and FGFR2, while epithelial FGF9 functions as an autocrine factor to regulate epithelial branching through an as yet unidentified receptor. (f–h) Induction of the otic placode and differentiation of the otic vesicle. (f, g) FGF3, derived from the hindbrain and FGF10 derived from head mesenchyme, together, induce formation of the otic placode and its progression to the otic cup and otic vesicle. (h) After formation of the otic vesicle, FGF20 signals to FGFR1 within the prosensory epithelium (white hash) as a permissive autocrine factor required for differentiation of outer hair cells and outer supporting cells in the organ of Corti.

Although this pattern of reciprocal signaling is essential for the development of some organs, it is not universal. For example, the tissue-specific regulation of alternative splicing is less stringent for Fgfr3, where both splice variants have been found in epithelial cell types.295,296 The FGF9 subfamily, though primarily expressed in epithelial cells, has the unique ability to activate FGFR3b in addition to IIIc splice variants of FGFRs 1–3237,253 (Figure 2). Fgf10 expression can be found in some epithelial cell types, such as the developing inner ear where it likely signals in an autocrine manner to epithelial cells.237 During somitogenesis, Fgf4 and Fgf8 are expressed and signal within presomitic mesenchyme and nascent somites where they suppress differentiation.29

Pathway Regulation

Extracellular FGF Associated Cofactors and Binding Proteins

Heparan Sulfate Proteoglycans

HS is now recognized to function as a potent cofactor for canonical FGF signaling as well as a wide range of other signaling pathways including bone morphogenetic proteins (BMPs), WNTs, and Hedgehogs197,297–299 (Figure 3(a)). Heparin was found to potentiate the biological activity of FGF1 in 1985220–222 and was first shown to directly enhance FGFR binding and activity in 1991.200,201,254 Using a cell line (BaF3) that lacks cell surface HS, or through inhibition of HS sulfation (with chlorate), the signaling ability of all canonical FGFs were shown to require heparin/HS200,237,238,254,300 (Figure 2).

HS is a long linear carbohydrate chain of repeating sulfated disaccharides, glucuronic acid linked to N-acetylglucosamine. The HS chains are covalently linked to specific core proteins such as syndecan, perlecan, glypican, and agrin. These HS proteoglycans (HSPGs) are cell surface transmembrane type proteins (e.g. syndecans), cell surface glycerophosphatidylinositide-anchored type proteins (e.g. glypicans), or diffusible proteins localized in the ECM198,298,301–304 (e.g. perlecan and agrin). HS independently can interact with both FGFs and FGFRs and is proposed to cooperatively increase the affinity of a 1:1 FGF-FGFR dimer by binding to a cleft formed between the HS binding sites on FGFs and the N-terminal region of immunoglobulin-like domain 2301,305 (Figure 3(a)). This 1:1:1 FGF-HS-FGFR complex leads to conformational changes that stabilize a symmetric 2:2:2 dimer. FGFR dimerization then directs the juxtaposition and activation of the intracellular tyrosine kinase domains, followed by the activation of intracellular signaling pathways.198,301 As a component of the ECM, HS also functions to sequester FGFs and modulate their diffusion through tissue to effectively regulate the shape of a gradient. For example, differences in binding affinity of FGF7 and FGF10 for HS, underlie differences in epithelial branching patterns during glandular organogenesis.306

The structure of HS is complex and heterogeneous; with variations in chain length, and patterns of sulfation and acetylation along the length of the glycosaminoglycan (GAG) chain.307–309 Synthesis of the HS chain is catalyzed by the glycosyltransferases, EXT1 and EXT2.310 The HS molecule consists of repeating disaccharide units of N-acetylglucosamine and glucuronic acid. The HS chain matures in the Golgi where N-acetylglucosamine residues are partially N-deacetylated and N-sulfated by a family of four N-deacetylase/N-sulfotransferase enzymes311 (NDST1-4). Subsequently, 2-O-sulfotransferases, 6-O-sulfotransferases, and 3-O-sulfotransferases add O linked sulfate groups.309 The pattern and density of deactylation and sulfation varies along the length of the GAG chain. In the extracellular environment, the 6-O-endosulfatases, SULF1 and SULF2, can also selectively desulfate HS.

The sulfation pattern and length of HS chains regulate FGF signaling.198,312 In the embryo, specific HS chains can regulate the cell-specific patterns of FGF and FGFR binding to the extracellular matrix, the direct interactions between FGFs and FGFRs, and activation of FGFR signaling.313–315 In general, higher levels of sulfation of HS chains facilitate FGF signaling and the formation of ternary complexes with FGFs and FGFRs.316,317 Furthermore, oligosaccharides with eight or more sugar residues are most active, but shorter HS chains can also facilitate the formation of ternary complexes with FGFs and FGFRs.254,316,318,319 Cleavage of the HSPG core protein also modulates FGF signaling.198 The cleavage by serine proteinases possibly facilities FGF signaling by releasing FGFs that were sequestered at the cell-surface.315 In addition, the cleavage by endoglycosidases such as heparanase possibly modulates FGF signaling.198 For example, FGF10 in the basement membrane, that is released by heparanase, promotes FGF signaling in branching morphogenesis.320

Klotho Family Proteins

The αKlotho gene was originally identified as a candidate gene responsible for a premature aging syndrome.321 Based on the phenotypic similarity of αKlotho and Fgf23 knockout mice, αKlotho was identified as a cofactor for FGF23 signaling through FGFR1c, FGFR3c and FGFR4140,141,247,248,322 (Figure 2). The αKlotho gene is highly expressed in the distal convoluted tubules in the kidney and choroid plexus in the brain.321 A major function of FGF23-αKlotho-FGFR signaling in the kidney is to regulate phosphate and calcium homeostasis. Mice lacking Fgf23 or αKlotho develop hyperphosphatemia and hypercalcemia by two weeks of age.258,323

The Klotho family is comprised of three members including αKlotho, βKlotho, and KLPH.98,324 αKlotho contains ∼1000 amino acid, a single transmembrane domain, and a short cytoplasmic domain (Figure 3(c)). There are no known functions of the cytoplasmic domains of Klotho proteins. The large extracellular part of the Klotho molecule has two repeated internal domains, KL1 and KL2, which are structurally similar to β-glucosidases. However, there is no evidence for glucosidase activity of αKlotho. βKlotho is also a single-pass transmembrane protein similar to αKlotho. The βKlotho gene is predominantly expressed in the liver and white adipose tissue.325 βKlotho is a cofactor for FGF15/19 and FGF21 signaling through FGFR4 and FGFR1c, respectively (Figure 3(b)).322 KLPH is also a single-pass transmembrane protein similar to αKlotho.326 The KLPH gene is expressed in the eye and brown adipose tissue. KLPH efficiently interacts with FGFR1b, FGFR1c, FGFR2c, and FGFR4. In KLPH-transfected HEK293 cells, FGF19, but not FGF21 and FGF23, causes ERK phosphorylation.160 However, the physiological function of KLPH remains unclear. Although Klotho proteins act as cofactors for the endocrine FGFs through formation of an FGF-FGFR-Klotho ternary complex, they also directly compete with a receptor docking site for canonical FGF8 family ligands, and thus may actively suppress these canonical FGFs while activating endocrine FGFs.327

FGF Binding Proteins

FGFBP1 (FGF Binding Protein 1)

FGFBP1 (HBP17) was originally isolated as a heparin-binding protein that co-eluted with FGF2 from a heparin affinity column.328 The Fgfbp1 cDNA encodes a secreted 234 amino acid polypeptide (Mr 17,000) that binds both heparin and FGF1 and FGF2.328 In these initial studies, FGFBP1 was shown to inhibit the biological activity of these FGFs by inhibiting receptor binding. However, in later studies, FGFBP1 was shown to mobilize FGF from HS binding sites in the extracellular matrix and function to present FGF to the FGFR.329

FGFBP1 is expressed in several human tumors, including breast and colon cancer, and FGFBP1 can be rate-limiting for tumor growth, but pro-angiogenic, thus acting to facilitate tumor invasion.330 In mice, Fgfbp1 is abundantly expressed in the colon, stomach, ileum, and eye.160 FGFBP1 also binds to and activates FGF7, FGF10 and FGF22, and functions to enhance wound healing.331,332

FGFRL1/FGFR5

FGFRL1 was identified as a protein structurally similar to FGFRs203,333 (Figure 1(c)). The Fgfrl1 cDNA, originally cloned from human cartilage, encodes a ∼500 amino acid protein containing three extracellular immunoglobulin-like domains with similarity to FGFRs, a single transmembrane domain, and a short intracellular tail with no tyrosine kinase domain.333,334Fgfrl1 (termed Fgfr5) was also cloned from human and mouse cDNA libraries.335,336 A soluble form of FGFRL1 binds to heparin and to FGF2, 3, 4, 8, 10, 22, and ectopic expression antagonized FGF signaling during Xenopus development and inhibited cell proliferation in vitro.334,337 Interestingly, the short cytoplasmic domain of FGFRL1 contains an SH2 binding motif that interacts with the tyrosine phosphatase SHP1338 (Figure 3(d)). Overexpression of Fgfrl1 results in increased ERK1/2 signaling.338 This result suggests that FGFRL1 is not a decoy receptor, but rather a non-tyrosine kinase signaling molecule.

Fgfrl1 knockout mice die immediately after birth from respiratory failure due to a hypoplastic diaphragm.148 Analysis of these mice reveals agenesis of slow muscle fibers.339 These mice also show kidney agenesis due to a reduction in mesenchymal nephron progenitors (cap mesenchyme), arrested branching of the urogenic epithelium, failure to form functional nephrons, and a hypoplastic collecting duct system147 (Table2(b)). Interestingly, mice that lack the intracellular domain of FGFRL1 are viable, fertile, and phenotypically normal, suggesting that the extracellular domain of FGFRL1 mediates most of its activity (Box 1).340

BOX 1 Inhibitory Mechanisms that Regulate FGFR Signaling

Inhibition of FGFR signaling is important for the precise control of cellular functions. Several mechanisms have evolved to regulate FGF signaling. These range from internalization and degradation of the receptor to modulation of receptor kinase activity by phosphatases and regulation of accessibility to downstream signaling pathways.

In recent studies,389,749 a dimeric form of GRB2, the adaptor protein that couples FRS2 to the RAS-MAPK and PI3K-AKT pathways (Figure 3(a)), was found to interact directly with the FGFR2 C-terminal 10 amino acid residues, where it stabilized a FGFR dimer which could autophosphorylate a limited number of tyrosine residues including Y653 and Y654 in the activation loop (Figure 3(b)). However, additional C-terminal phosphorylation and recruitment of signaling proteins was sterically hindered by the bound GRB2 dimer. Following ligand mediated receptor activation, phosphorylation of GRB2 caused GRB2 to dissociate from the FGFR C-terminus permitting full receptor activation.749 Additionally, high levels of GRB2 inhibited phosphorylation-independent binding of PLCγ (through its SH3 domain) to the very C-terminus of the FGFR. Lower levels of GRB2 allowed PLCγ binding and increased phospholipase activity, resulting in increased cell motility, an activity that can promote metastatic behavior of melanoma cells.750

The RAS-MAPK pathway can also exert direct negative feedback inhibition of FGFRs. ERK1 and ERK2, which are activated by FGFR and other receptor tyrosine kinases, can phosphorylate the C-terminus of FGFR2 at Ser777 to functionally inhibit FGFR2 tyrosine kinase activity.751 This provides a negative feedback pathway for FGF signaling and a means for other receptor tyrosine kinases that use the RAS-MAPK pathways to communicate with FGFRs.

Intracellular Signal Transduction

Cytosolic Signaling Pathways

FGF binding activates the FGFR tyrosine kinase by inducing receptor dimerization and trans-autophosphorylation of the kinase domain1 (Figure 3(a)). For FGFR1, six tyrosine residues are sequentially phosphorylated to fully activate the kinase domain341,342 (Figure 3(b)). In the first phase of activation, Y653 is phosphorylated, resulting in a 50- to 100-fold increase in tyrosine kinase activity. In the second phase of activation, Y583, and then Y463, Y766, and Y585 are phosphorylated. In the third phase of activation, Y654 is phosphorylated, resulting in a further 10 fold (overall 500- to 1000-fold) increase in tyrosine kinase activity. Phosphorylation of two additional tyrosine residues, 677 and 766, is required, respectively, for STAT3 and phospholipase Cγ (PLCγ) binding.343–345 The adaptor protein, FGFR substrate 2α (FRS2α) is constitutively docked to its binding site in the juxtamembrane region of FGFRs and anchored to the cell membrane through myristoylation207,346,347 (Figure 3(b)).

The activated FGFR phosphorylates adaptor proteins for four major intracellular signaling pathways, RAS-MAPK, PI3K-AKT, PLCγ, and signal transducer and activator of transcription (STAT)1,151–153,344 (Figure 3(a) and (b)). Activation of the RAS-MAPK and PI3K-AKT pathway is initiated by phosphorylation of FRS2α. FRS2α phosphorylation and ERK1/2 activation is partially dependent on phosphorylation of Y463 and the presence of CRKL.348,349 pY463 directly interacts with the adapter protein CRKL and with much lower affinity to the related protein, CRK.348–350 Downstream of RAS and PI3K, FGFR signaling has been shown to regulate several distinct MAP kinases including ERK1/2, JNK and p38.178,179,351–353

Activated (phosphorylated) FRS2α binds the membrane anchored adaptor protein, growth factor receptor-bound 2 (GRB2) and the tyrosine phosphatase SHP2.207,354 GRB2 further activates the RAS-MAPK pathway through recruitment of SOS, and the PI3K-AKT pathway through recruitment of GAB1 to the signaling complex (Figure 3(a)).207,355 The RAS-MAPK pathway regulates the expression of diverse target genes through activation of E26 transformation-specific (ETS) transcription factors. Etv4 (Pea3) and Etv5 (Erm) are ETS transcription factors that are often transcriptionally induced by FGF signaling.356–359 Phosphorylation of ETS transcription factors by activated MAPK allows interaction with DNA and regulation of target gene expression.352

In contrast to the RAS-MAPK pathway, the PI3K-AKT pathway functions to inhibit the activity of target molecules such as the forkhead box class transcription factor, FOXO1, and the cytosolic tuberous sclerosis complex 2, TSC2. FOXO1, a pro-apoptotic effector, is inactivated by AKT phosphorylation, causing it to exit the nucleus and promote cell survival.360 AKT also activates the mTOR complex 1 through phosphorylation and inhibition of TSC2, ultimately stimulating cell growth and proliferation.360 Phosphorylation of PLCγ by the activated FGFR tyrosine kinase leads to the hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce inositol triphosphate (IP3) and diacylglycerol (DAG) (Figure 3(a)). IP3 increases intracellular calcium ion levels and DAG activates protein kinase C (PKC). The adaptor protein, GRB14, also interacts with the activated FGFR1 at multiple sites, including pY766361 (and possibly pY776). Binding of GRB14 to pY766 inhibits tyrosine phosphorylation and activation of PLCγ362 (Figure 3(a) and (b)). Additionally, the SRC homology-2 protein, SHB, interacts with pY766 and acts to enhance phosphorylation of FRS2α and the mitogenic response to FGFs in an immortalized brain endothelial cell line.363

The activated FGFR also phosphorylates and activates STAT1, STAT3, and STAT5, to regulate STAT pathway target gene expression343,364–367 (Figure 3(a) and (b)). STAT1 was activated in chondrocytes derived from Thanatophoric dysplasia patients with a constitutively active mutant of FGFR3,364 and STAT1 activation in response to FGF1 in primary growth plate chondrocytes was necessary to suppress proliferation.368 However, using a rat chondrosarcoma cell line that stops growing in response to FGF1, it has been controversial as to whether STAT1 or MAPK signaling mediates the observed growth arrest.368,369 In cancer cells, under conditions of gene amplification or overexpression of FGFR3, STAT3 was phosphorylated resulting in activation of downstream target genes.343 In brain microvascular endothelial cells, FGF signaling was found to activate STAT5, which was necessary for migration, invasion, and tube formation.370

To the best of our knowledge, quantitative similarities and differences in the signaling output of the four FGFR kinase domains have not been assessed. However, activation of downstream signaling pathways are thought to be qualitatively similar for Fgfr1 and Fgfr2 and different from Fgfr3 and Fgfr4.238,249,288 Similarities and differences in signaling of the four FGFRs could be mediated by differential rates of endocytosis,371 by differential subcellular trafficking after ligand activation,372,373 or by differences in the affinity or specificity for adaptor proteins that couple to downstream signaling cascades.374

Inhibitors of FGFR Signaling

Sprouty (SPRY) is an intracellular negative regulator of receptor tyrosine kinases including FGFR, vascular-endothelial growth factor receptor, platelet-derived growth factor receptor, and nerve growth factor receptor.375,376 The human/mouse SPRY family is composed of four members, SPRY1-SPRY4. Most Spry genes are ubiquitously expressed in both embryos and adult tissues. In FGF signaling, SPRY interacts with GRB2 to inhibit the RAS-MAPK pathway and to regulate the PI3K-AKT pathway206,377 (Figure 3(a)). The phenotypes of Spry knockout mice indicate that SPRYs are essential for development and growth. The deregulation of SPRY function often results in human cancers and autoimmune diseases.375,376

SEF (similar expression to Fgf) is a transmembrane protein that functions as an antagonist of FGF signaling through the Ras-MAPK pathway378,379 (Figure 3(a)). SEF functions by binding to activated MEK to inhibit dissociation of the MEK–MAPK (ERK1/2) complex, thus blocking nuclear translocation of activated MAPK.377,380 The extracellular domain of SEF may also interact directly with the FGFR to inhibit receptor phosphorylation.381

Dusp6 (Dual-specificity phosphatase 6) encodes an ERK-specific MAPK phosphatase (MKP3)382Dusp6 expression is transcriptionally upregulated by FGFR signaling and Dusp6 expression patterns closely resemble those of Fgfs.383–386 DUSP6 serves in vivo as a negative feedback regulator of FGFR signaling by directly dephosphorylating MAPK (ERK1 and ERK2) on phosphotyrosine and phosphothreonine residues382 (Figure 3(a)).

CBL, an E3 ubiquitin ligase, forms a ternary complex with phosphorylated FRS2α and GRB2, resulting in the ubiquitination and degradation of FGFR and FRS2 in response to FGF stimulation387 (Figure 3(a)). FGFR2 activation can also increase CBL-PI3K interactions, leading to PI3K degradation and attenuated signaling.388

SHP2 binds to phosphorylated FRS2 following ligand activation of the FGFR.354 SHP2 functions to dephosphorylate FGFR2 and GRB2 (Figure 3(a)). However, activation of SHP2 (by phosphorylation) and access to the FGFR are also inhibited by receptor-bound GRB2.389,390

Regulation of the Cellular Response to FGFR Activation

The cellular response to FGFR signaling is regulated by differences in the intrinsic signaling properties of FGFRs and by the dynamics of subcellular FGFR trafficking in response to ligand binding. Cytosolic signaling pathways can be differentially activated by cell surface FGFRs and internalized FGFRs. Furthermore, regulating synthesis and degradation of FGFRs can modulate the strength of the FGFR signal. Differential cellular response can also result from differences in signal output from multiple FGFRs. For example, FGF1 stimulates lung epithelial cells to form buds resulting in branching, while FGF7 stimulates lung epithelial cells to form cyst-like structures.391,393 This could be due to activation of FGFR2 and FGFR4 by FGF1 and only activation of FGFR2b in response to FGF7. Two FGFs that are even more similar, FGF7 and FGF10, still can elicit different cellular responses. FGF10 specifically induced the formation of a Y734-phosphorylated FGFR2b-PI3K-SH3BP4 complex that targets FGFR2b to recycling endosomes and controls cell migration and epithelial branching, whereas FGF7 leads to cell proliferation and degradation of FGFR2b.373,392,393

Function of FGFs and FGFRs in the Nucleus

Both FGF ligands and receptors can localize to the cell nucleus where they carry out signaling functions that can be independent of receptor tyrosine kinase activity.394,395 FGF1 localization in the nucleus was found to stimulate DNA synthesis independent of FGFRs, and FGF2 nuclear localization was associated with glioma cell proliferation.396,397 It is not clear whether FGFs have direct transcriptional functions or exert their activity in the nucleus through interactions with other molecules.

Following ligand-mediated internalization, FGFR1 can be transported to the nucleus by interactions with importin β. Nuclear FGFR1 is required for neuronal differentiation and functions by activating transcription in cooperation with cyclic AMP response element-binding protein (CREB).398,399 Nuclear translocation of FGFR1, along with its ligand, FGF2, promoted pancreatic stellate cell proliferation and changes in the elaborated ECM, making it more permissive for pancreatic cancer cell invasion.400 In breast cancer cells, activation of FGFR1b by FGF10 activated granzyme B cleavage of FGFR1. Transport of the resulting C-terminal fragment of FGFR1 to the nucleus was required for cell migration.401

MicroRNA Regulation of FGF and FGFR Expression and Signaling

MicroRNAs (miRNAs) are small (approximately 21–24 nucleotides) non-coding RNAs, which are post-transcriptional regulators of gene expression.402 miRNAs participate in diverse biological processes including development, differentiation, cell proliferation, metabolism, as well as in human diseases including metabolic disorders and cancers.403,404 FGF pathway activity during development or regeneration can be regulated by miRNAs and loss of miRNA regulation of FGF signaling can result in disease progression or cancer.

During development, miRNAs can affect cell differentiation by directly regulating Fgf or Fgfr expression. For example, in the osteoblast, miR-338 was found to directly regulate the 3′ untranslated region (UTR) of Fgfr2 to suppress Fgfr2 expression. Decreased miR-338 increased Fgfr2 expression resulting in enhanced osteoblast differentiation.405 miRNAs can also affect FGF signaling during development by regulating downstream effectors of the pathway. For example, the miR-17 family directly targets Stat3 and Mapk14 in lung epithelium to modulate the response to FGF10-FGFR2b signaling.406

In disease pathogenesis, such as in pulmonary arterial hypertension (PAH), hyperproliferation of pulmonary artery endothelial and smooth-muscle cells leads to destruction of the pulmonary vascular plexus. miR-424 and miR-503 directly regulate (suppress) Fgf2 and Fgfr1 expression in pulmonary artery endothelial cells. Decreased expression of miR-424 and miR-503 in PAH leads to increased FGF2 and FGFR1 and consequent vascular hyperproliferation.407 In a model for tissue repair, inhibition of miR-710, a direct regulator of Fgf15 expression in myofibroblasts, increased FGF15 in conditioned media and enhanced in vitro intestinal epithelial wound repair.408

The metabolic functions of endocrine FGFs can be regulated by miRNAs. miR-34a is highly elevated in adipose tissue in obese mice and in liver in patients with steatosis. Elevated miR-34a in obesity attenuates hepatic FGF19 signaling and adipose FGF21 signaling by directly targeting the 3′ UTR of β-Klotho and Fgfr1.409,410 Downregulation of miR-34a increases the levels of the FGF21 receptor components, FGFR1 and βKlotho (and also SIRT1), resulting in FGF21/SIRT1-dependent induction of genes that favor brown fat and improved hepatic FGF21 signaling and lipid oxidation.410

In several cancers, decreased expression of miRNAs that normally suppress FGF expression have been identified as a potential mechanism for promoting cancer progression. For example, in non-small-cell lung cancer (NSCLC) miR-152 and miR-198 are downregulated, and FGF2, a direct target of miR-152, and Fgfr1, a direct target of miR-198, are overexpressed, leading to decreased apoptosis and increased proliferation and invasion.411,412 In a breast cancer cell line, miR-503 expression is suppressed by HBXIP (hepatitis B X-interacting protein). Reduced expression of miR-503, which directly targets the 3′ UTR of FGF8, results in increased FGF8 and consequent increased angiogenesis and proliferation of the breast cancer cells.413 In gastric cancer and hepatocellular carcinoma, miR-26a and miR-140-5p, respectively, are strongly downregulated, and FGF9, a direct target of both of these miRNAs is increased.414,415 Interestingly, decreased miR-140-5p and miR-99b expression has also been observed in NSCLC tissue.416,417 High FGF9 expression observed in 10% of human NSCLC specimens,418 suggests an additional pathogenic relationship between miR-140-5p and FGF9 in lung cancer. Increased expression of FGFR3, a direct target of miR-99b, was observed in human NSCLC tissue.417 Of relevance to this mechanism, FGFR3 is the obligate FGFR mediating FGF9 induced adenocarcinoma in a mouse model for lung cancer.419

Developmental, Genetic, and Pathological Functions

FGF Signaling during Peri-implantation Development

The earliest requirement for FGF signaling is in the preimplantation embryo, where Fgf4 is first expressed in the morula and later in the epiblast cells of the inner cell mass (ICM).420Fgf4 gene inactivation in mice shows that FGF4 is required for ICM proliferation and for formation of the primitive ectoderm.167,14 The receptor for FGF4 in the ICM is more controversial. Campbell et al. detected Fgfr1 (Flg) but not Fgfr2 (Bek) transcripts in mouse blastocysts,421 Orr-Urtreger et al. concluded that both Fgfr1 and Fgfr2 are expressed in the ICM and Fgfr2 is expressed in the embryonic ectoderm,422 while Guo et al. concluded that Fgfr2 is not expressed in the epiblast lineage but is highly expressed in embryonic ectoderm.423Fgfr knockout studies are also controversial (Table2(b)). Arman et al. generated a mutant allele of Fgfr2 and found defects in the outgrowth, differentiation, and maintenance of the inner cell mass424; however, it is possible that this allele functions as a dominant negative that partially interferes with Fgfr1 signaling, as mice homozygous for two other engineered null alleles of Fgfr2 survived until embryonic day 10–11115,116 (Table2(b)). Inactivation of Fgfr1 or Fgf8, which are also expressed in the blastocyst, indicates a function slightly later in development, with phenotypes affecting axis formation and mesoderm specification105,425,426 (Table2(a) and (b)). We are not aware of studies in which both Fgfr1 and Fgfr2 have been conditionally inactivated in the ICM.

FGF Signaling in Organogenesis

FGF signaling is involved almost ubiquitously throughout organogenesis.161 A key function of FGF signaling is to regulate interactions between epithelial (and mesothelial) cells and mesenchyme. A general principle that applies to branched organs (lung, salivary gland, lacrimal gland), intestine, liver, and limb bud development involves mesenchymal expressed FGFs, such as FGF10 signaling to the epithelial IIIb splice variant of FGFR1 and FGFR2.171,117,427 Reciprocal signaling, from epithelium to mesenchyme is mediated by FGFs expressed in epithelia, such as FGF8 and FGF9, which signal to mesenchymal IIIc splice variants of FGFR1 and FGFR2.428,429 However, this general principle does not apply to all tissues. For example, in the developing central nervous system, FGF8 signals as an autocrine/paracrine factor in the anterior neural primordium430 and during development of the inner ear, autocrine/paracrine FGF signaling regulates differentiation of the cochlear sensory epithelium.90,103,104

Epithelial-Mesenchymal Signaling in Limb, Lung, and Neurogenic Placode Development

FGF signaling is essential for initiation and proximal-distal growth of the limb bud (Figure 4(a)–(c)). Fgf10 is expressed diffusely in the lateral plate mesoderm.54 FGF10 was recently shown to signal to coelomic epithelium where it induces an epithelial-mesenchymal transition to generate mesenchyme in the presumptive limb fields.431 Later, FGF10 signals to overlying ectoderm to initiate formation of the apical ectodermal ridge (AER), a specialized thickening of epithelium at the tip of the growing limb that is required for proximal-distal limb growth. Inactivation of FGFR2 in the AER at different times during development results in blunt truncations of the limb117,427 (Table2(b)). FGF10 signaling to the AER activates expression of Wnt3a and expression of the downstream transcription factors SP6 and SP8, which are required for Fgf8 expression.432–434Fgf8 is first expressed as the lateral ectoderm begins to swell and then throughout the AER. Fgf4, Fgf9, and Fgf17 are subsequently expressed in the posterior AER.15,30,435,436 AER FGFs signal to distal limb mesenchyme through FGFR1 and FGFR2 to activate ETV1 and EWSR1, which are required to maintain Fgf10 expression117,437 (Table2(b)).

FGF signaling in lung development follows similar principles to that in limb development (Figure 4(d) and (e)). Fgf10 expression in mesenchyme adjacent to the sites of lung bud formation is regulated by the transcription factor Tbx4.293,438,439 FGF10 signals to FGFR2 in foregut endoderm to induce expression of Nkx2.1, a transcription factor that demarcates the lung field in the foregut.118,393,439 In the absence of FGF10, primary lung buds fail to form.54,55,440 Conditional inactivation of FGF10 or FGFR2, after initial lung bud formation, results in reduced epithelial branching.57,441 FGF10 signaling in lung epithelium is inhibited by Spry1, Spry2, and Spry4, which are expressed in the distal ductal epithelium proximal to sites of Fgf10 expression in mesenchyme.442,443 Inactivation of Spry1 and Spry2 results in increased epithelial proliferation, branching, and differentiation toward distal airway cell-types.444,445 Inactivation of Spry2 and Spry4 results in epithelial dilation and reduced branching.446 Interestingly, Fgf10 appears to be expressed in a lung mesenchymal progenitor that can give rise to parabronchial cells, vascular smooth muscle cells and lipofibroblasts.447

FGF9 has a complementary role to that of FGF10. Fgf9 is expressed in the mesothelium and epithelium.448,449 Mice lacking Fgf9 have severely hypoplastic lung development, characterized by reduced distal mesenchyme and decreased epithelial branching.42,43 The primary target of FGF9 in lung mesenchyme is FGFR1 and FGFR2.43 Most of the mesenchymal proliferation can be accounted for by FGF9 derived from the mesothelium, whereas epithelial-derived FGF9 is important for branching.44 In lung mesenchyme, an interaction with FGFR and canonical WNT signaling is essential for development. FGFR activation is required for the expression of Wnt2a and WNT/β-catenin signaling is required to maintain mesenchymal Fgfr1 and Fgfr2 expression.450 Thus WNT/β-catenin signaling functions to modulate the tissue responsiveness to FGF signals.

FGF signaling is required for the induction of neurogenic placodes.451 For example, the otic placode, which gives rise to the entire inner ear including sensory hair cells, specialized supporting cells and the innervating sensory neurons, requires direct signaling from FGF3 and FGF10 (Figure 4(f) and (g)). FGF3 is derived from the hindbrain and FGF10 is expressed in head mesenchyme. Both of these FGFs signal to pre-otic ectoderm to induce the otic placode.452,453 The size of the otic placode is initially regulated by FGF-induced proliferation and expression of the FGF pathway inhibitors, Spry1 and Spry2.454,455 FGF8 is also necessary for otic placode development; however, FGF8 functions indirectly, signaling from cranial endoderm to regulate Fgf10 expression in adjacent head mesenchyme.28

Canonical FGF Signaling within the Nervous System

Canonical FGF signaling within an epithelial or mesenchymal compartment is used in an autocrine, paracrine, or juxtacrine manner during the development of some neuronal tissues. For example, in the developing central nervous system, Fgf8 is expressed in localized organizing centers such as the anterior neural primordium (neuroepithelium) where it signals as a paracrine factor to regulate anterior–posterior patterning of the telencephalon430 and maintain the survival of telencephalic progenitors.456 Similarly, FGF signaling is important for patterning around the midbrain-hindbrain junction and around rhombomere 4.31,457–464

During development of the cochlear duct in the inner ear, Fgf20 is expressed in the prosensory epithelium and signals as an autocrine/paracrine factor to FGFR1 to regulate differentiation of the cochlear sensory epithelium103,90 (Figure 4(h)). FGF signaling is also required for neuronal migration in the cortical ventricular zone and for the translocation of astroglial cells from the ventricular zone to the cortical surface.465,466 In myelinating nerves, FGFs expressed in neurons, signal to FGFR1 and FGFR2 in oligodendrocytes to regulate myelination122 and in synaptogenesis, FGF7 and FGF22, expressed in specific neuronal populations, are required for the induction of inhibitory and excitatory synapses, respectively, in the neurons that they innervate.22,467

Canonical FGF Diffusion Controlled by ECM Interactions Regulates Development

Interactions of FGF ligands and the ECM affect receptor affinity and their diffusion through tissue.197,468 Receptor binding and diffusion through tissue can have synergistic or antagonistic effects on overall FGF signaling. An example of this is the elbow knee synostosis (EKS) mutation and multiple synostosis syndrome, both of which result from missense mutations in Fgf9469,470 (discussed under Heritable disease mutations below). The Fgf9EKS mutation reduces its affinity for heparan sulfate proteoglycan and increases diffusion of FGF9 through developing joint tissue. This increases FGF9 signaling distally in the presumptive joint space and results in failure to form a joint cavity. In lacrimal gland development, Fgf10 is expressed in perioccular mesenchyme. Lacrimal gland development was impaired in mice in which the mesenchymal biosynthetic enzyme for glycosaminoglycans, UDP-glucose dehydrogenase, or enzymes required for heparan sulfation, NDST1 and NDST2, were inactivated.471 Phenotypic analysis indicated that these mutations resulted in increased FGF10 diffusion, decreased local concentrations, and defective epithelial branching into the FGF10-deficient mesenchyme.

Loss-of-Function Fgf and Fgfr Mutations in Mice

Fgf1 Subfamily

FGF1 and FGF2 appear to have relatively minor roles in embryonic development but are important regulators of the injury response.3,5,6,181,472–475Fgf1 expression in adipose tissue is induced in response to a high fat diet and mice lacking Fgf1 develop a diabetes phenotype when placed on a high fat diet4 (Table2(a)). Mice lacking Fgf2 also develop normally, but show reduced vascular tone, impaired cardiac hypertrophy, reduced cortical neuron density, and defects in response to cutaneous, pulmonary, or cardiac injury3,5,7,181,473,476–478 (Table2(a)).

Fgf4 Subfamily

Fgf4 knockout mice die at early embryonic stages due to impaired proliferation of the blastocyst inner cell mass14 (Table2(a)). Conditional inactivation of Fgf4 in limb bud apical ectodermal ridge cells identified redundancy with Fgf8 for survival of cells located distal to the apical ectodermal ridge.292 Similarly, Fgf4 and Fgf8 show redundancy in somitogenesis and conditional loss of both genes results in loss of presomitic mesoderm and its premature differentiation.29 Genetic analysis in domestic dog breeds identified a retrovirus-mediated duplication of Fgf4 associated with a short-legged phenotype resembling chondrodysplasia.16Fgf5 and Fgf6 knockout mice are viable. Inactivation of the Fgf5 gene results in a long hair phenotype in angora mice and in engineered knockouts18 (Table2(a)). Fgf6 knockout mice have defects in muscle regeneration19 and the combined loss of Fgf2, Fgf6 and the Mdx gene leads to severe dystrophic changes with reduced formation of new myotubes in regenerating muscle20 (Table2(a)).

Fgf7 Subfamily

Fgf3 knockout mice are viable, but have phenotypes that include inner ear agenesis and dysgenesis, microtia, and microdontia12,56,479 (Table2(a)). Fgf7 knockout mice, which are also viable, have impaired hair and kidney development23,24 and defects in the formation of neuronal synapses22 (Table2(a)). Fgf10 knockout mice die shortly after birth. Fgf10 is critical for epithelial-mesenchymal interactions necessary for the development of epithelial components of multiple organs including the limb, lung, salivary glands kidney, and white adipose tissue54,55,58,480 (Table2(a)). Fgf22 knockout mice are viable, but like Fgf7 have defects in synaptogenesis.467 Interestingly, Fgf22 knockout mice have defects in the formation of excitatory synapses, while Fgf7 knockout mice have defects in inhibitory synapses. Consistent with this, Fgf7 and Fgf22 knockout mice are either resistant to or prone to epileptic seizures, respectively22,95 (Table2(a)).

Fgf8 Subfamily

Fgf8 knockout mice lack all embryonic mesoderm and endoderm-derived structures and die by embryonic day 9.5.426 Subsequent analysis revealed that FGF8 is required for Fgf4 expression in the primitive streak resulting in impaired migration away from the primitive streak.32 Conditional inactivation of Fgf8 identified additional roles in limb bud development and organogenesis15 (Table2(a)). Fgf17 knockout mice are viable, but show impaired hindbrain development and a selective reduction in the size of the dorsal frontal cortex31,84 (Table2(a)). Fgf18 knockout mice die shortly after birth. Fgf18 has essential roles in the development of mesenchymal components of multiple organs including the skeleton, lung, and brain.85–88,481 Late in embryonic development FGF18 is involved in lung alveolar development88 (Table2(a)).

Fgf9 Subfamily

Mice lacking Fgf9 have hypoplastic lungs, sex reversal and impaired survival of male germ cells, impaired skeletal growth, impaired cardiomyocyte growth, impaired growth of the small intestine and cecum, and defects in inner ear development41,42,45–49,482 (Table2(a)). Mice lacking Fgf16 are viable but have decreased proliferation of cardiomyocytes in embryos and neonatal mice82,83 and enhanced cardiac hypertrophy and fibrosis in response to angiotensin II as adults81 (Table2(a)). Mice lacking Fgf20 are viable but lack guard hairs, have impaired differentiation of sensory cells in the cochlea, small kidneys, and defects in tooth development.40,90–92Fgf9 and Fgf20 show redundancy in their requirement for kidney development, where they function to maintain the stemness of cap mesenchyme progenitor cells40 (Table2(a)).

Fgf15/19 Subfamily

Mice lacking Fgf15 develop normally until E10.5, but then gradually die due to variably penetrant defects in morphogenesis of the cardiac outflow tract.76,483 At postnatal stages, intestinal FGF15/19 functions to regulate hepatic bile acid synthesis78 (Table2(a)). Following partial hepatectomy, mice lacking Fgf15 have severe defects in regeneration; showing reduced or delayed expression of early response genes and transcription factors that regulate the cell cycle.79,484 Mice lacking Fgf21 are phenotypically normal under homeostatic conditions. However, when fasted, Fgf21 expression is rapidly upregulated in the liver,485–487 and in response to fasting, mice lacking Fgf21 showed increased lipolysis93 and an impaired adaptation to a ketogenic diet.488 Subsequent studies showed that FGF21 is an upstream effector of adiponectin in white adipocytes and that adiponectin mediates many of the systemic effects of FGF21 on energy metabolism and insulin sensitivity in liver and skeletal muscle489,490 (Table2(a)). Fgf23 knockout mice survive until birth, but then gradually die.100Fgf23 knockout mice and mice in which FGF23 is inhibited with antibodies show hyperphosphatemia and increased levels of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D). Fgf23, which is expressed in osteocytes, signals to the kidney where it induces the vitamin D activating enzyme Cyp27b1 and inhibits Cyp24, which inactivates vitamin D. Injection of recombinant FGF23 rapidly reduces circulating parathyroid hormone (PTH) and levels of the sodium-dependent phosphate co-transporters, NPT2a and NPT2c, in the kidney, resulting in phosphaturia.491,492 FGF23 has also been shown to signal directly to cardiomyocytes to induce hypertrophy,493 and increase myocyte Ca2+ levels and cardiac contractility494 (Table2(a)).

Fgf11 Subfamily

Mice lacking Fgf13, though viable, have defects in neuronal migration and deficits in learning and memory70 (Table2(a)). Mice lacking Fgf14 have paroxysmal dyskinesia, movement disorders, and impaired spatial learning71,72,74 (Table2(a)). FGF14 and other members of the iFGF family interact with the cytoplasmic carboxy terminal tail of voltage gated sodium channel (Nav) α subunits69,263,264,495–498. FGF13 was also found to interact directly with and stabilize microtubules70 and bind junctophilin-2, a protein that regulates L-type Ca2+ channels.499

Mice lacking Fgf14 have defective neuronal firing due to altered Nav channel physiology69,72,73,500 (Table2(a)). Inactivation of Fgf14 in adult mouse Purkinje neurons results in loss of spontaneous firing and deficits in coordination,501 suggesting that FGF14 functions as a physiological regulator of Nav channels in vivo. Interestingly, FGF14 interactions with Nav channels may be regulated downstream of glycogen synthase kinase 3 providing a pathway that could link intercellular signaling and neuronal excitability.498,502–504 Consistent with phenotypes seen in Fgf14 deficient mice, mutations in Fgf14 in humans result in a progressive spinocerebellar ataxia syndrome (SCA27)505,506 (see below).

Fgfr Family

Most embryos lacking both alleles of Fgfr1 do not survive past embryonic day 8.5. Analysis of earlier stages of development shows that Fgfr1-null embryos are smaller, but do initiate gastrulation (mesoderm formation), have impaired mesoderm migration, but fail to initiate somitogenesis105,425 (Table2(b)). Mice lacking Fgfr2 survive until embryonic day 10–11. These embryos fail to form a functional placenta and do not form limb buds115,116 (Table2(b)). As discussed above, another presumed null allele of Fgfr2 that dies earlier in development may have dominant negative effects on other Fgfrs, uncovering potential redundancies and resulting in earlier and more severe phenotypes.424 At later stages of development, several studies have demonstrated redundant function of Fgfr1 and Fgfr2 in organogenesis.43,49,121,507

Mice lacking Fgfr3 are viable. In the absence of Fgfr3, the most prominent phenotype is skeletal overgrowth127,128 (Table2(b)). However, close examination of Fgfr3 null mice revealed defects in inner ear development resulting in sensorineural hearing loss,127,129,508 decreased growth of the cerebral cortex and telencephalon,509 reduced numbers of differentiated oligodendrocytes,130 and fewer intestinal crypts with impaired paneth cell differentiation.510

Mice lacking Fgfr4 are viable and overtly healthy.131 Although, they have normal liver histology and regenerative response to partial hepatectomy, mice lacking Fgfr4 exhibit depleted gallbladders, elevated bile acid reserves, elevated bile acid excretion, increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, insulin resistance, and hypercholesterolemia143,511 (Table2(b)). The role of FGFR4 in tumorigenesis is controversial. In one study, mice lacking Fgfr4 have increased susceptibility to chemically induced hepatocellular carcinoma, indicating that FGFR4 may function as a tumor suppressor in the liver.512 However, in a second study, FGFR4 was found to be required for FGF15/19 induced hepatocellular carcinoma and mice lacking Fgf15 are resistant to chemically induced hepatocellular carcinogenesis.257,513 FGFR3 and FGFR4 show redundant function in the regulation of vitamin D levels and in regulating alveolar septation131,140,142 (Table2(b)). FGFR1 and FGFR4 show redundant function in phosphate homeostasis141 (Table2(b)).

Heritable Disease Mutations in FGFs and FGFRs in Humans and Other Mammals

FGF4 Subfamily

Chondrodysplasia is a short-legged phenotype that defines at least 19 dog breeds. The expression of a recently acquired expressed retrogene encoding Fgf4 is strongly associated with the chondrodysplasia phenotype16 (Table3(a)). Genome-wide association studies (GWAS) in dogs identified a mutation in Fgf5 that is associated with hair length518 (Table3(a)). A missense mutation in Fgf5 was also found in longhaired cats and the Angora mouse mutant18,519 (Table3(a)).

Table 3
Heritable Mutations in FGFs Associated with Disease in Humans (and Mice)
(a) Heritable mutations in FGFs associated with disease in humans (and other mammals)(b) Heritable mutations in FGFRs associated with disease in humans (and other mammals)
Gene NameMutationAssociated DiseaseSelected References
FGF1
FGF2
FGF3HaploinsufficiencyOto-dental syndrome479,514–517
Missense/frameshift mutationMichel aplasia (inner ear agenesis, microtia, and microdontia), LAMM syndrome (labyrinthine aplasia, microtia, and microdontia)
FGF4Retroviral overexpressionChondrodysplasia (dogs)16
FGF5Deletion mutationAngora mutation (mice)18,518–521
Missense/splice-site mutationCoat variability (pure bred dogs)
Missense/insertion/deletion mutationLong-hair (cats)
FGF6
FGF7PolymorphismChronic obstructive pulmonary disease risk522
FGF8Nonsense mutationHypogonadotropic hypogonadism523–528
Missense mutationCleft lip and palate, Holoprosencephaly, craniofacial defects, Hypothalamo-pituitary dysfunction, Kallman syndrome type 6
Hypomorphic alleleLack of hypothalamic GnRH neurons
FGF9Missense mutationMultiple synostoses syndrome, Elbow knee synostosis (mice)469,470,529
Promoter polymorphismSertoli cell-only syndrome
FGF10Nonsense mutationAplasia of lacrimal and salivary glands, LADD syndrome530–534
PolymorphismExtreme myopia
FGF11
FGF12Missense mutationBrugada syndrome (candidate gene)535
FGF13Nonsense mutationBörjeson-Forssman-Lehmann syndrome (BFLS) (candidate gene)536,537
Position effectX-linked congenital generalized hypertrichosis
FGF14Missense mutation/translocation/deletionSpinocerebellar ataxia 27 (SCA27)505,538,539
FGF15/19
FGF16Nonsense mutationMetacarpal 4–5 fusion540,541
FGF17Missense mutationHypogonadotropic hypogonadism542
FGF18PolymorphismNonsyndromic cleft lip and palate524
FGF20PolymorphismParkinson disease risk40,543–545
Missense mutationKidney agenesis (human)
FGF21PolymorphismMacronutrient intake, obesity, and type-2 diabetes risk546–548
FGF22
FGF23Missense mutationAutosomal dominant hypophosphataemic rickets, Familial hyperphosphatemic tumoral calcinosis242,549–555
PolymorphismCardiac abnormality risk in Kawasaki syndrome (increased serum FGF23)
FGFR1Missense mutationPfeifer syndrome, Kallman syndrome 2, Normosmic idiopathic hypogonadotropic hypogonadism, Split hand/foot malformation, Osteoglophonic dyplasia, Harstfield syndrome556–566
Missense or frameshift mutationJackson-Weiss syndrome
FGFR2Missense mutationApert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Pfeifer syndrome, Non syndromic craniosynostosis, Bent bone dysplasia567–579
DeletionSaethre-Chotzen-syndrome
FGFR3Missense mutationHypochondroplasia, Achondroplasia, Thanatophoric dysplasia, Coronal craniosynostosis, Crouzon syndrome with acanthosis nigricans, Platyspondylic lethal skeletal dysplasia, Achondroplasia with developmental delay, and acanthosis nigricans (SADDAN), Muenke syndrome, Saethre-Chotzen-syndrome, CATSHL syndrome, Mouse models for aberrant osteogenesis, Achondroplasia, Muenke syndrome288,574,580–611
FGFR4OverexpressionFacioscapulohumeral muscular dystrophy612–614
Missense mutationGallstone disease
PolymorphismBronchopulmonary dysplasia, Neonatal respiratory distress syndrome
FGFRL1Frameshift mutationCraniosynostosis, Antley–Bixler-like syndrome615–617
DeletionWolf-Hirshchhorn syndrome

FGF7 Subfamily

Michel aplasia is a unique autosomal recessive syndrome characterized by type I microtia, microdontia, and profound congenital deafness associated with a complete absence of inner ear structures. Michel aplasia is caused by mutations in FGF3514 (Table3(a)). Human chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by chronically poor airflow. Genome wide association studies identified single nucleotide polymorphisms in FGF7 significantly associated with COPD522 (Table3(a)). Aplasia of the lacrimal and salivary glands (ALSG) is an autosomal dominant congenital anomaly characterized by aplasia, atresia, or hypoplasia of the lacrimal and salivary systems. Lacrimo-auriculo-dento-digital (LADD) syndrome is an autosomal-dominant multiple congenital anomaly disorder characterized by aplasia, atresia, or hypoplasia of the lacrimal and salivary systems, cup-shaped ears, hearing loss, and dental and digital anomalies. Both ALSG and LADD syndromes are caused by FGF10 mutations530,531 (Table3(a)). Severe myopia (nearsightedness) is associated with a single nucleotide polymorphism in FGF10532 (Table3(a)). In strong support of an FGF10-FGFR2b signal, loss-of-function mutations in FGFR2 are also a cause of LADD syndrome (see below).

FGF8 Subfamily

Nonsense mutations in FGF8 and destabilizing missense mutations in FGF17 were found in familial hypogonadotropic hypogonadism with variable degrees of gonadotropin-releasing hormone deficiency and olfactory phenotypes523,542 (Table3(a)). Cleft lip and/or palate (CLP) appear when the two halves of the palatal shelves fail to fuse completely. A missense mutation in FGF8 which is predicted to cause loss-of-function by destabilizing the N-terminal structure of the protein (important for FGFR binding affinity and specificity) was found in a patient with CLP524 (Table3(a)).

FGF9 Subfamily

An autosomal dominant missense mutation in FGF9 was found in patients with multiple synostosis syndrome (SYNS). The mutation leads to significantly impaired FGF9 receptor binding, reduced chondrocyte proliferation, increased osteoblast differentiation, and matrix mineralization resulting in joint fusions (synostosis)470 (Table3(a)). An autosomal dominant missense mutation in Fgf9 is also responsible for the mouse mutant, elbow knee synostosis (EKS), showing elbow and knee joint synostosis, and premature fusion of cranial sutures. The mutation prevents homodimerization of the FGF9 protein, resulting in reduced affinity for heparin. Even though receptor binding affinity is decreased by this mutation, the EKS phenotype resembles that of a gain-of-function mutation. The reduced affinity for heparan sulfate results in increased diffusion of FGF9 through tissue, leading to ectopic FGF9 signaling and repression of joint and suture development469 (Table3(a)). Overexpression of an activated form of FGFR1 in developing chondrocytes results in a similar joint fusion phenotype.618

Sertoli cell–only syndrome (SCOS) patients commonly have atrophic testes, azoospermia, and hypogonadism. FGF9 is expressed in the Leydig cells of the testis and FGF9 expression is significantly decreased in patients with SCOS. A promoter mutation in FGF9 results in weak promoter activity and the resulting low expression of testicular FGF9529 (Table3(a)). Metacarpal 4–5 fusion is a rare congenital malformation of the hand characterized by the partial or complete fusion of the fourth and fifth metacarpals in humans. Nonsense mutations in FGF16 are associated with X-linked recessive metacarpal 4–5 fusion, indicating the involvement of FGF16 in the fine tuning of skeletal development540,619 (Table3(a)). Parkinson disease is a common neurodegenerative disorder resulting in the inability to control movement. The disease has been attributed to the severe loss of dopaminergic neurons within the substantia nigra. The significant correlation of Parkinson disease with single nucleotide polymorphisms in FGF20 indicates that the genetic variability of FGF20 may be a risk factor for Parkinson disease543–545 (Table3(a)). A frameshift mutation in FGF20 also results in bilateral renal agenesis in humans, indicating that FGF20 is essential for metanephric kidney development40 (Table3(a)).

FGF15/19 Subfamily

Dietary intake of macronutrients has been associated with risk of obesity and type 2 diabetes. Polymorphisms in FGF21 are potentially associated with macronutrient consumption and risk of obesity and type 2 diabetes in humans546–548 (Table3(a)). Mutations resulting in either gain- or loss-of-function of FGF23 result in human disease620 (Table3(a)). Autosomal dominant hypophosphatemic rickets (AHDR) is caused by gain-of-function mutations in FGF23.242 Tumors that over-produce FGF23 also cause tumor-induced osteomalacia (TIO), which is a paraneoplastic disease characterized by renal phosphate wasting and resulting hypophosphatemia.621 Reduced FGF23 signaling also causes familial tumoral calcinosis (FTC); a disease characterized by ectopic calcification and hyperphosphatemia549,550 (Table3(a)). Kawasaki syndrome (KS) is a childhood vascular inflammatory disease with an increased risk of developing subsequent cardiac abnormalities. Thirty three percent of patients examined were found to have a polymorphism in FGF23 and elevated serum levels of FGF23.551,552FGF23 polymorphisms were significantly associated with cardiac abnormalities (Table3(a)).

FGF11 Subfamily

Brugada syndrome (BrS) is a potentially life-threatening inherited cardiac arrhythmia. FGF12 (FHF1) is the major intracellular FGF expressed in the human ventricle. A single missense mutation in FGF12 in Brugada syndrome patients reduces binding to the voltage gated sodium channel (NaV1.5) C-terminus, resulting in reduced Na+ channel current density and availability without affecting Ca2+ channel function535 (Table3(a)). Börjeson–Forssman–Lehmann syndrome (BFLS) is an X-linked mental retardation syndrome. A duplication breakpoint identified in a patient with BFLS maps near the FGF13 (FHF2) gene at Xq26.3. This disease association and the high expression of FGF13 in brain and skeletal muscle makes it a good candidate gene for BFLS536 (Table3(a)). X-linked congenital generalized hypertrichosis is an extremely rare condition of hair overgrowth on different body sites. This disease maps to Xq24-27 and a large interchromosomal insertion at Xq27.1 co-segregates with the disease. In patients with this disease, FGF13 expression is significantly decreased throughout the outer root sheath of affected hair follicles, suggesting a role for FGF13 in hair follicle growth and in the hair cycle537 (Table3(a)). Spinocerebellar ataxias (SCAs) are neurodegenerative disorders with multiple genetic etiologies. SCA27 is characterized by early onset tremor, dyskinesia, and slowly progressive cerebellar ataxia. SCA27 is caused by missense, translocation, or deletion mutations in FGF14506,622,623 (Table3(a)). Loss of binding of the mutant FGF14 protein to Nav channel α subunits and instability of the mutant protein are thought to be the primary factors leading to this disease505,624 (Table3(a)).

FGFR1

Gain-of-function missense mutations in FGFR1 are found in several craniosynostosis syndromes including Pfeiffer syndrome, Jackson-Weiss syndrome, Muenke syndrome, and osteoglophonic dysplasia556,557,567,625,626 (Table3(a)). These are autosomal dominant syndromes that affect cranial suture closure and have various additional skeletal and soft tissue phenotypes. Interestingly, Pfeiffer syndrome, Jackson-Weiss syndrome, and Muenke syndrome phenotypes also can be caused by activating mutations in FGFR2 (Pfeiffer) or FGFR3 (Pfeiffer, Muenke), suggesting possible redundant or parallel function of these FGFRs in skeletal development.568,626

Loss-of-function missense mutations have also been identified in FGFR1 as a cause of Kallmann syndrome 2 (hypogonadotropic hypogonadism 2) with or without anosmia558,559 (Table3(a)). Dominant or recessive mutations in FGFR1 that are likely loss-of-function are found in Harstfield syndrome (holoprosencephaly and ectrodactyly, with or without cleft lip and palate)560 (Table3(a)).

FGFR2

Autosomal dominant gain-of-function missense mutations, deletions, and insertions in FGFR2 result in Apert syndrome, Crouzon syndrome, non syndromic craniosynostosis syndrome, Saethe-Chotzen syndrome, Pfeiffer syndrome, and Jackson-Weiss syndrome567–574,627,628 (Table3(b)). Pfeiffer and Jackson-Weiss syndromes also result from mutations in FGFR1, as described above. All of these syndromes have in common synostosis of at least one cranial suture; many of these syndromes also affect the appendicular skeleton and other organs. For example, the Crouzon syndrome mutation, FGFR2C342Y, affects the shape of the brain, but not its overall volume.629

The biochemical consequences of the classic Apert syndrome mutations (FGFR2S252W and FGFR2P253R) and a relatively rare Alu element insertion, or deletion of an intronic splicing element in the intron between exon 8 (IIIb) and exon 9 (IIIc) of FGFR2 is to change the ligand binding affinity to an extent that mesenchymal ligands such as FGF10 are able to activate mesenchymal splice variants of FGFR2575,630 (Figure 5(b)). Importantly, the Apert mutations all remain ligand dependent. The Alu element insertion acts by disrupting splicing to exon 9, encoding the IIIc splice variant (Figure 1(b)), leading to alternative mesenchymal misexpression of exon 8, encoding the IIIb splice variant. The missense mutations directly affect ligand affinity for the mutant receptor.575,576,631–638

Figure 5
Activating mutations in FGFRs in heritable and acquired disease. (a) Wild type FGFR-FGF-HS complex. (b) Missense mutations in the linker between immunoglobulin-like domain II and III affect the affinity and specificity of the receptor. The Apert syndrome mutation, S252W, allows FGF10 to activate the IIIc splice variant of FGFR2. (c) Missense mutations in the transmembrane domain, as seen in the G380R Achondroplasia mutation, weakly activates the receptor in a ligand dependent manner by impeding receptor internalization. (d) The strongly activating ligand independent mutation, R248C, in Thanatophoric dysplasia, type I, causes constitutively active disulfide linked receptor dimers. (e) Mutations in the tyrosine kinase domain, as seen in the K640E Thanatophoric dysplasia, type II mutation, are often ligand independent and result in receptor autophosphorylation and signaling from intracellular sites such as the endoplasmic reticulum.

Bent bone dysplasia, which is a perinatal lethal skeletal dysplasia characterized by osteopenia, craniofacial dysmorphology and bent bones, results from mutations in FGFR2 that decrease plasma membrane signaling without affecting nuclear localization of the mutant receptor577 (Table3(b)). The consequence of this mutation is enhanced nucleolar occupancy of the receptor at the ribosomal DNA promoter where it activates rDNA transcription.639

Loss-of-function mutations in FGFR2 are seen in lacrimo-auriculo-dento-digital (LADD) syndrome, which is characterized by lacrimal-duct aplasia, dysplastic ears, hearing loss, small teeth, and digital malformations531 (Table3(b)). Mutations in FGFR2 disrupt the catalytic pocket of the tyrosine kinase domain resulting in reduced substrate binding and reduced tyrosine kinase activity.640,641 Other individuals with LADD syndrome have inactivating mutations in FGF10 (see above), a ligand for FGFR2b,533 or a missense mutation in FGFR3531 (Box 2).

BOX 2 Developing a Pharmacological Treatment for Achondroplasia

Achondroplasia is caused by a ligand dependent autosomal dominant mutation in FGFR3. Because the disease phenotypes form during the prepubertal years when bones are actively growing, it was anticipated that direct or indirect inhibition of the FGFR3 signaling pathway could form the basis of a therapy for Achondroplasia.738 The direct inhibition of the FGFR3 kinase has thus far not succeeded in vivo, possibly because of difficulties in achieving therapeutic levels of FGFR3 kinase inhibitors in the avascular growth plate. However, over the past 20 years, other therapies have been aimed at indirectly augmenting skeletal growth or indirectly suppressing FGFR3 signaling. One of the first therapies to be evaluated was the use of human growth hormone; however, no long-term benefit was observed.581,739 More recently, it was discovered that C-type natriuretic peptide (CNP) signaling through its receptor, natriuretic peptide receptor 2 (guanylate cyclase B) in chondrocytes, inhibits the MAPK signaling pathway at the level of RAF1, to regulate skeletal growth. Overexpression of CNP in mice or humans results in skeletal overgrowth through attenuation of FGFR3 signaling.740,741 BMN-111, a CNP agonist with an extended half-life, was found to normalize skeletal growth in a mouse model for Achondroplasia604,742,743 and this drug is currently being evaluated in a clinical trial for the treatment of Achondroplasia.

Other indirect strategies involve the use of a soluble FGFR3 extracellular domain (sFGFR3) to interfere with endogenous FGFR3 signaling by binding FGF ligands (FGF9 and FGF18) that normally are required to activate the receptor during postnatal skeletal development.47,85–87,744 In a mouse model for Achondroplasia,132 subcutaneous injections of recombinant sFGFR3 throughout the growth period normalized skeletal growth and decreased mortality without having any apparent toxic side effects. Several inhibitory antibodies have also been developed to target the FGFR3 extracellular domain for potential cancer therapeutics, but these have not yet been evaluated for treatment of Achondroplasia.745–747

Statins (drugs that inhibit cholesterol biosynthesis) were recently identified through a screen for drugs that could improve chondrogenic differentiation of induce pluripotent stem cells (iPSCs) derived from patients with Thanatophoric dysplasia.748 Treatment of a mouse model for Achondroplasia132 with Rosuvastatin, which is one of the statin drugs, increased anteroposterior skull length and the lengths of the ulnas, femurs and tibiae.748 Although the mechanism is poorly defined, statin treatment was found to increase degradation of the mutant FGFR3.

FGFR3

Hypochondroplasia, Achondroplasia, Thanatophoric dysplasia, and Platyspondylic lethal skeletal dysplasia are autosomal dominant disorders characterized by short-limbed dwarfism.580,581 These syndromes are caused by gain-of-function missense mutations in FGFR3. Among the mutations, the G380R mutation in the transmembrane domain of FGFR3 activates the receptor in a ligand dependent manner resulting in Achondroplasia, the most common form of skeletal dwarfism in humans (Figure 5(c)). By contrast, in the lethal skeletal dysplasia syndrome, Thanatophoric dysplasia, type I or type II, the R248C mutation in the extracellular domain or the K650E mutation in the intracellular domain activates FGFR3 in a ligand independent manner288,582–595,642,643 (Figure 5(d) and (e)). Muenke syndrome (Muenke nonsyndromic coronal craniosynostosis) is an autosomal dominant disorder characterized by synostosis, macrocephaly, midfacial hypoplasia, and hearing loss caused by gain-of-function missense mutations in FGFR3596–602,644 (Table3(b)). Mouse models for aberrant osteogenesis, Achondroplasia, and Muenke syndrome have been developed603–606 (Table3(b)). Two craniosynostosis syndromes, Crouzon syndrome and Saethe-Chotzen syndrome, can result from mutations in FGFR2 or FGFR3, suggesting overlapping or redundant functions of these FGFRs.592,607,608

Loss-of-function missense mutations, that likely function through a dominant negative mechanism, have been identified in FGFR3 as the cause of CATSHL syndrome (autosomal dominant syndrome characterized by camptodactyly, tall stature, and hearing loss)609 (Table3(b)). A recessive loss-of-function mutations in FGFR3 has also been identified in two siblings with tall stature, severe skeletal abnormalities, camptodactyly, arachnodactyly, scoliosis and hearing impairment.610 A similar disease, spider-lamp syndrome in sheep, is characterized by abnormally long limbs, kyphoscoliosis, malformed ribs and sternebrae, hooked or ‘Roman’ nose, lack of body fat, and muscular atrophy.645,646 This disease is associated with a missense mutation in the FGFR3 tyrosine kinase domain coupled with poorly described interactions with other genetic and environmental factors.

A mutation in FGFR3 has also been associated with LADD syndrome (Table3(b)). Although the function of the mutation, localized to the conserved proximal tyrosine kinase domain (TK1, Figure 1(b)), is not known, the phenotypes of affected individuals are distinct from both known gain-of-function mutations causing chondrodysplasia syndromes and loss-of-function mutations resulting in skeletal overgrowth and hearing loss.531,581,609

FGFR4

Facioscapulohumeral muscular dystrophy is an autosomal dominant disorder, ranging from mild dysfunction to severe respiratory failure. Overexpression of FGFR4 in muscle and surrounding connective tissue and overexpression of FGF1 and FGF2 on the sarcolemma may be associated with this disease.612 Bronchopulmonary dysplasia, characterized by impaired alveolar development and inflammation is the most common chronic lung disease resulting from premature birth. Neonatal respiratory distress syndrome is a pulmonary disease affecting preterm neonates. A single nucleotide polymorphism (I > V) in exon 10 of FGFR4 is a potential risk factor for these diseases613 (Table3(b)). The common allelic variant (G388R) in FGFR4 is associated with breast cancer progression and increased insulin secretion and risk of diabetes.647

FGFRL1/FGFR5

Antley–Bixler syndrome is a disorder characterized by craniosynostosis, radio-ulnar synostosis, and genital abnormalities. A C-terminal frameshift mutation in FGFRL1 was found in one patient with this disease. The mutation results in preferential localization of the mutant protein to the plasma membrane, compared to the localization of wild-type FGFRL1 to vesicular structures and the Golgi complex615 (Table3(b)). Wolf-Hirschhorn syndrome (WHS) is a disease resulting in growth delay, craniofacial dysgenesis, developmental delay, and epilepsy. Micro deletions containing FGFRL1, but not the WHSC1 gene have craniofacial features resembling that seen in WHS patients, suggesting that FGFRL1 could be a possible candidate gene616 (Table3(b)). Analysis of a new null allele for Fgfrl1 in mice revealed skeletal and other defects that resemble WHS.617

FGFs and FGFRs: Mutations and Expression in Cancer

Deregulation of FGF signaling pathways have been implicated in many types of human and animal cancers. Deregulation can occur at the level of gene/protein expression of ligands or receptors, which can result from changes in transcriptional activity or gene amplification. Deregulation can also result from mutations in FGF ligands, receptors, or downstream signaling pathways. A more detailed discussion of FGF signaling in cancer can be found in a review by Turner and Grose.152

FGF Family

Mechanisms of FGF ligand activation involve aberrant expression, gene amplification leading to overexpression, or mutations that increase diffusion through tissue or increase affinity for FGFRs (Table4(a)). Aberrant expression and mutations in FGFs have been observed in many human cancers.163,418,649–653,656–662,664,665,667–669,671,672 Gene amplification of FGFs has also been observed.648,654 Overexpression and gene amplification leads to excessive FGF signaling, which can result in cancer initiation or progression. In contrast to the oncogenic properties of many FGF ligands, in some human colon and endometrial cancers that lack β-catenin activation, homozygosity for loss-of-function somatic mutations in FGF9 have been observed. Additionally, mice lacking Fgf22 have normal skin, but show increased papilloma formation in a DMBA/TPA induced tumorigenesis model96 (Table4(a)). These examples show that in at least some cases, FGF signaling can also function to suppress tumorigenesis, possibly by promoting cell differentiation.664 Single nucleotide polymorphisms in FGF23 have been associated with an increased risk of prostate cancer, although it remains unclear whether polymorphisms result in gain- or loss-of-function.673

Table 4
Acquired and Heritable Mutations in FGFs and FGFRs in Malignancy
Gene NameMutationType of CancerSelected References
(a) Contributions of FGFs to malignancy (in vivo)
FGF1AmplificationOvarian cancer648
FGF2Over expressionBladder cancer, Prostate cancer, Small cell lung carcinoma, Melanoma, Hepatocellular carcinoma649–653
FGF3AmplificationBreast cancer654
FGF4AmplificationBreast cancer655
FGF5Over expressionGlioblastoma656
FGF6Over expressionProstate cancer657
FGF7Over expressionLung adenocarcinoma658
FGF8Over expressionBreast cancer, Prostate cancer, Hepatocellular carcinoma, Colorectal cancer659–663
Fgf9Frameshift/missense/nonsense mutationColorectral and endometrial carcinomas418,664–666
Over expressionNon small cell lung cancer
FGF10Over expressionBreast carcinomas, Prostate cancer667,668
FGF15/19Over expressionProstate cancer, Hepatocellular carcinoma162,163,513,669,670
FGF16Over expressionOvarian cancer671
FGF17Over expressionProstate cancer, Hepatocellular carcinoma660,672
FGF18Over expressionHepatocellular carcinoma660
FGF22KnockoutSuppresses skin papilloma (in mice)96
FGF23PolymorphismIncreased risk of prostate cancer673
(b) Contributions of FGFRs to malignancy (in vivo)
FGFR1AmplificationSmall cell lung cancer, Squamous cell lung cancer, Breast cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Tongue squamous cell carcinoma191,192,674–682
Missense mutationMelanoma, Pilocytic astrocytoma683
TranslocationLeukemia, Lymphoma, Alveolar rhabdomyosarcoma, Glioblastoma, Myeloproliferative syndrome (fusion with CUX1, FGFROP2, FIM, RANBP2/NUP358, SQSTM1, TRP, ZNF198)681,684–692
Over expressionGlioblastoma656
FGFR2AmplificationGastric cancer, Breast cancer693–697
Missense mutationEndometrial carcinoma, Gastric cancer693,698
TranslocationCholangiocarcinoma699–702
FGFR3Missense mutationGastric cancer, Colorectal cancer, Breast cancer, Endometrial carcinoma, Urothelial carcinoma, Bladder tumor, Skin tumor, Myeloma608,693,703–706
Mis-localizationBrest cancer707
TranslocationMyeloma, Squamous cell lung cancer, Bladder cancer, Glioblastoma, Lymphoma708–712
Over expressionBreast cancer, Colon cancer (FGFR3c)713,714
FGFR4Missense mutationRhabdomyosarcoma, Adenoid cystic carcinoma, Breast Cancer (resistance to adjuvant therapy)715–717
Over expressionOvarian cancer, hepatocellular carcinoma256,718,719

FGFR Family

FGFRs can be activated by gene amplification leading to receptor overexpression, by activating mutations (Figure 5), or by translocations resulting in activating gene fusions.720,721FGFR1 gene amplification has been identified in 20% of lobular breast cancer, in 3% of lung adenocarcinomas and 21% of squamous cell lung cancer.192,674,722,723FGFR1 or FGFR2 was amplified in 47% of hormone resistant prostate cancers.724FGFR3 was amplified in 3% of bladder cancers.725FGFR4 overexpression (65% of cases) and amplification (30% of adult tumors) were observed in adrenocortical tumors and amplification was associated with worse prognosis.726FGFR4 amplification was also found in 10% of primary breast tumors.727 Thus, FGFR gene amplification may be pathogenic in a large fraction of some of the major cancer subtypes (Table4(b)).

Oncogenic gene fusions that activate the FGFR tyrosine kinase domain is a relatively common occurrence in myeloproliferative syndrome, glioblastoma, bladder, lung, breast, thyroid, oral, and prostate cancers.193,684 In the 8p11 myeloproliferative syndrome (myeloid and lymphoid neoplasms with FGFR1 abnormalities), FGFR1 translocations result in at least 10 fusion proteins with N-terminal dimer forming partners fused to the C-terminal FGFR1 tyrosine kinase domain684 (Table4(b)). FGFR1–FGFR3 are also closely linked to the transforming, acidic coiled-coil containing protein 1–3 genes (TACC1–TACC3).236FGFR1 and TACC1 or FGFR3 and TACC3 gene fusions have been identified in glioblastoma, non–small cell lung cancers (NSCLC), bladder cancer, multiple myeloma, and lung squamous cell carcinoma685,708,728–730 (Table4(b)). These gene fusions can generate constitutively active FGFR kinase domains that are localized to the mitotic spindle. FGFR2 translocations resulting in gene fusions with AHCYL1, BICC1, MGEA5, AFF3, and TACC3 have been identified in subtypes of cholangiocarcinoma.699–701 Gene fusions can also result in 3′ UTR deletion, allowing escape from regulation by microRNAs, as seen in an FGFR3-TACC3 fusion in multiple myeloma729 (Table4(b)).

Activation of FGFR3 in multiple myeloma can occur through several mechanisms and is thought to contribute to the neoplastic transformation. A common translocation between the immunoglobulin heavy chain locus on chromosome 14q32 and the FGFR3 and MMSET (multiple myeloma set domain) region of chromosome 4 is found in 15–20% of multiple myeloma cases and many of these result in increased expression of FGFR3731,732 (Table4(b)). However, although this translocation is associated with poor survival, survival does not correlate with FGFR3 expression.733,734

Activation of FGFRs by somatic acquisition of missense mutations is another common tumorigenic mechanism. Missense mutations in FGFR2 have been found in gastric and endometrial cancer693,698,735 (Table4(b)). Missense mutations in FGFR3 have been observed in 25% of cervical carcinomas and 35% of bladder carcinomas736 (Table4(b)). Interestingly, these mutations are identical to the activating mutations that cause Thanatophoric dysplasia. Tyrosine kinase domain mutations were found in 7.5% of rhabdomyosarcomas.715 In gastric cancer, at least one allele of the common G388R variant of FGFR4 was present in 57% of patients, and expression of this allele was associated with worse prognosis737 (Table4(b)).

Conclusion

Since the purification of the first FGF over thirty years ago, an amazing amount of research has uncovered biochemical and biological functions of FGFs, FGFRs, and other interacting molecules that are essential for almost all aspects of life through the regulation of developmental, physiological, and pathological processes, from the earliest stages of embryonic development, to organogenesis, tissue maturation, homeostasis, response to injury, and cancer. Biochemical studies have identified mechanisms that regulate the expression of FGFs, their bioavailability, and their ability to activate cellular responses through interaction with cell surface receptors. Within the cell, signal transduction mechanisms have been identified that reveal interactions with multiple cellular signaling pathways, complex feedback mechanisms, and regulatory molecules that control FGF signaling, both extracellularly and intracellularly. Developmental studies have uncovered redundant functions of FGFs and FGFRs, and interactions with most of the other major signaling pathways, including BMP, WNT, Notch and Hedgehog. The discovery of endocrine FGFs has uncovered new mechanisms that regulate metabolism, lipid, and mineral homeostasis, and has provided potential therapeutic targets for a variety of common diseases, including type 2 diabetes, chronic kidney disease, and obesity. Understanding pathogenic mechanisms resulting from mutations, gene fusions, and gene amplifications in FGFs and FGFRs has led to therapeutic approaches for chondrodysplasia and craniosynostosis syndromes, as well as a variety of cancers. Future directions will be aimed at acquiring a deeper mechanistic understanding of the roles of FGF signaling in development and in adult tissues with a goal of understanding how these pathways become reactivated during injury response and cancer. The development of highly selective pharmacological agonists and antagonists that function at all levels of FGF signaling should provide new tools to protect tissues from injury, enhance cell and tissue repair, treat a variety of metabolic diseases, and inhibit cancer.

Acknowledgments

This work was supported by NIH grants HL105732, HL111190, and HD049808, March of Dimes (FY14-329), Action on Hearing Loss, and a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (25460065).

Further Reading

General Reviews

Belov AA, Mohammadi M. Grb2, a double-edged sword of receptor tyrosine kinase signaling. Sci Signal 2012, 5:pe49.

Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP. The ins and outs of Fibroblast Growth Factor receptor signalling. Clin Sci (Lond) 2014, 127:217–231.

Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013, 14:166–180.

Itoh N, Ornitz DM. Fibroblast Growth Factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011,149:121–130.

Oulion S, Bertrand S, Escriva H. Evolution of the FGF gene family. Int J Evol Biol 2012, 2012:298147.

FGFs and Development

Du X, Xie Y, Xian CJ, Chen L. Role of FGFs/FGFRs in skeletal development and bone regeneration. J Cell Physiol 2012, 227:3731–3743.

El Agha E, Bellusci S. Walking along the Fibroblast Growth Factor 10 route: a key pathway to understand the control and regulation of epithelial and mesenchymal cell-lineage formation during lung development and repair after injury. Scientifica (Cairo) 2014, 2014:538379.

Freter S, Muta Y, Mak SS, Rinkwitz S, Ladher RK. Progressive restriction of otic fate: the role of FGF and Wnt in resolving inner ear potential. Development 2008, 135:3415–3424.

Hogan BL, Barkauskas CE, Chapman HA, Epstein JA, Jain R, et al. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 2014, 15:123–138.

Miraoui H, Marie PJ. Fibroblast Growth Factor receptor signaling crosstalk in skeletogenesis. Sci Signal 2010, 3:re9.

Ornitz DM, Yin Y. Signaling networks regulating development of the lower respiratory tract. Cold Spring Harb Perspect Biol 2012, 4:1–19.

Pownall ME, Isaacs HV. FGF Signalling in Vertebrate Development. San Rafael CA: Morgan & Claypool Life Sciences; 2010.

Towers M, Wolpert L, Tickle C. Gradients of signalling in the developing limb. Curr Opin Cell Biol 2012, 24:181–187.

FGFs and Genetic Diseases

Laederich MB, Horton WA. FGFR3 targeting strategies for achondroplasia. Expert Rev Mol Med 2012, 14:e11.

Melville H, Wang Y, Taub PJ, Jabs EW. Genetic basis of potential therapeutic strategies for craniosynostosis. Am J Med Genet A 2010, 152A:3007–3015.

Valdes-Socin H, Rubio Almanza M, Tome Fernandez-Ladreda M, Debray FG, Bours V, et al. Reproduction, smell, and neurodevelopmental disorders: genetic defects in different hypogonadotropic hypogonadal syndromes. Front Endocrinol (Lausanne) 2014, 5:109.

FGFs and Cancer

Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast Growth Factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013, 3:264–279.

Kelleher FC, O'Sullivan H, Smyth E,McDermott R, Viterbo A. Fibroblast Growth Factor receptors, developmental corruption and malignant disease. Carcinogenesis 2013, 34:2198–2205.

Turner N, Grose R. Fibroblast Growth Factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116–129.

Endocrine FGFs

Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast Growth Factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013, 75:503–533.

Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front Endocrinol (Lausanne) 2014, 5:107.

Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine Fibroblast Growth Factors 15/19 and 21: from feast to famine. Genes Dev 2012, 26:312–324.

Ray K. Liver: Fgf15 maintains bile acid homeostasis and is a key mediator of liver regeneration in mice. Nat Rev Gastroenterol Hepatol 2013, 10:65.

Sapir-Koren R, Livshits G. Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of Fibroblast Growth Factor 23. Biofactors 2014, 40:555–568.

Smith ER, McMahon LP, Holt SG. Fibroblast Growth Factor 23. Ann Clin Biochem 2014, 51:203–227.

References

  • 1. GoetzRMohammadiMExploring mechanisms of FGF signalling through the lens of structural biologyNat Rev Mol Cell Biol201314166180[PubMed][Google Scholar]
  • 2. GoetzRDoverKLaezzaFShtraizentNHuangXTchetchikDEliseenkovaAVXuCFNeubertTAOrnitzDMCrystal structure of a Fibroblast Growth Factor homologous factor (FHF) defines a conserved surface on FHFS for binding and modulation of voltage-gated sodium channelsJ Biol Chem20092841788317896et al.[PubMed][Google Scholar]
  • 3. MillerDLOrtegaSBashayanOBaschRBasilicoCCompensation by Fibroblast Growth Factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null miceMol Cell Biol20002022602268Mol Cell Biol [published erratum appears in 2000, 20:3752][PubMed][Google Scholar]
  • 4. JonkerJWSuhJMAtkinsARAhmadianMLiPWhyteJHeMJuguilonHYinYQPhillipsCTA PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasisNature2012485391394et al.[PubMed][Google Scholar]
  • 5. ZhouMSutliffRLPaulRJLorenzJNHoyingJBHaudenschildCCYinMCoffinJDKongLKraniasEGFibroblast Growth Factor 2 control of vascular toneNat Med19984201207et al.[PubMed][Google Scholar]
  • 6. SchultzJEWittSANiemanMLReiserPJEngleSJZhouMPawlowskiSALorenzJNKimballTRDoetschmanTFibroblast Growth Factor-2 mediates pressure-induced hypertrophic responseJ Clin Invest1999104709719[PubMed][Google Scholar]
  • 7. OrtegaSIttmannMTsangSHEhrlichMBasilicoCNeuronal defects and delayed wound healing in mice lacking Fibroblast Growth Factor 2Proc Natl Acad Sci USA19989556725677[PubMed][Google Scholar]
  • 8. RaballoRRheeJLyn-CookRLeckmanJFSchwartzMLVaccarinoFMBasic Fibroblast Growth Factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortexJ Neurosci20002050125023[PubMed][Google Scholar]
  • 9. MonteroAOkadaYTomitaMItoMTsurukamiHNakamuraTDoetschmanTCoffinJDHurleyMMDisruption of the Fibroblast Growth Factor-2 gene results in decreased bone mass and bone formationJ Clin Invest200010510851093[PubMed][Google Scholar]
  • 10. TimmerMCesnuleviciusKWinklerCKolbJLipokatic-TakacsEJungnickelJGrotheCFibroblast Growth Factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesionJ Neurosci200727459471[PubMed][Google Scholar]
  • 11. Homer-BouthietteCDoetschmanTXiaoLHurleyMMKnockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasisJ Biol Chem20142893630336314[PubMed][Google Scholar]
  • 12. MansourSLGoddardJMCapecchiMRMice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner earDevelopment19931171328[PubMed][Google Scholar]
  • 13. UrnessLDBleylSBWrightTJMoonAMMansourSLRedundant and dosage sensitive requirements for Fgf3 and Fgf10 in cardiovascular developmentDev Biol2011356383397[PubMed][Google Scholar]
  • 14. FeldmanBPoueymirouWPapaioannouVEDeChiaraTMGoldfarbMRequirement of FGF-4 for postimplantation mouse developmentScience1995267246249[PubMed][Google Scholar]
  • 15. SunXLewandoskiMMeyersENLiuYHMaxsonREJrMartinGRConditional inactivation of Fgf4 reveals complexity of signalling during limb bud developmentNat Genet2000258386[PubMed][Google Scholar]
  • 16. ParkerHGVonHoldtBMQuignonPMarguliesEHShaoSMosherDSSpadyTCElkahlounACargillMJonesPGAn expressed fgf4 retrogene is associated with breed-defining chondrodysplasia in domestic dogsScience2009325995998et al.[PubMed][Google Scholar]
  • 17. MoonAMBouletAMCapecchiMRNormal limb development in conditional mutants of Fgf4Development2000127989996[PubMed][Google Scholar]
  • 18. HébertJMRosenquistTGötzJMartinGRFGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutationsCell19947810171025[PubMed][Google Scholar]
  • 19. FlossTArnoldHHBraunTA role for Fgf-6 in skeletal muscle regenerationGenes Dev19971120402051[PubMed][Google Scholar]
  • 20. NeuhausPOustaninaSLochTKrugerMBoberEDonoRZellerRBraunTReduced mobility of Fibroblast Growth Factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant miceMol Cell Biol20032360376048[PubMed][Google Scholar]
  • 21. ArmandASParisetCLazizILaunayTFioreFDella GasperaBBirnbaumDCharbonnierFChanoineCFGF6 regulates muscle differentiation through a calcineurin-dependent pathway in regenerating soleus of adult miceJ Cell Physiol2005204297308[PubMed][Google Scholar]
  • 22. TerauchiAJohnson-VenkateshEMTothABJavedDSuttonMAUmemoriHDistinct FGFs promote differentiation of excitatory and inhibitory synapsesNature2010465783787[PubMed][Google Scholar]
  • 23. GuoLDegensteinLFuchsEKeratinocyte growth factor is required for hair development but not for wound healingGenes Dev199610165175[PubMed][Google Scholar]
  • 24. QiaoJUzzoRObara-IshiharaTDegensteinLFuchsEHerzlingerDFGF-7 modulates ureteric bud growth and nephron number in the developing kidneyDevelopment1999126547554[PubMed][Google Scholar]
  • 25. AlpdoganOHubbardVMSmithOMPatelNLuSGoldbergGLGrayDHFeinmanJKochmanAAEngJMKeratinocyte growth factor (KGF) is required for postnatal thymic regenerationBlood200610724532460et al.[PubMed][Google Scholar]
  • 26. PengCHeQLuoCLack of keratinocyte growth factor retards angiogenesis in cutaneous woundsJ Int Med Res201139416423[PubMed][Google Scholar]
  • 27. PerantoniAOTimofeevaONaillatFRichmanCPajni-UnderwoodSWilsonCVainioSDoveLFLewandoskiMInactivation of FGF8 in early mesoderm reveals an essential role in kidney developmentDevelopment200513238593871[PubMed][Google Scholar]
  • 28. LadherRKWrightTJMoonAMMansourSLSchoenwolfGCFGF8 initiates inner ear induction in chick and mouseGenes Dev200519603613[PubMed][Google Scholar]
  • 29. NaicheLAHolderNLewandoskiMFGF4 and FGF8 comprise the wavefront activity that controls somitogenesisProc Natl Acad Sci USA201110840184023[PubMed][Google Scholar]
  • 30. LewandoskiMSunXMartinGRFgf8 signalling from the AER is essential for normal limb developmentNat Genet200026460463[PubMed][Google Scholar]
  • 31. XuJLiuZOrnitzDMTemporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structuresDevelopment200012718331843[PubMed][Google Scholar]
  • 32. SunXMeyersENLewandoskiMMartinGRTargeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryoGenes Dev19991318341846[PubMed][Google Scholar]
  • 33. MoonAMCapecchiMRFgf8 is required for outgrowth and patterning of the limbsNat Genet200026455459[PubMed][Google Scholar]
  • 34. BrownCBWenningJMLuMMEpsteinDJMeyersENEpsteinJACre-mediated excision of Fgf8 in the Tbx1 expression domain reveals a critical role for Fgf8 in cardiovascular development in the mouseDev Biol2004267190192[PubMed][Google Scholar]
  • 35. IlaganRAbu-IssaRBrownDYangYPJiaoKSchwartzRJKlingensmithJMeyersENFgf8 is required for anterior heart field developmentDevelopment200613324352445[PubMed][Google Scholar]
  • 36. ParkEJOgdenLATalbotAEvansSCaiCLBlackBLFrankDUMoonAMRequired, tissue-specific roles for Fgf8 in outflow tract formation and remodelingDevelopment200613324192433[PubMed][Google Scholar]
  • 37. JacquesBEMontcouquiolMELaymanEMLewandoskiMKelleyMWFgf8 induces pillar cell fate and regulates cellular patterning in the mammalian cochleaDevelopment200713430213029[PubMed][Google Scholar]
  • 38. ZelarayanLCVendrellVAlvarezYDominguez-FrutosETheilTAlonsoMTMaconochieMSchimmangTDifferential requirements for FGF3, FGF8 and FGF10 during inner ear developmentDev Biol2007308379391[PubMed][Google Scholar]
  • 39. HasegawaKSagaYFGF8-FGFR1 signaling acts as a niche factor for maintaining undifferentiated spermatogonia in the mouseBiol Reprod201491145[PubMed][Google Scholar]
  • 40. BarakHHuhSHChenSJeanpierreCMartinovicJParisotMBole-FeysotCNitschkePSalomonRAntignacCFGF9 and FGF20 maintain the stemness of nephron progenitors in mice and manDev Cell20122211911207et al.[PubMed][Google Scholar]
  • 41. PirvolaUZhangXMantelaJOrnitzDMYlikoskiJFgf9 signaling regulates inner ear morphogenesis through epithelial-mesenchymal interactionsDev Biol2004273350360[PubMed][Google Scholar]
  • 42. ColvinJSWhiteAPrattSJOrnitzDMLung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchymeDevelopment200112820952106[PubMed][Google Scholar]
  • 43. WhiteACXuJYinYSmithCSchmidGOrnitzDMFGF9 and SHH signaling coordinate lung growth and development through regulation of distinct mesenchymal domainsDevelopment200613315071517[PubMed][Google Scholar]
  • 44. YinYWangFOrnitzDMMesothelial and epithelial derived FGF9 have distinct functions in the regulation of lung developmentDevelopment201113831693177[PubMed][Google Scholar]
  • 45. ColvinJSGreenRPSchmahlJCapelBOrnitzDMMale-to-female sex reversal in mice lacking Fibroblast Growth Factor 9Cell2001b104875889[PubMed][Google Scholar]
  • 46. DinapoliLBatchvarovJCapelBFGF9 promotes survival of germ cells in the fetal testisDevelopment200613315191527[PubMed][Google Scholar]
  • 47. HungIHYuKLavineKJOrnitzDMFGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopodDev Biol2007307300313[PubMed][Google Scholar]
  • 48. GeskeMJZhangXPatelKKOrnitzDMStappenbeckTSFgf9 signaling regulates small intestinal elongation and mesenchymal developmentDevelopment200813529592968[PubMed][Google Scholar]
  • 49. LavineKJYuKWhiteACZhangXSmithCPartanenJOrnitzDMEndocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivoDev Cell200588595[PubMed][Google Scholar]
  • 50. SchmahlJKimYColvinJSOrnitzDMCapelBFgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determinationDevelopment200413136273636[PubMed][Google Scholar]
  • 51. LinYChenLLinCLuoYTsaiRYWangFNeuron-derived FGF9 is essential for scaffold formation of Bergmann radial fibers and migration of granule neurons in the cerebellumDev Biol20093294454[PubMed][Google Scholar]
  • 52. MarguerieABajolleFZaffranSBrownNADicksonCBuckinghamMEKellyRGCongenital heart defects in Fgfr2-IIIb and Fgf10 mutant miceCardiovasc Res2006715060[PubMed][Google Scholar]
  • 53. NyengPNorgaardGAKobberupSJensenJFGF10 signaling controls stomach morphogenesisDev Biol2006303295310[PubMed][Google Scholar]
  • 54. MinHDanilenkoDMScullySABolonBRingBDTarpleyJEDeRoseMSimonetWSFgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchlessGenes Dev19981231563161[PubMed][Google Scholar]
  • 55. SekineKOhuchiHFujiwaraMYamasakiMYoshizawaTSatoTYagishitaNMatsuiDKogaYItohNFgf10 is essential for limb and lung formationNat Genet199921138141et al.[PubMed][Google Scholar]
  • 56. AlvarezYAlonsoMTVendrellVZelarayanLCChameroPTheilTBoslMRKatoSMaconochieMRiethmacherDRequirements for FGF3 and FGF10 during inner ear formationDevelopment200313063296338et al.[PubMed][Google Scholar]
  • 57. AblerLLMansourSLSunXConditional gene inactivation reveals roles for Fgf10 and Fgfr2 in establishing a normal pattern of epithelial branching in the mouse lungDev Dyn200923819992013[PubMed][Google Scholar]
  • 58. OhuchiHHoriYYamasakiMHaradaHSekineKKatoSItohNFGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ developmentBiochem Biophys Res Commun2000277643649[PubMed][Google Scholar]
  • 59. BhushanAItohNKatoSThieryJPCzernichowPBellusciSScharfmannRFgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesisDevelopment200112851095117[PubMed][Google Scholar]
  • 60. WrightTJMansourSLFgf3 and Fgf10 are required for mouse otic placode inductionDevelopment200313033793390[PubMed][Google Scholar]
  • 61. RiceRSpencer-DeneBConnorECGritli-LindeAMcMahonAPDicksonCThesleffIRiceDPDisruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal interactions causes cleft palateJ Clin Invest200411316921700[PubMed][Google Scholar]
  • 62. JaskollTAbichakerGWitcherDSalaFGBellusciSHajihosseiniMKMelnickMFGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesisBMC Dev Biol2005511[PubMed][Google Scholar]
  • 63. VeltmaatJMRelaixFLeLTKratochwilKSalaFGvan VeelenWRiceRSpencer-DeneBMailleuxAARiceDPGli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axesDevelopment200613323252335et al.[PubMed][Google Scholar]
  • 64. MichosOCebrianCHyinkDGrieshammerUWilliamsLD'AgatiVLichtJDMartinGRCostantiniFKidney development in the absence of Gdnf and Spry1 requires Fgf10PLoS Genet20106e1000809[PubMed][Google Scholar]
  • 65. QuXCarbeCTaoCPowersALawrenceRvan KuppeveltTHCardosoWVGrobeKEskoJDZhangXLacrimal gland development and Fgf10-Fgfr2b signaling are controlled by 2-O- and 6-O-sulfated heparan sulfateJ Biol Chem20112861443514444[PubMed][Google Scholar]
  • 66. SalaFGDel MoralPMTiozzoCAlamDAWarburtonDGrikscheitTVeltmaatJMBellusciSFGF10 controls the patterning of the tracheal cartilage rings via ShhDevelopment2011138273282[PubMed][Google Scholar]
  • 67. SohnWJJungHIChoiMAHanJHGwonGJYamamotoHLeeSRyooZYParkEKShinHIReciprocal interactions of Fgf10/Fgfr2b modulate the mouse tongue epithelial differentiationCell Tissue Res2011345265273et al.[PubMed][Google Scholar]
  • 68. Al AlamDSalaFGBaptistaSGalzoteRDanopoulosSTiozzoCGagePGrikscheitTWarburtonDFreyMRFGF9-Pitx2-FGF10 signaling controls cecal formation in miceDev Biol2012369340342et al.[PubMed][Google Scholar]
  • 69. GoldfarbMSchoorlemmerJWilliamsADiwakarSWangQHuangXGizaJTchetchikDKelleyKVegaAFibroblast Growth Factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channelsNeuron200755449463et al.[PubMed][Google Scholar]
  • 70. WuQFYangLLiSWangQYuanXBGaoXBaoLZhangXFibroblast Growth Factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migrationCell201214915491564[PubMed][Google Scholar]
  • 71. WozniakDFXiaoMXuLYamadaKAOrnitzDMImpaired spatial learning and defective theta burst induced LTP in mice lacking Fibroblast Growth Factor 14Neurobiol Dis2007261426[PubMed][Google Scholar]
  • 72. XiaoMXuLLaezzaFYamadaKFengSOrnitzDMImpaired hippocampal synaptic transmission and plasticity in mice lacking Fibroblast Growth Factor 14Mol Cell Neurosci200734366377[PubMed][Google Scholar]
  • 73. ShakkottaiVGXiaoMXuLWongMNerbonneJMOrnitzDMYamadaKAFGF14 regulates the intrinsic excitability of cerebellar Purkinje neuronsNeurobiol Dis2009338188[PubMed][Google Scholar]
  • 74. WangQBardgettMEWongMWozniakDFLouJMcNeilBDChenCNardiAReidDCYamadaKAtaxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14Neuron2002352538et al.[PubMed][Google Scholar]
  • 75. PotthoffMJKliewerSAMangelsdorfDJEndocrine Fibroblast Growth Factors 15/19 and 21: from feast to famineGenes Dev201226312324[PubMed][Google Scholar]
  • 76. VincentzJWMcWhirterJRMurreCBaldiniAFurutaYFgf15 is required for proper morphogenesis of the mouse cardiac outflow tractGenesis200541192201[PubMed][Google Scholar]
  • 77. BorelloUCobosILongJEMcWhirterJRMurreCRubensteinJLFGF15 promotes neurogenesis and opposes FGF8 function during neocortical developmentNeural Dev2008317[PubMed][Google Scholar]
  • 78. InagakiTChoiMMoschettaAPengLCumminsCLMcDonaldJGLuoGJonesSAGoodwinBRichardsonJAFibroblast Growth Factor 15 functions as an enterohepatic signal to regulate bile acid homeostasisCell Metab20052217225et al.[PubMed][Google Scholar]
  • 79. KongBHuangJZhuYLiGWilliamsJShenSAleksunesLMRichardsonJRApteURudnickDAFibroblast Growth Factor 15 deficiency impairs liver regeneration in miceAm J Physiol Gastrointest Liver Physiol2014306G893G902et al.[PubMed][Google Scholar]
  • 80. ChoiMMoschettaABookoutALPengLUmetaniMHolmstromSRSuino-PowellKXuHERichardsonJAGerardRDIdentification of a hormonal basis for gallbladder fillingNat Med20061212531255et al.[PubMed][Google Scholar]
  • 81. MatsumotoESasakiSKinoshitaHKitoTOhtaHKonishiMKuwaharaKNakaoKItohNAngiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16Genes Cells201318544553[PubMed][Google Scholar]
  • 82. HottaYSasakiSKonishiMKinoshitaHKuwaharaKNakaoKItohNFgf16 is required for cardiomyocyte proliferation in the mouse embryonic heartDev Dyn200823729472954[PubMed][Google Scholar]
  • 83. LuSYSheikhFSheppardPCFresnozaADuckworthMLDetillieuxKACattiniPAFGF-16 is required for embryonic heart developmentBiochem Biophys Res Commun2008373270274[PubMed][Google Scholar]
  • 84. CholfinJARubensteinJLPatterning of frontal cortex subdivisions by Fgf17Proc Natl Acad Sci USA200710476527657[PubMed][Google Scholar]
  • 85. OhbayashiNShibayamaMKurotakiYImanishiMFujimoriTItohNTakadaSFGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesisGenes Dev200216870879[PubMed][Google Scholar]
  • 86. LiuZLavineKJHungIHOrnitzDMFGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plateDev Biol20073028091[PubMed][Google Scholar]
  • 87. LiuZXuJColvinJSOrnitzDMCoordination of chondrogenesis and osteogenesis by Fibroblast Growth Factor 18Genes Dev200216859869[PubMed][Google Scholar]
  • 88. UsuiHShibayamaMOhbayashiNKonishiMTakadaSItohNFgf18 is required for embryonic lung alveolar developmentBiochem Biophys Res Commun2004322887892[PubMed][Google Scholar]
  • 89. WhitsettJAClarkJCPicardLTichelaarJWWertSEItohNPerlAKStahlmanMTFibroblast Growth Factor 18 influences proximal programming during lung morphogenesisJ Biol Chem20022772274322749[PubMed][Google Scholar]
  • 90. HuhSHJonesJWarcholMEOrnitzDMDifferentiation of the lateral compartment of the cochlea requires a temporally restricted FGF20 signalPLoS Biol201210e1001231[PubMed][Google Scholar]
  • 91. HaaraOHarjunmaaELindforsPHHuhSHFliniauxIAbergTJernvallJOrnitzDMMikkolaMLThesleffIEctodysplasin regulates activator-inhibitor balance in murine tooth development through Fgf20 signalingDevelopment201213931893199[PubMed][Google Scholar]
  • 92. HuhSHNärhiKLindforsPHHääräOYangLOrnitzDMMikkolaMLFgf20 governs formation of primary and secondary dermal condensations in developing hair folliclesGenes Dev201327450458[PubMed][Google Scholar]
  • 93. HottaYNakamuraHKonishiMMurataYTakagiHMatsumuraSInoueKFushikiTItohNFibroblast Growth Factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liverEndocrinology200915046254633[PubMed][Google Scholar]
  • 94. MurataYNishioKMochiyamaTKonishiMShimadaMOhtaHItohNFgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic dietPLoS One20138e69330[PubMed][Google Scholar]
  • 95. LeeCHUmemoriHSuppression of epileptogenesis-associated changes in response to seizures in FGF22-deficient miceFront Cell Neurosci2013743[PubMed][Google Scholar]
  • 96. JaroszMRobbez-MassonLChioniAMCrossBRosewellIGroseRFibroblast Growth Factor 22 is not essential for skin development and repair but plays a role in tumorigenesisPLoS One20127e39436[PubMed][Google Scholar]
  • 97. SinghRSuJBrooksJTerauchiAUmemoriHFoxMAFibroblast Growth Factor 22 contributes to the development of retinal nerve terminals in the dorsal lateral geniculate nucleusFront Mol Neurosci2012461[PubMed][Google Scholar]
  • 98. HuMCShiizakiKKuro-oMMoeOWFibroblast Growth Factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolismAnnu Rev Physiol201375503533[PubMed][Google Scholar]
  • 99. YuXWhiteKEFGF23 and disorders of phosphate homeostasisCytokine Growth Factor Rev200516221232[PubMed][Google Scholar]
  • 100. ShimadaTKakitaniMYamazakiYHasegawaHTakeuchiYFujitaTFukumotoSTomizukaKYamashitaTTargeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolismJ Clin Invest2004113561568[PubMed][Google Scholar]
  • 101. SitaraDRazzaqueMSHesseMYoganathanSTaguchiTErbenRGJuppnerHLanskeBHomozygous ablation of Fibroblast Growth Factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient miceMatrix Biol200423421432[PubMed][Google Scholar]
  • 102. LysaghtACYuanQFanYKalwaniNCarusoPCunnaneMLanskeBStankovicKMFGF23 deficiency leads to mixed hearing loss and middle ear malformation in micePLoS One20149e107681[PubMed][Google Scholar]
  • 103. PirvolaUYlikoskiJTrokovicRHebertJMMcConnellSKPartanenJFGFR1 is required for the development of the auditory sensory epitheliumNeuron200235671680[PubMed][Google Scholar]
  • 104. OnoKKitaTSatoSO'NeillPMakSSPaschakiMItoMGotohNKawakamiKSasaiYFGFR1-Frs2/3 signalling maintains sensory progenitors during inner ear hair cell formationPLoS Genet201410e1004118et al.[PubMed][Google Scholar]
  • 105. YamaguchiTPHarpalKHenkemeyerMRossantJFGFR-1 is required for embryonic growth and mesodermal patterning during mouse gastrulationGenes Dev1994830323044[PubMed][Google Scholar]
  • 106. ZhaoMRossJTItkinTPerryJMVenkatramanAHaugJSHembreeMJDengCXLapidotTHeXCFGF signaling facilitates postinjury recovery of mouse hematopoietic systemBlood201212018311842et al.[PubMed][Google Scholar]
  • 107. JacobALSmithCPartanenJOrnitzDMFibroblast Growth Factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturationDev Biol2006296315328[PubMed][Google Scholar]
  • 108. VerheydenJMLewandoskiMDengCHarfeBDSunXConditional inactivation of Fgfr1 in mouse defines its role in limb bud establishment, outgrowth and digit patterningDevelopment200513242354245[PubMed][Google Scholar]
  • 109. LiCXuXNelsonDKWilliamsTKuehnMRDengCXFGFR1 function at the earliest stages of mouse limb development plays an indispensable role in subsequent autopod morphogenesisDevelopment200513247554764[PubMed][Google Scholar]
  • 110. OhkuboYUchidaAOShinDPartanenJVaccarinoFMFibroblast Growth Factor receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal growth in mouseJ Neurosci20042460576069[PubMed][Google Scholar]
  • 111. XuXLLiCLTakahashiKSlavkinHCShumLDengCXMurine Fibroblast Growth Factor receptor 1 alpha isoforms mediate node regression and are essential for posterior mesoderm developmentDev Biol1999208293306[PubMed][Google Scholar]
  • 112. AdamsACYangCCoskunTChengCCGimenoRELuoYKharitonenkovAThe breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissueMol Metab201223137[PubMed][Google Scholar]
  • 113. ChenPYQinLTellidesGSimonsMFibroblast Growth Factor receptor 1 is a key inhibitor of TGFbeta signaling in the endotheliumSci Signal20147ra90[PubMed][Google Scholar]
  • 114. DingBSCaoZLisRNolanDJGuoPSimonsMPenfoldMEShidoKRabbanySYRafiiSDivergent angiocrine signals from vascular niche balance liver regeneration and fibrosisNature201450597102[PubMed][Google Scholar]
  • 115. XuXWeinsteinMLiCNaskiMCohenRIOrnitzDMLederPDengCFibroblast Growth Factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb inductionDevelopment1998125753765[PubMed][Google Scholar]
  • 116. YuKXuJLiuZSosicDShaoJOlsonENTowlerDAOrnitzDMConditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growthDevelopment200313030633074[PubMed][Google Scholar]
  • 117. YuKOrnitzDMFGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axisDevelopment2008135483491[PubMed][Google Scholar]
  • 118. De MoerloozeLSpencer-DeneBRevestJHajihosseiniMRosewellIDicksonCAn important role for the IIIb isoform of Fibroblast Growth Factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesisDevelopment2000127483492[PubMed][Google Scholar]
  • 119. GuastiLCandy SzeWCMcKayTGroseRKingPJFGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex developmentMol Cell Endocrinol201337182188[PubMed][Google Scholar]
  • 120. ZhaoHKeggHGradySTruongHTRobinsonMLBaumMBatesCMRole of Fibroblast Growth Factor receptors 1 and 2 in the ureteric budDev Biol2004276403415[PubMed][Google Scholar]
  • 121. PoladiaDPKishKKutayBHainsDKeggHZhaoHBatesCMRole of Fibroblast Growth Factor receptors 1 and 2 in the metanephric mesenchymeDev Biol2006291325339[PubMed][Google Scholar]
  • 122. FurushoMDupreeJLNaveKABansalRFibroblast Growth Factor receptor signaling in oligodendrocytes regulates myelin sheath thicknessJ Neurosci20123266316641[PubMed][Google Scholar]
  • 123. OladipupoSSSmithCSantefordAParkCSeneAWileyLAOsei-OwusuPHsuJZapataNLiuFEndothelial cell FGF signaling is required for injury response but not for vascular homeostasisProc Natl Acad Sci USA20141111337913384et al.[PubMed][Google Scholar]
  • 124. MurakamiMNguyenLTZhuangZWMoodieKLCarmelietPStanRVSimonsMThe FGF system has a key role in regulating vascular integrityJ Clin Invest200811833553366[PubMed][Google Scholar]
  • 125. ChenZHuangJLiuYDattiloLKHuhSHOrnitzDBeebeDCFGF signaling activates a Sox9-Sox10 pathway for the formation and branching morphogenesis of mouse ocular glandsDevelopment201414126912701[PubMed][Google Scholar]
  • 126. BohmFSpeicherTHellerbrandCDicksonCPartanenJOrnitzDWernerSFGF receptors 1 and 2 control chemically-induced injury and compound detoxification in regenerating livers of miceGastroenterology201013913851396[PubMed][Google Scholar]
  • 127. ColvinJSBohneBAHardingGWMcEwenDGOrnitzDMSkeletal overgrowth and deafness in mice lacking Fibroblast Growth Factor receptor 3Nat Genet199612390397[PubMed][Google Scholar]
  • 128. DengCWynshaw-BorisAZhouFKuoALederPFibroblast Growth Factor receptor 3 is a negative regulator of bone growthCell199684911921[PubMed][Google Scholar]
  • 129. PuligillaCFengFIshikawaKBertuzziSDabdoubAGriffithAJFritzschBKelleyMWDisruption of Fibroblast Growth Factor receptor 3 signaling results in defects in cellular differentiation, neuronal patterning, and hearing impairmentDev Dyn200723619051917[PubMed][Google Scholar]
  • 130. OhLYDenningerAColvinJSVyasAToleSOrnitzDMBansalRFibroblast Growth Factor receptor 3 signaling regulates the onset of oligodendrocyte terminal differentiationJ Neurosci200323883894[PubMed][Google Scholar]
  • 131. WeinsteinMXuXOhyamaKDengCXFGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lungDevelopment199812536153623[PubMed][Google Scholar]
  • 132. NaskiMCColvinJSCoffinJDOrnitzDMRepression of hedgehog signaling and BMP4 expression in growth plate cartilage by Fibroblast Growth Factor receptor 3Development199812549774988[PubMed][Google Scholar]
  • 133. SzaramaKBStepanyanRPetraliaRSGavaraNFrolenkovGIKelleyMWChadwickRSFibroblast Growth Factor receptor 3 regulates microtubule formation and cell surface mechanical properties in the developing organ of CortiBioarchitecture20122214219[PubMed][Google Scholar]
  • 134. EswarakumarVPSchlessingerJSkeletal overgrowth is mediated by deficiency in a specific isoform of Fibroblast Growth Factor receptor 3Proc Natl Acad Sci USA200710439373942[PubMed][Google Scholar]
  • 135. Valverde-FrancoGBinetteJSLiWWangHChaiSLaflammeFTran-KhanhNQuennevilleEMeijersTPooleARDefects in articular cartilage metabolism and early arthritis in Fibroblast Growth Factor receptor 3 deficient miceHum Mol Genet20061517831792et al.[PubMed][Google Scholar]
  • 136. Valverde-FrancoGLiuHDavidsonDChaiSValderrama-CarvajalHGoltzmanDOrnitzDMHendersonJEDefective bone mineralization and osteopenia in young adult FGFR3−/− miceHum Mol Genet200413271284[PubMed][Google Scholar]
  • 137. MuellerKLJacquesBEKelleyMWFibroblast Growth Factor signaling regulates pillar cell development in the organ of cortiJ Neurosci20022293689377[PubMed][Google Scholar]
  • 138. SuNXuXLiCHeQZhaoLChenSLuoFYiLDuXHuangHGeneration of Fgfr3 conditional knockout miceInt J Biol Sci20106327332et al.[PubMed][Google Scholar]
  • 139. SrisumaSBhattacharyaSSimonDMSolletiSKTyagiSStarcherBMarianiTJFibroblast Growth Factor receptors control epithelial-mesenchymal interactions necessary for alveolar elastogenesisAm J Respir Crit Care Med2010181838850[PubMed][Google Scholar]
  • 140. GattineniJTwombleyKGoetzRMohammadiMBaumMRegulation of serum 1,25(OH)2 vitamin D3 levels by Fibroblast Growth Factor 23 is mediated by FGF receptors 3 and 4Am J Physiol Renal Physiol2011301F371F377[PubMed][Google Scholar]
  • 141. GattineniJAlphonsePZhangQMathewsNBatesCMBaumMRegulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4Am J Physiol Renal Physiol2014306F351F358[PubMed][Google Scholar]
  • 142. LiHMartinADavidVQuarlesLDCompound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotypeAm J Physiol Endocrinol Metab2011300E508E517[PubMed][Google Scholar]
  • 143. YuCWangFKanMJinCJonesRBWeinsteinMDengCXMcKeehanWLElevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4J Biol Chem20002751548215489[PubMed][Google Scholar]
  • 144. YuCWangFJinCWuXChanWKMcKeehanWLIncreased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient miceAmerican Journal of Pathology200216120032010[PubMed][Google Scholar]
  • 145. Arnaud-DabernatSKritzikMKayaliAGZhangYQLiuGUnglesCSarvetnickNFGFR3 is a negative regulator of the expansion of pancreatic epithelial cellsDiabetes20075696106[PubMed][Google Scholar]
  • 146. Arnaud-DabernatSYadavDSarvetnickNFGFR3 contributes to intestinal crypt cell growth arrestJ Cell Physiol2008216261268[PubMed][Google Scholar]
  • 147. GerberSDSteinbergFBeyelerMVilligerPMTruebBThe murine Fgfrl1 receptor is essential for the development of the metanephric kidneyDev Biol2009335106119[PubMed][Google Scholar]
  • 148. BaertschiSZhuangLTruebBMice with a targeted disruption of the Fgfrl1 gene die at birth due to alterations in the diaphragmFEBS J200727462416253[PubMed][Google Scholar]
  • 149. PowersCJMcLeskeySWWellsteinAFibroblast Growth Factors, their receptors and signalingEndocr Relat Cancer20007165197[PubMed][Google Scholar]
  • 150. OrnitzDMItohNFibroblast Growth FactorsGenome Biol20012REVIEWS3005[PubMed][Google Scholar]
  • 151. EswarakumarVPLaxISchlessingerJCellular signaling by Fibroblast Growth Factor receptorsCytokine Growth Factor Rev200516139149[PubMed][Google Scholar]
  • 152. TurnerNGroseRFibroblast Growth Factor signalling: from development to cancerNat Rev Cancer201010116129[PubMed][Google Scholar]
  • 153. BeenkenAMohammadiMThe FGF family: biology, pathophysiology and therapyNat Rev Drug Discov20098235253[PubMed][Google Scholar]
  • 154. GoldfarbMFibroblast Growth Factor homologous factors: evolution, structure, and functionCytokine Growth Factor Rev200516215220[PubMed][Google Scholar]
  • 155. KharitonenkovAFGFs and metabolismCurr Opin Pharmacol20099805810[PubMed][Google Scholar]
  • 156. AngelinBLarssonTERudlingMCirculating Fibroblast Growth Factors as metabolic regulators--a critical appraisalCell Metab201216693705[PubMed][Google Scholar]
  • 157. ItohNHormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and diseaseCell Tissue Res2010342111[PubMed][Google Scholar]
  • 158. ItohNOrnitzDMFibroblast Growth Factors: from molecular evolution to roles in development, metabolism and diseaseJ Biochem2011149121130[PubMed][Google Scholar]
  • 159. DoreyKAmayaEFGF signalling: diverse roles during early vertebrate embryogenesisDevelopment201013737313742[PubMed][Google Scholar]
  • 160. Fon TacerKBookoutALDingXKurosuHJohnGBWangLGoetzRMohammadiMKuro-oMMangelsdorfDJResearch resource: comprehensive expression atlas of the Fibroblast Growth Factor system in adult mouseMol Endocrinol20102420502064et al.[PubMed][Google Scholar]
  • 161. PownallMEIsaacsHVFGF Signalling in Vertebrate Development2010San Rafael CAMorgan & Claypool Life Sciences
  • 162. WuXGeHLemonBVonderfechtSWeiszmannJHechtRGupteJHagerTWangZLindbergRFGF19-induced hepatocyte proliferation is mediated through FGFR4 activationJ Biol Chem201028551655170et al.[PubMed][Google Scholar]
  • 163. FengSDakhovaOCreightonCJIttmannMEndocrine Fibroblast Growth Factor FGF19 promotes prostate cancer progressionCancer Res20137325512562[PubMed][Google Scholar]
  • 164. YamanakaYLannerFRossantJFGF signal-dependent segregation of primitive endoderm and epiblast in the mouse blastocystDevelopment2010137715724[PubMed][Google Scholar]
  • 165. LannerFRossantJThe role of FGF/Erk signaling in pluripotent cellsDevelopment201013733513360[PubMed][Google Scholar]
  • 166. KangMPiliszekAArtusJHadjantonakisAKFGF4 is required for lineage restriction and salt-and-pepper distribution of primitive endoderm factors but not their initial expression in the mouseDevelopment2013140267279[PubMed][Google Scholar]
  • 167. KrawchukDHonma-YamanakaNAnaniSYamanakaYFGF4 is a limiting factor controlling the proportions of primitive endoderm and epiblast in the ICM of the mouse blastocystDev Biol20133846571[PubMed][Google Scholar]
  • 168. KellyRGMolecular inroads into the anterior heart fieldTrends Cardiovasc Med2005155156[PubMed][Google Scholar]
  • 169. ZaffranSKellyRGNew developments in the second heart fieldDifferentiation2012841724[PubMed][Google Scholar]
  • 170. OhuchiHNakagawaTYamamotoAAragaAOhataTIshimaruYYoshiokaHKuwanaTNohnoTYamasakiMThe mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factorDevelopment199712422352244et al.[PubMed][Google Scholar]
  • 171. WangJRheeSPalariaATremblayKDFGF signaling is required for anterior but not posterior specification of the murine liver budDev Dyn2015244431443[PubMed][Google Scholar]
  • 172. NayeFVozMLDetryNHammerschmidtMPeersBManfroidIEssential roles of zebrafish bmp2a, fgf10, and fgf24 in the specification of the ventral pancreasMol Biol Cell201223945954[PubMed][Google Scholar]
  • 173. HayashiTRayCABermingham-McDonoghOFgf20 is required for sensory epithelial specification in the developing cochleaJ Neurosci20082859915999[PubMed][Google Scholar]
  • 174. TrokovicRJukkolaTSaarimakiJPeltopuroPNaserkeTWeisenhornDMTrokovicNWurstWPartanenJFgfr1-dependent boundary cells between developing mid- and hindbrainDev Biol2005278428439[PubMed][Google Scholar]
  • 175. BlakAANaserkeTSaarimaki-VireJPeltopuroPGiraldo-VelasquezMVogt WeisenhornDMPrakashNSendtnerMPartanenJWurstWFgfr2 and Fgfr3 are not required for patterning and maintenance of the midbrain and anterior hindbrainDev Biol2007303231243[PubMed][Google Scholar]
  • 176. MullerAKMeyerMWernerSThe roles of receptor tyrosine kinases and their ligands in the wound repair processSemin Cell Dev Biol201223963970[PubMed][Google Scholar]
  • 177. KardamiEDetillieuxKMaXJiangZSantiagoJJJimenezSKCattiniPAFibroblast Growth Factor-2 and cardioprotectionHeart Fail Rev200712267277[PubMed][Google Scholar]
  • 178. HouseSLBranchKNewmanGDoetschmanTSchultz JelJCardioprotection induced by cardiac-specific overexpression of Fibroblast Growth Factor-2 is mediated by the MAPK cascadeAm J Physiol Heart Circ Physiol2005289H2167H2175[PubMed][Google Scholar]
  • 179. LiaoSPorterDScottANewmanGDoetschmanTSchultz JelJThe cardioprotective effect of the low molecular weight isoform of Fibroblast Growth Factor-2: the role of JNK signalingJ Mol Cell Cardiol200742106120[PubMed][Google Scholar]
  • 180. BraunSauf dem KellerUSteilingHWernerSFibroblast Growth Factors in epithelial repair and cytoprotectionPhilos Trans R Soc Lond B Biol Sci2004359753757[PubMed][Google Scholar]
  • 181. GuzyRDStoilovIEltonTJMechamRPOrnitzDMFGF2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycinAm J Respir Cell Mol Biol201552116128[PubMed][Google Scholar]
  • 182. MeyerMMullerAKYangJMoikDPonzioGOrnitzDMGroseRWernerSFGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skinJ Cell Sci201212556905701[PubMed][Google Scholar]
  • 183. XiaoLDuYShenYHeYZhaoHLiZTGF-beta 1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathwayFront Biosci (Landmark Ed)20121726672674[PubMed][Google Scholar]
  • 184. WarburtonDDevelopmental responses to lung injury: repair or fibrosisFibrogenesis Tissue Repair20125Suppl 1S2[PubMed][Google Scholar]
  • 185. GupteVVRamasamySKReddyRLeeJWeinrebPHVioletteSMGuentherAWarburtonDDriscollBMinooPOverexpression of Fibroblast Growth Factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in miceAm J Respir Crit Care Med2009180424436et al.[PubMed][Google Scholar]
  • 186. LongYCKharitonenkovAHormone-like Fibroblast Growth Factors and metabolic regulationBiochim Biophys Acta18122011791795[Google Scholar]
  • 187. ItohNFGF21 as a hepatokine, adipokine, and myokine in metabolism and diseasesFront Endocrinol (Lausanne)20145107[PubMed][Google Scholar]
  • 188. BrooksANKilgourESmithPDMolecular pathways: Fibroblast Growth Factor signaling: a new therapeutic opportunity in cancerClin Cancer Res20121818551862[PubMed][Google Scholar]
  • 189. DuXXieYXianCJChenLRole of FGFs/FGFRs in skeletal development and bone regenerationJ Cell Physiol201222737313743[PubMed][Google Scholar]
  • 190. WynesMWHinzTKGaoDMartiniMMarekLAWareKEEdwardsMGBohmDPernerSHelfrichBAFGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologiesClin Cancer Res20142032993309et al.[PubMed][Google Scholar]
  • 191. SchultheisAMBosMSchmitzKWilsbergLBinotEWolfJButtnerRSchildhausHUFibroblast Growth Factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancerMod Pathol201427214221[PubMed][Google Scholar]
  • 192. MalchersFDietleinFSchottleJLuXNogovaLAlbusKFernandez-CuestaLHeuckmannJMGautschiODieboldJCell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerCancer Discov20144246257et al.[PubMed][Google Scholar]
  • 193. ParkerBCEngelsMAnnalaMZhangWEmergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursJ Pathol2014232415[PubMed][Google Scholar]
  • 194. YadavVZhangXLiuJEstremSLiSGongXQBuchananSHenryJRStarlingJJPengSBReactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanomaJ Biol Chem20122872808728098[PubMed][Google Scholar]
  • 195. WareKEHinzTKKleczkoESingletonKRMarekLAHelfrichBACummingsCTGrahamDKAstlingDTanACA mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loopOncogenesis20132e39et al.[PubMed][Google Scholar]
  • 196. TeraiHSoejimaKYasudaHNakayamaSHamamotoJAraiDIshiokaKOhginoKIkemuraSSatoTActivation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLCMol Cancer Res201311759767et al.[PubMed][Google Scholar]
  • 197. OrnitzDMFGFs, heparan sulfate and FGFRs: complex interactions essential for developmentBioessays200022108112[PubMed][Google Scholar]
  • 198. MatsuoIKimura-YoshidaCExtracellular modulation of Fibroblast Growth Factor signaling through heparan sulfate proteoglycans in mammalian developmentCurr Opin Genet Dev201323399407[PubMed][Google Scholar]
  • 199. SarrazinSLamannaWCEskoJDHeparan sulfate proteoglycansCold Spring Harb Perspect Biol20113133[Google Scholar]
  • 200. RapraegerACKrufkaAOlwinBBRequirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiationScience199125217051708[PubMed][Google Scholar]
  • 201. YayonAKlagsbrunMEskoJDLederPOrnitzDMCell surface, heparin-like molecules are required for binding of basic Fibroblast Growth Factor to its high affinity receptorCell199164841848[PubMed][Google Scholar]
  • 202. SmithERMcMahonLPHoltSGFibroblast Growth Factor 23Ann Clin Biochem201451203227[PubMed][Google Scholar]
  • 203. TruebBBiology of FGFRL1, the fifth Fibroblast Growth Factor receptorCell Mol Life Sci201168951964[PubMed][Google Scholar]
  • 204. GotohNRegulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteinsCancer Sci20089913191325[PubMed][Google Scholar]
  • 205. YuTYaguchiYEchevarriaDMartinezSBassonMASprouty genes prevent excessive FGF signalling in multiple cell types throughout development of the cerebellumDevelopment201113829572968[PubMed][Google Scholar]
  • 206. YangXGongYTangYLiHHeQGowerLLiawLFrieselRESpry1 and Spry4 differentially regulate human aortic smooth muscle cell phenotype via Akt/FoxO/myocardin signalingPLoS One20138e58746[PubMed][Google Scholar]
  • 207. KouharaHHadariYRSpivak-KroizmanTSchillingJBar-SagiDLaxISchlessingerJA lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathwayCell199789693702[PubMed][Google Scholar]
  • 208. SchoorlemmerJGoldfarbMFibroblast Growth Factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinaseJ Biol Chem20022774911149119[PubMed][Google Scholar]
  • 209. KonigHGFennerBJByrneJCSchwambornRFBernasTJefferiesCAPrehnJHFibroblast Growth Factor homologous factor 1 interacts with NEMO to regulate NF-kappaB signaling in neuronsJ Cell Sci201212560586070[PubMed][Google Scholar]
  • 210. ItohNOrnitzDMFunctional evolutionary history of the mouse Fgf gene familyDev Dyn20082371827[PubMed][Google Scholar]
  • 211. TrowellOAChirBWillmerENStudies on the growth of tissues in vitroJ Exp Biol1939166070[Google Scholar]
  • 212. ArmelinHAPituitary extracts and steroid hormones in the control of 3T3 cell growthProc Natl Acad Sci USA19737027022706[PubMed][Google Scholar]
  • 213. GospodarowiczDPurification of a Fibroblast Growth Factor from bovine pituitaryJ Biol Chem197525025152520[PubMed][Google Scholar]
  • 214. LemmonSKBradshawRAPurification and partial characterization of bovine pituitary Fibroblast Growth FactorJ Cell Biochem198321195208[PubMed][Google Scholar]
  • 215. ThomasKARios-CandeloreMFitzpatrickSPurification and characterization of acidic Fibroblast Growth Factor from bovine brainProc Natl Acad Sci USA198481357361[PubMed][Google Scholar]
  • 216. ThomasKARileyMCLemmonSKBaglanNCBradshawRABrain Fibroblast Growth Factor: nonidentity with myelin basic protein fragmentsJ Biol Chem198025555175520[PubMed][Google Scholar]
  • 217. LemmonSKRileyMCThomasKAHooverGAMaciagTBradshawRABovine Fibroblast Growth Factor: comparison of brain and pituitary preparationsJ Cell Biol198295162169[PubMed][Google Scholar]
  • 218. Gimenez-GallegoGConnGHatcherVBThomasKAThe complete amino acid sequence of human brain-derived acidic Fibroblast Growth FactorBiochem Biophys Res Commun1986138611617[PubMed][Google Scholar]
  • 219. Gimenez-GallegoGRodkeyJBennettCRios-CandeloreMDiSalvoJThomasKBrain-derived acidic Fibroblast Growth Factor: complete amino acid sequence and homologiesScience198523013851388[PubMed][Google Scholar]
  • 220. ThomasKARios-CandeloreMGimenez-GallegoGDiSalvoJBennettCRodkeyJFitzpatrickSPure brain-derived acidic Fibroblast Growth Factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1Proc Natl Acad Sci USA19858264096413[PubMed][Google Scholar]
  • 221. SchreiberABKenneyJKowalskiWJFrieselRMehlmanTMaciagTInteraction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognitionProc Natl Acad Sci USA19858261386142[PubMed][Google Scholar]
  • 222. SchreiberABKenneyJKowalskiJThomasKAGimenez-GallegoGRios-CandeloreMDi SalvoJBarritaultDCourtyJCourtoisYA unique family of endothelial cell polypeptide mitogens: the antigenic and receptor cross-reactivity of bovine endothelial cell growth factor, brain-derived acidic Fibroblast Growth Factor, and eye-derived growth factor-IIJ Cell Biol198510116231626et al.[PubMed][Google Scholar]
  • 223. JayeMHowkRBurgessWRiccaGAChiuI-MRaveraMWO'BrienSJModiWSMaciagTDrohanWNHuman endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localizationScience1986233541545[PubMed][Google Scholar]
  • 224. AbrahamJAMergiaAWhangJLTumoloAFriedmanJHjerrildKAGospodarowiczDFiddesJCNucleotide sequence of a bovine clone encoding the angiogenic protein, basic Fibroblast Growth FactorScience1986233545548[PubMed][Google Scholar]
  • 225. KrejciPProchazkovaJBryjaVKozubikAWilcoxWRMolecular pathology of the Fibroblast Growth Factor familyHum Mutat20093012451255[PubMed][Google Scholar]
  • 226. OulionSBertrandSEscrivaHEvolution of the FGF gene familyInt J Evol Biol20122012298147[PubMed][Google Scholar]
  • 227. PrudovskyIKumarTKSterlingSNeivandtDProtein-phospholipid interactions in nonclassical protein secretion: problem and methods of studyInt J Mol Sci20131437343772[PubMed][Google Scholar]
  • 228. PrudovskyIMandinovaASoldiRBagalaCGrazianiILandriscinaMTarantiniFDuarteMBellumSDohertyHThe non-classical export routes: FGF1 and IL-1alpha point the wayJ Cell Sci200311648714881et al.[PubMed][Google Scholar]
  • 229. LandriscinaMSoldiRBagalaCMicucciIBellumSTarantiniFPrudovskyIMaciagTS100A13 participates in the release of Fibroblast Growth Factor 1 in response to heat shock in vitroJ Biol Chem20012762254422552[PubMed][Google Scholar]
  • 230. WescheJMaleckiJWiedlochaASkjerpenCSClausPOlsnesSFGF-1 and FGF-2 require the cytosolic chaperone Hsp90 for translocation into the cytosol and the cell nucleusJ Biol Chem20062811140511412[PubMed][Google Scholar]
  • 231. SorensenVWiedlochaAHaugstenEMKhnykinDWescheJOlsnesSDifferent abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tailJ Cell Sci200611943324341[PubMed][Google Scholar]
  • 232. OlsnesSKlingenbergOWiedlochaATransport of exogenous growth factors and cytokines to the cytosol and to the nucleusPhysiol Rev200383163182[PubMed][Google Scholar]
  • 233. PlanqueNNuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancersCell Commun Signal200647[PubMed][Google Scholar]
  • 234. BouleauSGrimalHRinchevalVGodefroyNMignotteBVayssiereJLRenaudFFGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathwayOncogene20052478397849[PubMed][Google Scholar]
  • 235. Rodriguez-EnfedaqueABouleauSLaurentMCourtoisYMignotteBVayssiereJLRenaudFFGF1 nuclear translocation is required for both its neurotrophic activity and its p53-dependent apoptosis protectionBiochim Biophys Acta2009179317191727[PubMed][Google Scholar]
  • 236. ItohNOrnitzDMEvolution of the Fgf and Fgfr gene familiesTrends Genet200420563569[PubMed][Google Scholar]
  • 237. ZhangXIbrahimiOAOlsenSKUmemoriHMohammadiMOrnitzDMReceptor specificity of the Fibroblast Growth Factor family. The complete mammalian FGF familyJ Biol Chem20062811569415700[PubMed][Google Scholar]
  • 238. OrnitzDMXuJColvinJSMcEwenDGMacArthurCACoulierFGaoGGoldfarbMReceptor specificity of the Fibroblast Growth Factor familyJ Biol Chem19962711529215297[PubMed][Google Scholar]
  • 239. MiyakawaKHatsuzawaKKurokawaTAsadaMKuroiwaTImamuraTA hydrophobic region locating at the center of Fibroblast Growth Factor-9 is crucial for its secretionJ Biol Chem19992742935229357[PubMed][Google Scholar]
  • 240. RevestJMDeMoerloozeLDicksonCFibroblast Growth Factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequenceJ Biol Chem200027580838090[PubMed][Google Scholar]
  • 241. MiyakawaKImamuraTSecretion of FGF-16 requires an uncleaved bipartite signal sequenceJ Biol Chem20032783571835724[PubMed][Google Scholar]
  • 242. ConsortiumAAutosomal dominant hypophosphataemic rickets is associated with mutations in FGF23Nat Genet200026345348[PubMed][Google Scholar]
  • 243. GoetzRBeenkenAIbrahimiOAKalininaJOlsenSKEliseenkovaAVXuCNeubertTAZhangFLinhardtRJMolecular insights into the klotho-dependent, endocrine mode of action of Fibroblast Growth Factor 19 subfamily membersMol Cell Biol20072734173428et al.[PubMed][Google Scholar]
  • 244. KliewerSAMangelsdorfDJFibroblast Growth Factor 21: from pharmacology to physiologyAm J Clin Nutr201091254s257s[PubMed][Google Scholar]
  • 245. DingXBoney-MontoyaJOwenBMBookoutALCoateKCMangelsdorfDJKliewerSAbetaKlotho is required for Fibroblast Growth Factor 21 effects on growth and metabolismCell Metab201216387393[PubMed][Google Scholar]
  • 246. SuzukiMUeharaYMotomura-MatsuzakaKOkiJKoyamaYKimuraMAsadaMKomi-KuramochiAOkaSImamuraTbetaKlotho is required for Fibroblast Growth Factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3cMol Endocrinol20082210061014[PubMed][Google Scholar]
  • 247. KurosuHOgawaYMiyoshiMYamamotoMNandiARosenblattKPBaumMGSchiaviSHuMCMoeOWRegulation of Fibroblast Growth Factor-23 signaling by klothoJ Biol Chem200628161206123et al.[PubMed][Google Scholar]
  • 248. UrakawaIYamazakiYShimadaTIijimaKHasegawaHOkawaKFujitaTFukumotoSYamashitaTKlotho converts canonical FGF receptor into a specific receptor for FGF23Nature2006444770774[PubMed][Google Scholar]
  • 249. OrnitzDMLederPLigand specificity and heparin dependence of Fibroblast Growth Factor receptors 1 and 3J Biol Chem19922671630516311[PubMed][Google Scholar]
  • 250. WangJKGaoGXGoldfarbMFibroblast growth-factor receptors have different signaling and mitogenic potentialsMol Cell Biol199414181188[PubMed][Google Scholar]
  • 251. MathieuMChatelainEOrnitzDBresnickJMasonIKieferPDicksonCReceptor binding and mitogenic properties of mouse Fibroblast Growth Factor 3. Modulation of response by heparinJ Biol Chem19952702419724203[PubMed][Google Scholar]
  • 252. BluntAGLawsheACunninghamMLSetoMLOrnitzDMMacarthurCAOverlapping expression and redundant activation of mesenchymal Fibroblast Growth Factor (FGF) receptors by alternatively spliced FGF-8 ligandsJ Biol Chem199727237333738[PubMed][Google Scholar]
  • 253. Santos-OcampoSColvinJSChellaiahATOrnitzDMExpression and biological activity of mouse Fibroblast Growth Factor-9J Biol Chem199627117261731[PubMed][Google Scholar]
  • 254. OrnitzDMYayonAFlanaganJGSvahnCMLeviELederPHeparin is required for cell-free binding of basic Fibroblast Growth Factor to a soluble receptor and for mitogenesis in whole cellsMol Cell Biol199212240247[PubMed][Google Scholar]
  • 255. WuALKolumamGStawickiSChenYLiJZavala-SolorioJPhamluongKFengBLiLMarstersSAmelioration of type 2 diabetes by antibody-mediated activation of Fibroblast Growth Factor receptor 1Sci Transl Med20113113ra126et al.[Google Scholar]
  • 256. HoHKPokSStreitSRuheJEHartSLimKSLooHLAungMOLimSGUllrichAFibroblast Growth Factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic interventionJ Hepatol200950118127[PubMed][Google Scholar]
  • 257. FrenchDMLinBCWangMAdamsCShekTHotzelKBolonBFerrandoRBlackmoreCSchroederKTargeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse modelsPLoS One20127e36713et al.[PubMed][Google Scholar]
  • 258. NabeshimaYThe discovery of alpha-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasisCell Mol Life Sci20086532183230[PubMed][Google Scholar]
  • 259. SmallwoodPMMunoz-SanjuanITongPMackeJPHendrySHGilbertDJCopelandNGJenkinsNANathansJFibroblast Growth Factor (FGF) homologous factors: new members of the FGF family implicated in nervous system developmentProc Natl Acad Sci USA19969398509857[PubMed][Google Scholar]
  • 260. OlsenSKGarbiMZampieriNEliseenkovaAVOrnitzDMGoldfarbMMohammadiMFibroblast Growth Factor (FGF) homologous factors share structural but not functional homology with FGFsJ Biol Chem20032783422634236[PubMed][Google Scholar]
  • 261. HsuWCNilssonCLLaezzaFRole of the axonal initial segment in psychiatric disorders: function, dysfunction, and interventionFront Psychiatry20145109[PubMed][Google Scholar]
  • 262. XiaoMBoschMKNerbonneJMOrnitzDMFGF14 localization and organization of the axon initial segmentMol Cell Neurosci201356393403[PubMed][Google Scholar]
  • 263. LouJYLaezzaFGerberBRXiaoMYamadaKAHartmannHCraigAMNerbonneJMOrnitzDMFibroblast Growth Factor 14 is an intracellular modulator of voltage-gated sodium channelsJ Physiol (Lond)2005569179193[PubMed][Google Scholar]
  • 264. WangCHennesseyJAKirktonRDGrahamVPuranamRSRosenbergPBBursacNPittGSFibroblast Growth Factor homologous factor 13 regulates Na+ channels and conduction velocity in murine heartsCirc Res2011109775782[PubMed][Google Scholar]
  • 265. SchoorlemmerJGoldfarbMFibroblast Growth Factor homologous factors are intracellular signaling proteinsCurr Biol200111793797[PubMed][Google Scholar]
  • 266. HuangSSHuangJSAssociation of bovine brain-derived growth factor receptor with protein tyrosine kinase activityJ Biol Chem198626195689571[PubMed][Google Scholar]
  • 267. CoughlinSRBarrPJCousensLSFrettoLJWilliamsLTAcidic and basic Fibroblast Growth Factors stimulate tyrosine kinase activity in vivoJ Biol Chem1988263988993[PubMed][Google Scholar]
  • 268. LeePLJohnsonDECousensLSFriedVAWilliamsLTPurification and complementary DNA cloning of a receptor for basic Fibroblast Growth FactorScience19892455760[PubMed][Google Scholar]
  • 269. KornbluthSPaulsonKEHanafusaHNovel tyrosine kinase identified by phosphotyrosine antibody screening of cDNA librariesMol Cell Biol1988855415544[PubMed][Google Scholar]
  • 270. KeeganKJohnsonDEWilliamsLTHaymanMJIsolation of an additional member of the Fibroblast Growth Factor receptor family, FGFR-3Proc Natl Acad Sci USA19918810951099[PubMed][Google Scholar]
  • 271. PartanenJMakelaTPEerolaEKorhonenJHirvonenHClaesson-WelshLAlitaloKFGFR-4, a novel acidic Fibroblast Growth Factor receptor with a distinct expression patternEMBO J19911013471354[PubMed][Google Scholar]
  • 272. StarkKLMcMahonJAMcMahonAPFGFR-4, a new member of the Fibroblast Growth Factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouseDevelopment1991113641651[PubMed][Google Scholar]
  • 273. PasqualeEBA distinctive family of embryonic protein-tyrosine kinase receptorsProc Natl Acad Sci USA19908758125816[PubMed][Google Scholar]
  • 274. MikiTFlemingTPBottaroDPRubinJSRonDAaronsonSAExpression cDNA cloning of the KGF receptor by creation of a transforming autocrine loopScience19912517275[PubMed][Google Scholar]
  • 275. YehBKIgarashiMEliseenkovaAVPlotnikovANSherIRonDAaronsonSAMohammadiMStructural basis by which alternative splicing confers specificity in Fibroblast Growth Factor receptorsProc Natl Acad Sci USA200310022662271[PubMed][Google Scholar]
  • 276. PlotnikovANHubbardSRSchlessingerJMohammadiMCrystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificityCell2000101413424[PubMed][Google Scholar]
  • 277. JohnsonDEWilliamsLTStructural and functional diversity in the FGF receptor multigene familyAdv Cancer Res199360141[PubMed][Google Scholar]
  • 278. KalininaJDuttaKIlghariDBeenkenAGoetzREliseenkovaAVCowburnDMohammadiMThe alternatively spliced acid box region plays a key role in FGF receptor autoinhibitionStructure2012207788[PubMed][Google Scholar]
  • 279. WangFKanMYanGXuJMcKeehanWLAlternately spliced NH2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1J Biol Chem19952701023110235[PubMed][Google Scholar]
  • 280. RoghaniMMoscatelliDProstate cells express two isoforms of Fibroblast Growth Factor receptor 1 with different affinities for Fibroblast Growth Factor-2Prostate200767115124[PubMed][Google Scholar]
  • 281. MikiTBottaroDPFlemingTPSmithCLBurgessWHChanAMAaronsonSADetermination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single geneProc Natl Acad Sci USA199289246250[PubMed][Google Scholar]
  • 282. ChellaiahATMcEwenDGWernerSXuJOrnitzDMFibroblast Growth Factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1J Biol Chem19942691162011627[PubMed][Google Scholar]
  • 283. WernerSDuanDSde VriesCPetersKGJohnsonDEWilliamsLTDifferential splicing in the extracellular region of Fibroblast Growth Factor receptor 1 generates receptor variants with different ligand-binding specificitiesMol Cell Biol1992128288[PubMed][Google Scholar]
  • 284. MistryNHarringtonWLasdaEWagnerEJGarcia-BlancoMAOf urchins and men: evolution of an alternative splicing unit in Fibroblast Growth Factor receptor genesRNA20039209217[PubMed][Google Scholar]
  • 285. DuanDSWernerSWilliamsLTA naturally occurring secreted form of Fibroblast Growth Factor (FGF) receptor 1 binds basic FGF in preference over acidic FGFJ Biol Chem19922671607616080[PubMed][Google Scholar]
  • 286. TomlinsonDCL'HoteCGKennedyWPittEKnowlesMAAlternative splicing of Fibroblast Growth Factor receptor 3 produces a secreted isoform that inhibits Fibroblast Growth Factor-induced proliferation and is repressed in urothelial carcinoma cell linesCancer Res2005651044110449[PubMed][Google Scholar]
  • 287. TeradaMShimizuASatoNMiyakazeSIKatayamaHKurokawa-SeoMFibroblast Growth Factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFsMol Cell Biol Res Commun20014365373[PubMed][Google Scholar]
  • 288. NaskiMCWangQXuJOrnitzDMGraded activation of Fibroblast Growth Factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasiaNat Genet199613233237[PubMed][Google Scholar]
  • 289. OlsenSKIbrahimiOARaucciAZhangFEliseenkovaAVYayonABasilicoCLinhardtRJSchlessingerJMohammadiMInsights into the molecular basis for Fibroblast Growth Factor receptor autoinhibition and ligand-binding promiscuityProc Natl Acad Sci USA2004101935940[PubMed][Google Scholar]
  • 290. BeenkenAEliseenkovaAVIbrahimiOAOlsenSKMohammadiMPlasticity in interactions of Fibroblast Growth Factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1J Biol Chem201228730673078[PubMed][Google Scholar]
  • 291. MacArthurCALawshéAXuJSantos-OcampoSHeikinheimoMChellaiahATOrnitzDMFGF-8 isoforms activate receptor splice forms that are expressed in mesenchymal regions of mouse developmentDevelopment199512136033613[PubMed][Google Scholar]
  • 292. SunXMarianiFVMartinGRFunctions of FGF signalling from the apical ectodermal ridge in limb developmentNature2002418501508[PubMed][Google Scholar]
  • 293. BellusciSGrindleyJEmotoHItohNHoganBLFibroblast Growth Factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lungDevelopment199712448674878[PubMed][Google Scholar]
  • 294. BeyerTAWernerSDicksonCGroseRFibroblast Growth Factor 22 and its potential role during skin development and repairExp Cell Res2003287228236[PubMed][Google Scholar]
  • 295. ScotetEHoussaintEThe choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specificBiochim Biophys Acta19951264238242[PubMed][Google Scholar]
  • 296. MurgueBTsunekawaSRosenbergIdeBeaumontMPodolskyDKIdentification of a novel variant form of Fibroblast Growth Factor receptor 3 (FGFR3 IIIb) in human colonic epitheliumCancer Res19945452065211[PubMed][Google Scholar]
  • 297. LoganCYNusseRThe Wnt signaling pathway in development and diseaseAnnu Rev Cell Dev Biol200420781810[PubMed][Google Scholar]
  • 298. LinXFunctions of heparan sulfate proteoglycans in cell signaling during developmentDevelopment200413160096021[PubMed][Google Scholar]
  • 299. KuoWJDigmanMALanderADHeparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerizationMol Biol Cell20102140284041[PubMed][Google Scholar]
  • 300. OlwinBRapraegerARepression of myogenic differentiation by aFGF, bFGF, and K-FGF is dependent on cellular heparan sulfateJ Cell Biol1992118631639[PubMed][Google Scholar]
  • 301. BelovAAMohammadiMMolecular mechanisms of Fibroblast Growth Factor signaling in physiology and pathologyCold Spring Harb Perspect Biol20135124[Google Scholar]
  • 302. KimMJCotmanSLHalfterWColeGJThe heparan sulfate proteoglycan agrin modulates neurite outgrowth mediated by FGF-2J Neurobiol200355261277[PubMed][Google Scholar]
  • 303. CotmanSLHalfterWColeGJIdentification of extracellular matrix ligands for the heparan sulfate proteoglycan agrinExp Cell Res19992495464[PubMed][Google Scholar]
  • 304. AviezerDHechtDSafranMEisingerMDavidGYayonAPerlecan, basal lamina proteoglycan, promotes basic Fibroblast Growth Factor-receptor binding, mitogenesis, and angiogenesisCell19947910051013[PubMed][Google Scholar]
  • 305. WuZLZhangLYabeTKuberanBBeelerDLLoveARosenbergRDThe involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complexJ Biol Chem20032781712117129[PubMed][Google Scholar]
  • 306. MakarenkovaHPHoffmanMPBeenkenAEliseenkovaAVMeechRTsauCPatelVNLangRAMohammadiMDifferential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesisSci Signal20092ra55[PubMed][Google Scholar]
  • 307. GrobeKLedinJRingvallMHolmbornKForsbergEEskoJDKjellenLHeparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymesBiochim Biophys Acta20021573209215[PubMed][Google Scholar]
  • 308. LindahlUKusche-GullbergMKjellenLRegulated diversity of heparan sulfateJ Biol Chem19982732497924982[PubMed][Google Scholar]
  • 309. BishopJRSchukszMEskoJDHeparan sulphate proteoglycans fine-tune mammalian physiologyNature200744610301037[PubMed][Google Scholar]
  • 310. BusseMFetaAPrestoJWilenMGronningMKjellenLKusche-GullbergMContribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongationJ Biol Chem20072823280232810[PubMed][Google Scholar]
  • 311. KjellenLGlucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and biologyBiochem Soc Trans200331340342[PubMed][Google Scholar]
  • 312. CaiZGrobeKZhangXRole of heparan sulfate proteoglycans in optic disc and stalk morphogenesisDev Dyn201424313101316[PubMed][Google Scholar]
  • 313. ChangZMeyerKRapraegerACFriedlADifferential ability of heparan sulfate proteoglycans to assemble the Fibroblast Growth Factor receptor complex in situFASEB J200014137144[PubMed][Google Scholar]
  • 314. AllenBLRapraegerACSpatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assemblyJ Cell Biol2003163637648[PubMed][Google Scholar]
  • 315. ShimokawaKKimura-YoshidaCNagaiNMukaiKMatsubaraKWatanabeHMatsudaYMochidaKMatsuoICell surface heparan sulfate chains regulate local reception of FGF signaling in the mouse embryoDev Cell201121257272[PubMed][Google Scholar]
  • 316. PatelVNLikarKMZisman-RozenSCowherdSNLassiterKSSherIYatesEATurnbullJERonDHoffmanMPSpecific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiationJ Biol Chem200828393089317[PubMed][Google Scholar]
  • 317. Escobar GalvisMLJiaJZhangXJastrebovaNSpillmannDGottfridssonEvan KuppeveltTHZchariaEVlodavskyILindahlUTransgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfateNat Chem Biol20073773778et al.[PubMed][Google Scholar]
  • 318. OstrovskyOBermanBGallagherJMulloyBFernigDGDeleheddeMRonDDifferential effects of heparin saccharides on the formation of specific Fibroblast Growth Factor (FGF) and FGF receptor complexesJ Biol Chem200227724442453[PubMed][Google Scholar]
  • 319. OrnitzDMHerrABNilssonMWestmanJSvahnCMWaksmanGFGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharidesScience1995268432436[PubMed][Google Scholar]
  • 320. PatelVNKnoxSMLikarKMLathropCAHossainREftekhariSWhitelockJMElkinMVlodavskyIHoffmanMPHeparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesisDevelopment200713441774186[PubMed][Google Scholar]
  • 321. Kuro-oMMatsumuraYAizawaHKawaguchiHSugaTUtsugiTOhyamaYKurabayashiMKanameTKumeEMutation of the mouse klotho gene leads to a syndrome resembling ageingNature19973904551et al.[PubMed][Google Scholar]
  • 322. Kuro-oMEndocrine FGFs and Klothos: emerging conceptsTrends Endocrinol Metab200819239245[PubMed][Google Scholar]
  • 323. KurosuHKuroOMThe Klotho gene family as a regulator of endocrine Fibroblast Growth FactorsMol Cell Endocrinol20092997278[PubMed][Google Scholar]
  • 324. Kuro-oMKlotho in health and diseaseCurr Opin Nephrol Hypertens201221362368[PubMed][Google Scholar]
  • 325. ItoSKinoshitaSShiraishiNNakagawaSSekineSFujimoriTNabeshimaYIMolecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family proteinMech Dev200098115119[PubMed][Google Scholar]
  • 326. ItoSFujimoriTHayashizakiYNabeshimaYIdentification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structureBiochim Biophys Acta20021576341345[PubMed][Google Scholar]
  • 327. GoetzROhnishiMDingXKurosuHWangLAkiyoshiJMaJGaiWSidisYPitteloudNKlotho coreceptors inhibit signaling by paracrine Fibroblast Growth Factor 8 subfamily ligandsMol Cell Biol20123219441954et al.[PubMed][Google Scholar]
  • 328. WuDQKanMKSatoGHOkamotoTSatoJDCharacterization and molecular cloning of a putative binding protein for heparin-binding growth factorsJ Biol Chem19912661677816785[PubMed][Google Scholar]
  • 329. CzubaykoFLiaudet-CoopmanEDAignerATuvesonATBerchemGJWellsteinAA secreted FGF-binding protein can serve as the angiogenic switch in human cancerNat Med1997311371140[PubMed][Google Scholar]
  • 330. AbuharbeidSCzubaykoFAignerAThe Fibroblast Growth Factor-binding protein FGF-BPInt J Biochem Cell Biol20063814631468[PubMed][Google Scholar]
  • 331. BeerHDBittnerMNiklausGMundingCMaxNGoppeltAWernerSThe Fibroblast Growth Factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repairOncogene20052452695277[PubMed][Google Scholar]
  • 332. TassiEMcDonnellKGibbyKATilanJUKimSEKodackDPSchmidtMOSharifGMWilcoxCSWelchWJImpact of Fibroblast Growth Factor-binding protein-1 expression on angiogenesis and wound healingAm J Pathol201117922202232et al.[PubMed][Google Scholar]
  • 333. WiedemannMTruebBCharacterization of a novel protein (FGFRL1) from human cartilage related to FGF receptorsGenomics200069275279[PubMed][Google Scholar]
  • 334. TruebBZhuangLTaeschlerSWiedemannMCharacterization of FGFRL1, a novel Fibroblast Growth Factor (FGF) receptor preferentially expressed in skeletal tissuesJ Biol Chem20032783385733865[PubMed][Google Scholar]
  • 335. KimIMoonSYuKKimUKohGYA novel Fibroblast Growth Factor receptor-5 preferentially expressed in the pancreas(1)Biochim Biophys Acta20011518152156[PubMed][Google Scholar]
  • 336. SleemanMFraserJMcDonaldMYuanSWhiteDGrandisonPKumbleKWatsonJDMurisonJGIdentification of a new Fibroblast Growth Factor receptor, FGFR5Gene2001271171182[PubMed][Google Scholar]
  • 337. SteinbergFZhuangLBeyelerMKalinREMullisPEBrandliAWTruebBThe FGFRL1 receptor is shed from cell membranes, binds FGFs and antagonizes FGF signaling in Xenopus embryosJ Biol Chem201028521932202[PubMed][Google Scholar]
  • 338. SilvaPNAltamentovaSMKilkennyDMRocheleauJVFibroblast Growth Factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activationJ Biol Chem20132881785917870[PubMed][Google Scholar]
  • 339. AmannRWyderSSlavotinekAMTruebBThe FgfrL1 receptor is required for development of slow muscle fibersDev Biol2014394228241[PubMed][Google Scholar]
  • 340. BluteauGZhuangLAmannRTruebBTargeted disruption of the intracellular domain of receptor FgfrL1 in micePLoS One20149e105210[PubMed][Google Scholar]
  • 341. FurduiCMLewEDSchlessingerJAndersonKSAutophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reactionMol Cell200621711717[PubMed][Google Scholar]
  • 342. LewEDFurduiCMAndersonKSSchlessingerJThe precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutationsSci Signal20092ra6[PubMed][Google Scholar]
  • 343. DudkaAASweetSMHeathJKSignal transducers and activators of transcription-3 binding to the Fibroblast Growth Factor receptor is activated by receptor amplificationCancer Res20107033913401[PubMed][Google Scholar]
  • 344. PetersKGMarieJWilsonEIvesHEEscobedoJDel RosarioMMirdaDWilliamsLTPoint mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesisNature1992358678681[PubMed][Google Scholar]
  • 345. MohammadiMHonnegerAMRotinDFisherRBellotFLiWDionneCAJayeMRubinsteinMSchlessingerJA tyrosine-phosphorylated carboxy-terminal peptide of the Fibroblast Growth Factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-g1Mol Cell Biol19911150685078[PubMed][Google Scholar]
  • 346. XuHLeeKWGoldfarbMNovel recognition motif on Fibroblast Growth Factor receptor mediates direct association and activation of SNT adapter proteinsJ Biol Chem19982731798717990[PubMed][Google Scholar]
  • 347. OngSHGuyGRHadariYRLaksSGotohNSchlessingerJLaxIFRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on Fibroblast Growth Factor and nerve growth factor receptorsMol Cell Biol200020979989[PubMed][Google Scholar]
  • 348. MoonAMGurisDLSeoJHLiLHammondJTalbotAImamotoACrkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromesDev Cell2006107180[PubMed][Google Scholar]
  • 349. SeoJHSuenagaAHatakeyamaMTaijiMImamotoAStructural and functional basis of a role for CRKL in a Fibroblast Growth Factor 8-induced feed-forward loopMol Cell Biol20092930763087[PubMed][Google Scholar]
  • 350. LarssonHKlintPLandgrenEClaesson-WelshLFibroblast Growth Factor receptor-1-mediated endothelial cell proliferation is dependent on the Src homology (SH) 2/SH3 domain-containing adaptor protein CrkJ Biol Chem19992742572625734[PubMed][Google Scholar]
  • 351. KanazawaSFujiwaraTMatsuzakiSShingakiKTaniguchiMMiyataSTohyamaMSakaiYYanoKHosokawaKbFGF regulates PI3-kinase-Rac1-JNK pathway and promotes fibroblast migration in wound healingPLoS One20105e12228et al.[PubMed][Google Scholar]
  • 352. TsangMDawidIBPromotion and attenuation of FGF signaling through the Ras-MAPK pathwaySci STKE20042004pe17[PubMed][Google Scholar]
  • 353. TanYRouseJZhangACariatiSCohenPCombMJFGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2EMBO J19961546294642[PubMed][Google Scholar]
  • 354. HadariYRKouharaHLaxISchlessingerJBinding of Shp2 tyrosine phosphatase to FRS2 is essential for Fibroblast Growth Factor-induced PC12 cell differentiationMol Cell Biol19981839663973[PubMed][Google Scholar]
  • 355. LamotheBYamadaMSchaeperUBirchmeierWLaxISchlessingerJThe docking protein Gab1 is an essential component of an indirect mechanism for Fibroblast Growth Factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathwayMol Cell Biol20042456575666[PubMed][Google Scholar]
  • 356. FirnbergNNeubuserAFGF signaling regulates expression of Tbx2, Erm, Pea3, and Pax3 in the early nasal regionDev Biol2002247237250[PubMed][Google Scholar]
  • 357. RaibleFBrandMTight transcriptional control of the ETS domain factors Erm and Pea3 by Fgf signaling during early zebrafish developmentMech Dev2001107105117[PubMed][Google Scholar]
  • 358. RoehlHNusslein-VolhardCZebrafish pea3 and erm are general targets of FGF8 signalingCurr Biol200111503507[PubMed][Google Scholar]
  • 359. BrentAETabinCJFGF acts directly on the somitic tendon progenitors through the Ets transcription factors Pea3 and Erm to regulate scleraxis expressionDevelopment200413138853896[PubMed][Google Scholar]
  • 360. ManningBDCantleyLCAKT/PKB signaling: navigating downstreamCell200712912611274[PubMed][Google Scholar]
  • 361. ReillyJFMickeyGMaherPAAssociation of Fibroblast Growth Factor receptor 1 with the adaptor protein Grb14. Characterization of a new receptor binding partnerJ Biol Chem200027577717778[PubMed][Google Scholar]
  • 362. Browaeys-PolyEBlanquartCPerdereauDAntoineAFGoenagaDLuzyJPChenHGarbayCIssadTCailliauKGrb14 inhibits FGF receptor signaling through the regulation of PLCgamma recruitment and activationFEBS Lett201058443834388et al.[PubMed][Google Scholar]
  • 363. CrossMJLuLMagnussonPNyqvistDHolmqvistKWelshMClaesson-WelshLThe Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cellsMol Biol Cell20021328812893[PubMed][Google Scholar]
  • 364. SuWCKitagawaMXueNXieBGarofaloSChoJDengCHortonWAFuXYActivation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfismNature1997386288292[PubMed][Google Scholar]
  • 365. YangXQiaoDMeyerKPierTKelesSFriedlAAngiogenesis induced by signal transducer and activator of transcription 5A (STAT5A) is dependent on autocrine activity of proliferinJ Biol Chem201228764906502[PubMed][Google Scholar]
  • 366. HartKCRobertsonSCKanemitsuMYMeyerANTynanJADonoghueDJTransformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4Oncogene20001933093320[PubMed][Google Scholar]
  • 367. HeathCCrossNCCritical role of STAT5 activation in transformation mediated by ZNF198-FGFR1J Biol Chem200427966666673[PubMed][Google Scholar]
  • 368. SahniMAmbrosettiDCMansukhaniAGertnerRLevyDBasilicoCFGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathwayGenes Dev19991313611366[PubMed][Google Scholar]
  • 369. KrejciPSalazarLGoodridgeHSKashiwadaTASchiblerMJJelinkovaPThompsonLMWilcoxWRSTAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytesJ Cell Sci2008121272281[PubMed][Google Scholar]
  • 370. YangXQiaoDMeyerKFriedlASignal transducers and activators of transcription mediate Fibroblast Growth Factor-induced vascular endothelial morphogenesisCancer Res20096916681677[PubMed][Google Scholar]
  • 371. HaugstenEMZakrzewskaMBrechAPustSOlsnesSSandvigKWescheJClathrin- and dynamin-independent endocytosis of FGFR3–implications for signallingPLoS One20116e21708[PubMed][Google Scholar]
  • 372. AucielloGCunninghamDLTatarTHeathJKRappoportJZRegulation of Fibroblast Growth Factor receptor signalling and trafficking by Src and Eps8J Cell Sci2013126613624[PubMed][Google Scholar]
  • 373. FrancavillaCRigboltKTEmdalKBCarraroGVernetEBekker-JensenDBStreicherWWikstromMSundstromMBellusciSFunctional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputsMol Cell201351707722et al.[PubMed][Google Scholar]
  • 374. DaileyLAmbrosettiDMansukhaniABasilicoCMechanisms underlying differential responses to FGF signalingCytokine Growth Factor Rev200516233247[PubMed][Google Scholar]
  • 375. DikicIGiordanoSNegative receptor signallingCurr Opin Cell Biol200315128135[PubMed][Google Scholar]
  • 376. GuyGRJacksonRAYusoffPChowSYSprouty proteins: modified modulators, matchmakers or missing links?J Endocrinol2009203191202[PubMed][Google Scholar]
  • 377. ThisseBThisseCFunctions and regulations of Fibroblast Growth Factor signaling during embryonic developmentDev Biol2005287390402[PubMed][Google Scholar]
  • 378. FurthauerMLinWAngSLThisseBThisseCSef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signallingNat Cell Biol20024170174[PubMed][Google Scholar]
  • 379. TsangMFrieselRKudohTDawidIBIdentification of Sef, a novel modulator of FGF signallingNat Cell Biol20024165169[PubMed][Google Scholar]
  • 380. ToriiSKusakabeMYamamotoTMaekawaMNishidaESef is a spatial regulator for Ras/MAP kinase signalingDev Cell200473344[PubMed][Google Scholar]
  • 381. KovalenkoDYangXChenPYNadeauRJZubanovaOPigeonKFrieselRA role for extracellular and transmembrane domains of Sef in Sef-mediated inhibition of FGF signalingCell Signal20061819581966[PubMed][Google Scholar]
  • 382. CampsMNicholsAGillieronCAntonssonBMudaMChabertCBoschertUArkinstallSCatalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinaseScience199828012621265[PubMed][Google Scholar]
  • 383. LiCScottDAHatchETianXMansourSLDusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse developmentDevelopment2007134167176[PubMed][Google Scholar]
  • 384. EkerotMStavridisMPDelavaineLMitchellMPStaplesCOwensDMKeenanIDDickinsonRJStoreyKGKeyseSMNegative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoterBiochem J2008412287298[PubMed][Google Scholar]
  • 385. DickinsonRJEblaghieMCKeyseSMMorriss-KayGMExpression of the ERK-specific MAP kinase phosphatase PYST1/MKP3 in mouse embryos during morphogenesis and early organogenesisMech Dev2002113193196[PubMed][Google Scholar]
  • 386. EblaghieMCLunnJSDickinsonRJMunsterbergAESanz-EzquerroJJFarrellERMathersJKeyseSMStoreyKTickleCNegative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryosCurr Biol20031310091018[PubMed][Google Scholar]
  • 387. WongALamotheBLeeASchlessingerJLaxIFRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase CblProc Natl Acad Sci USA20029966846689[PubMed][Google Scholar]
  • 388. DufourCGuenouHKaabecheKBouvardDSanjayAMariePJFGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survivalBone20084210321039[PubMed][Google Scholar]
  • 389. AhmedZGeorgeRLinCCSuenKMLevittJASuhlingKLadburyJEDirect binding of Grb2 SH3 domain to FGFR2 regulates SHP2 functionCell Signal2010222333[PubMed][Google Scholar]
  • 390. AhmedZLinCCSuenKMMeloFALevittJASuhlingKLadburyJEGrb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activityJ Cell Biol2013200493504[PubMed][Google Scholar]
  • 391. CardosoWVItohANogawaHMasonIBrodyJSFGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epitheliumDev Dyn1997208398405[PubMed][Google Scholar]
  • 392. BelleudiFLeoneLNobiliVRaffaSFrancescangeliFMaggioMMorroneSMarcheseCTorrisiMRKeratinocyte growth factor receptor ligands target the receptor to different intracellular pathwaysTraffic2007818541872[PubMed][Google Scholar]
  • 393. VolckaertTDe LangheSPWnt and FGF mediated epithelial-mesenchymal crosstalk during lung developmentDev Dyn2015244342366[PubMed][Google Scholar]
  • 394. BryantDMStowJLNuclear translocation of cell-surface receptors: lessons from Fibroblast Growth FactorTraffic20056947954[PubMed][Google Scholar]
  • 395. ColemanSJBruceCChioniAMKocherHMGroseRPThe ins and outs of Fibroblast Growth Factor receptor signallingClin Sci (Lond)2014127217231[PubMed][Google Scholar]
  • 396. WiedlochaAFalnesPOMadshusIHSandvigKOlsnesSDual mode of signal transduction by externally added acidic Fibroblast Growth FactorCell19947610391051[PubMed][Google Scholar]
  • 397. JoyAMoffettJNearyKMordechaiEStachowiakEKCoonsSRankin-ShapiroJFlorkiewiczRZStachowiakMKNuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cellsOncogene199714171183[PubMed][Google Scholar]
  • 398. StachowiakMKMaherPAStachowiakEKIntegrative nuclear signaling in cell development--a role for FGF receptor-1DNA Cell Biol200726811826[PubMed][Google Scholar]
  • 399. FangXStachowiakEKDunham-EmsSMKlejborIStachowiakMKControl of CREB-binding protein signaling by nuclear Fibroblast Growth Factor receptor-1: a novel mechanism of gene regulationJ Biol Chem20052802845128462[PubMed][Google Scholar]
  • 400. ColemanSJChioniAMGhallabMAndersonRKLemoineNRKocherHMGroseRPNuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasionEMBO Mol Med20146467481[PubMed][Google Scholar]
  • 401. ChioniAMGroseRFGFR1 cleavage and nuclear translocation regulates breast cancer cell behaviorJ Cell Biol2012197801817[PubMed][Google Scholar]
  • 402. ChekulaevaMFilipowiczWMechanisms of miRNA-mediated post-transcriptional regulation in animal cellsCurr Opin Cell Biol200921452460[PubMed][Google Scholar]
  • 403. AdamsBDKasinskiALSlackFJAberrant regulation and function of microRNAs in cancerCurr Biol201424R762r776[PubMed][Google Scholar]
  • 404. RosaABrivanlouAHmicroRNAs in early vertebrate developmentCell Cycle2009835133520[PubMed][Google Scholar]
  • 405. LiuHSunQWanCLiLZhangLChenZMicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2J Cell Physiol201422914941502[PubMed][Google Scholar]
  • 406. CarraroGEl-HashashAGuidolinDTiozzoCTurcatelGYoungBMDe LangheSPBellusciSShiWParnigottoPPmiR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-cadherin distributionDev Biol2009333238250et al.[PubMed][Google Scholar]
  • 407. KimJKangYKojimaYLighthouseJKHuXAldredMAMcLeanDLParkHComhairSAGreifDMAn endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertensionNat Med2013197482et al.[PubMed][Google Scholar]
  • 408. UchiyamaKNaitoYTakagiTMizushimaKHayashiNHarusatoAHirataIOmatsuTHandaOIshikawaTCarbon monoxide enhance colonic epithelial restitution via FGF15 derived from colonic myofibroblastsBiochem Biophys Res Commun201039111221126et al.[PubMed][Google Scholar]
  • 409. FuTChoiSEKimDHSeokSSuino-PowellKMXuHEKemperJKAberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-KlothoProc Natl Acad Sci USA20121091613716142[PubMed][Google Scholar]
  • 410. FuTSeokSChoiSHuangZSuino-PowellKXuHEKemperBKemperJKMiR-34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte FGF21 signaling and SIRT1 functionMol Cell Biol20143441304142[PubMed][Google Scholar]
  • 411. ChengZMaRTanWZhangLMiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2Exp Mol Med201446e112[PubMed][Google Scholar]
  • 412. YangJZhaoHXinYFanLMicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1J Cell Biochem2014115987995[PubMed][Google Scholar]
  • 413. LiuFYouXWangYLiuQLiuYZhangSChenLZhangXYeLThe oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGFCarcinogenesis20143511441153[PubMed][Google Scholar]
  • 414. DengMTangHLLuXHLiuMYLuXMGuYXLiuJFHeZMmiR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancerPLoS One20138e72662[PubMed][Google Scholar]
  • 415. YangHFangFChangRYangLMicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and Fibroblast Growth Factor 9 in hepatocellular carcinomaHepatology201358205217[PubMed][Google Scholar]
  • 416. YuanYShenYXueLFanHmiR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptorPLoS One20138e73604[PubMed][Google Scholar]
  • 417. KangJLeeSYKimYJParkJYKwonSJNaMJLeeEJJeonHSSonJWmicroRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting Fibroblast Growth Factor receptor 3Exp Ther Med20123149153[PubMed][Google Scholar]
  • 418. OhginoKSoejimaKYasudaHHayashiYHamamotoJNaokiKAraiDIshiokaKSatoTTeraiHExpression of Fibroblast Growth Factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerLung Cancer2014839096et al.[PubMed][Google Scholar]
  • 419. YinYBetsuyakuTGarbowJRMiaoJGovindanROrnitzDMRapid induction of lung adenocarcinoma by Fibroblast Growth Factor 9 signaling through FGF receptor 3Cancer Res20137357305741[PubMed][Google Scholar]
  • 420. YuanHCorbiNBasilicoCDaileyLDevelopmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3Genes Dev1995926352645[PubMed][Google Scholar]
  • 421. CampbellWJMillerKAAndersonTMShullJDRizzinoAExpression of Fibroblast Growth Factor receptors by embryonal carcinoma cells and early mouse embryosIn Vitro Cell Dev Biol1992>28a6166[PubMed][Google Scholar]
  • 422. Orr-UrtregerAGivolDYayonAYardenYLonaiPDevelopmental expression of two murine Fibroblast Growth Factor receptors, flg and bekDevelopment199111314191434[PubMed][Google Scholar]
  • 423. GuoGHussMTongGQWangCLi SunLClarkeNDRobsonPResolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocystDev Cell201018675685[PubMed][Google Scholar]
  • 424. ArmanEHaffner-KrauszRChenYHeathJKLonaiPTargeted disruption of Fibroblast Growth Factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian developmentProc Natl Acad Sci USA19989550825087[PubMed][Google Scholar]
  • 425. DengCXWynshaw-BorisAShenMMDaughertyCOrnitzDMLederPMurine FGFR-1 is required for early postimplantation growth and axial organizationGenes Dev1994830453057[PubMed][Google Scholar]
  • 426. MeyersENLewandoskiMMartinGRAn Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombinationNat Genet199818136141[PubMed][Google Scholar]
  • 427. LuPYuYPerdueYWerbZThe apical ectodermal ridge is a timer for generating distal limb progenitorsDevelopment200813513951405[PubMed][Google Scholar]
  • 428. OrnitzDMYinYSignaling networks regulating development of the lower respiratory tractCold Spring Harb Perspect Biol20124119[Google Scholar]
  • 429. BenazetJDZellerRVertebrate limb development: moving from classical morphogen gradients to an integrated 4-dimensional patterning systemCold Spring Harb Perspect Biol20091a001339[PubMed][Google Scholar]
  • 430. Fukuchi-ShimogoriTGroveEANeocortex patterning by the secreted signaling molecule FGF8Science200129410711074[PubMed][Google Scholar]
  • 431. GrosJTabinCJVertebrate limb bud formation is initiated by localized epithelial-to-mesenchymal transitionScience201434312531256[PubMed][Google Scholar]
  • 432. DanopoulosSParsaSAl AlamDTabatabaiRBaptistaSTiozzoCCarraroGWheelerMBarretoGBraunTTransient Inhibition of FGFR2b-ligands signaling leads to irreversible loss of cellular beta-catenin organization and signaling in AER during mouse limb developmentPLoS One20138e76248et al.[PubMed][Google Scholar]
  • 433. KawakamiYEstebanCRMatsuiTRodriguez-LeonJKatoSIzpisua BelmonteJCSp8 and Sp9, two closely related buttonhead-like transcription factors, regulate Fgf8 expression and limb outgrowth in vertebrate embryosDevelopment200413147634774[PubMed][Google Scholar]
  • 434. HaroEDelgadoIJuncoMYamadaYMansouriAObergKCRosMASp6 and Sp8 transcription factors control AER formation and dorsal-ventral patterning in limb developmentPLoS Genet201410e1004468[PubMed][Google Scholar]
  • 435. MarianiFVAhnCPMartinGRGenetic evidence that FGFs have an instructive role in limb proximal-distal patterningNature2008453401405[PubMed][Google Scholar]
  • 436. MartinGRThe roles of FGFs in the early development of vertebrate limbsGenes Dev19981215711586[PubMed][Google Scholar]
  • 437. Yamamoto-ShiraishiYIHiguchiHYamamotoSHiranoMKuroiwaAEtv1 and Ewsr1 cooperatively regulate limb mesenchymal Fgf10 expression in response to apical ectodermal ridge-derived Fibroblast Growth Factor signalDev Biol2014394181190[PubMed][Google Scholar]
  • 438. SakiyamaJYamagishiAKuroiwaATbx4-Fgf10 system controls lung bud formation during chicken embryonic developmentDevelopment200313012251234[PubMed][Google Scholar]
  • 439. QueJOkuboTGoldenringJRNamKTKurotaniRMorriseyEETaranovaOPevnyLHHoganBLMultiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endodermDevelopment200713425212531[PubMed][Google Scholar]
  • 440. El AghaEBellusciSWalking along the Fibroblast Growth Factor 10 route: a key pathway to understand the control and regulation of epithelial and mesenchymal cell-lineage formation during lung development and repair after injuryScientifica (Cairo)20142014538379[PubMed][Google Scholar]
  • 441. RamasamySKMailleuxAAGupteVVMataFSalaFGVeltmaatJMDel MoralPMDe LangheSParsaSKellyLKFgf10 dosage is critical for the amplification of epithelial cell progenitors and for the formation of multiple mesenchymal lineages during lung developmentDev Biol2007307237247et al.[PubMed][Google Scholar]
  • 442. HashimotoSNakanoHSinghGKatyalSExpression of Spred and Sprouty in developing rat lungGene Expr Patterns20022347353[PubMed][Google Scholar]
  • 443. ZhangSLinYItarantaPYagiAVainioSExpression of Sprouty genes 1, 2 and 4 during mouse organogenesisMech Dev2001109367370[PubMed][Google Scholar]
  • 444. TefftJDLeeMSmithSLeinwandMZhaoJBringasPJrCroweDLWarburtonDConserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesisCurr Biol19999219222[PubMed][Google Scholar]
  • 445. TangNMarshallWFMcMahonMMetzgerRJMartinGRControl of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shapeScience2011333342345[PubMed][Google Scholar]
  • 446. TaniguchiKAyadaTIchiyamaKKohnoRYonemitsuYMinamiYKikuchiAMaeharaYYoshimuraASprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signalingBiochem Biophys Res Commun2007352896902[PubMed][Google Scholar]
  • 447. El AghaEHeroldSAl AlamDQuantiusJMacKenzieBCarraroGMoiseenkoAChaoCMMinooPSeegerWFgf10-positive cells represent a progenitor cell population during lung development and postnatallyDevelopment2014141296306et al.[PubMed][Google Scholar]
  • 448. ColvinJSFeldmanBNadeauJHGoldfarbMOrnitzDMGenomic organization and embryonic expression of the mouse Fibroblast Growth Factor 9 geneDev Dyn19992167288[PubMed][Google Scholar]
  • 449. del MoralPMDe LangheSPSalaFGVeltmaatJMTefftDWangKWarburtonDBellusciSDifferential role of FGF9 on epithelium and mesenchyme in mouse embryonic lungDev Biol20062937789[PubMed][Google Scholar]
  • 450. YinYWhiteACHuhSHHiltonMJKanazawaHLongFOrnitzDMAn FGF-WNT gene regulatory network controls lung mesenchyme developmentDev Biol2008319426436[PubMed][Google Scholar]
  • 451. LassiterRNStarkMRZhaoTZhouCJSignaling mechanisms controlling cranial placode neurogenesis and delaminationDev Biol20143893949[PubMed][Google Scholar]
  • 452. UrnessLDPaxtonCNWangXSchoenwolfGCMansourSLFGF signaling regulates otic placode induction and refinement by controlling both ectodermal target genes and hindbrain Wnt8aDev Biol2010340595604[PubMed][Google Scholar]
  • 453. MauldingKPadanadMSDongJRileyBBMesodermal Fgf10b cooperates with other Fibroblast Growth Factors during induction of otic and epibranchial placodes in zebrafishDev Dyn201424312751285[PubMed][Google Scholar]
  • 454. ZhangJWrightKDMahoney RogersAABarrettMMShimKCompensatory regulation of the size of the inner ear in response to excess induction of otic progenitors by Fibroblast Growth Factor signalingDev Dyn201424313171327[PubMed][Google Scholar]
  • 455. Mahoney RogersAAZhangJShimKSprouty1 and Sprouty2 limit both the size of the otic placode and hindbrain Wnt8a by antagonizing FGF signalingDev Biol201135394104[PubMed][Google Scholar]
  • 456. PaekHGutinGHebertJMFGF signaling is strictly required to maintain early telencephalic precursor cell survivalDevelopment200913624572465[PubMed][Google Scholar]
  • 457. RhinnMPickerABrandMGlobal and local mechanisms of forebrain and midbrain patterningCurr Opin Neurobiol200616512[PubMed][Google Scholar]
  • 458. LiuALiJYBromleighCLaoZNiswanderLAJoynerALFGF17b and FGF18 have different midbrain regulatory properties from FGF8b or activated FGF receptorsDevelopment200313061756185[PubMed][Google Scholar]
  • 459. LeeSMDanielianPSFritzschBMcMahonAPEvidence that FGF8 signalling from the midbrain-hindbrain junction regulates growth and polarity in the developing midbrainDevelopment1997124959969[PubMed][Google Scholar]
  • 460. PartanenJFGF signalling pathways in development of the midbrain and anterior hindbrainJ Neurochem200710111851193[PubMed][Google Scholar]
  • 461. CrossleyPHMartinezSMartinGRMidbrain development induced by FGF8 in the chick embryoNature19963806668[PubMed][Google Scholar]
  • 462. Saarimaki-VireJPeltopuroPLahtiLNaserkeTBlakAAVogt WeisenhornDMYuKOrnitzDMWurstWPartanenJFibroblast Growth Factor receptors cooperate to regulate neural progenitor properties in the developing midbrain and hindbrainJ Neurosci20072785818592[PubMed][Google Scholar]
  • 463. MavesLJackmanWKimmelCBFGF3 and FGF8 mediate a rhombomere 4 signaling activity in the zebrafish hindbrainDevelopment200212938253837[PubMed][Google Scholar]
  • 464. WalsheJMaroonHMcGonnellIMDicksonCMasonIEstablishment of hindbrain segmental identity requires signaling by FGF3 and FGF8Curr Biol20021211171123[PubMed][Google Scholar]
  • 465. GuillemotFZimmerCFrom cradle to grave: the multiple roles of Fibroblast Growth Factors in neural developmentNeuron201171574588[PubMed][Google Scholar]
  • 466. SmithKMOhkuboYMaragnoliMERasinMRSchwartzMLSestanNVaccarinoFMMidline radial glia translocation and corpus callosum formation require FGF signalingNat Neurosci20069787797[PubMed][Google Scholar]
  • 467. UmemoriHLinhoffMWOrnitzDMSanesJRFGF22 and its close relatives are presynaptic organizing molecules in the mammalian brainCell2004118257270[PubMed][Google Scholar]
  • 468. FlaumenhaftRMoscatelliDRifkinDBHeparin and heparan sulfate increase the radius of diffusion and action of basic Fibroblast Growth FactorJ Cell Biol199011116511659[PubMed][Google Scholar]
  • 469. HaradaMMurakamiHOkawaAOkimotoNHiraokaSNakaharaTAkasakaRShiraishiYFutatsugiNMizutani-KosekiYFGF9 monomer/dimer equilibrium regulates extracellular matrix affinity and tissue diffusionNat Genet200941289298et al.[PubMed][Google Scholar]
  • 470. WuXLGuMMHuangLLiuXSZhangHXDingXYXuJQCuiBWangLLuSYMultiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 geneAm J Hum Genet2009855363et al.[PubMed][Google Scholar]
  • 471. QuXPanYCarbeCPowersAGrobeKZhangXGlycosaminoglycan-dependent restriction of FGF diffusion is necessary for lacrimal gland developmentDevelopment201213927302739[PubMed][Google Scholar]
  • 472. AmannKFaulhaberJCampeanVBalajewVDonoRMallGEhmkeHImpaired myocardial capillarogenesis and increased adaptive capillary growth in FGF2-deficient miceLab Invest2006864553[PubMed][Google Scholar]
  • 473. ViragJARolleMLReeceJHardouinSFeiglEOMurryCEFibroblast Growth Factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular functionAm J Pathol200717114311440[PubMed][Google Scholar]
  • 474. NusayrEDoetschmanTCardiac development and physiology are modulated by FGF2 in an isoform- and sex-specific mannerPhysiol Rep20131e00087[Google Scholar]
  • 475. NusayrESadideenDTDoetschmanTFGF2 modulates cardiac remodeling in an isoform- and sex-specific mannerPhysiol Rep20131e00088[Google Scholar]
  • 476. HouseSLHouseBEGlascockBKimballTNusayrESchultzJEDoetschmanTFibroblast Growth Factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinaseMol Cell Pharmacol20102143154[PubMed][Google Scholar]
  • 477. DonoRFaulhaberJGalliAZunigaAVolkTTexidoGZellerREhmkeHFGF2 signaling is required for the development of neuronal circuits regulating blood pressureCirc Res200290E5E10[PubMed][Google Scholar]
  • 478. GroseRWernerSWound healing studies in transgenic and knockout mice: a reviewMethods Mol Med200378191216[PubMed][Google Scholar]
  • 479. TekinMHismiBOFitozSOzdagHCengizFBSirmaciAAslanIInceogluBYuksel-KonukEBYilmazSTHomozygous mutations in Fibroblast Growth Factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontiaAm J Hum Genet200780338344et al.[PubMed][Google Scholar]
  • 480. SakaueHKonishiMOgawaWAsakiTMoriTYamasakiMTakataMUenoHKatoSKasugaMRequirement of Fibroblast Growth Factor 10 in development of white adipose tissueGenes Dev200216908912et al.[PubMed][Google Scholar]
  • 481. HasegawaHAshigakiSTakamatsuMSuzuki-MigishimaROhbayashiNItohNTakadaSTanabeYLaminar patterning in the developing neocortex by temporally coordinated Fibroblast Growth Factor signalingJ Neurosci20042487118719[PubMed][Google Scholar]
  • 482. ZhangXStappenbeckTSWhiteACLavineKJGordonJIOrnitzDMReciprocal epithelial-mesenchymal FGF signaling is required for cecal developmentDevelopment2006133173180[PubMed][Google Scholar]
  • 483. WrightTJLadherRMcWhirterJMurreCSchoenwolfGCMansourSLMouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic inductionDev Biol2004269264275[PubMed][Google Scholar]
  • 484. UriarteIFernandez-BarrenaMGMonteMJLatasaMUChangHCCarottiSVespasiani-GentilucciUMoriniSVicenteEConcepcionARIdentification of Fibroblast Growth Factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in miceGut201362899910et al.[PubMed][Google Scholar]
  • 485. BadmanMKPissiosPKennedyARKoukosGFlierJSMaratos-FlierEHepatic Fibroblast Growth Factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic statesCell Metab20075426437[PubMed][Google Scholar]
  • 486. InagakiTDutchakPZhaoGDingXGautronLParameswaraVLiYGoetzRMohammadiMEsserVEndocrine regulation of the fasting response by PPARalpha-mediated induction of Fibroblast Growth Factor 21Cell Metab20075415425et al.[PubMed][Google Scholar]
  • 487. LundasenTHuntMCNilssonLMSanyalSAngelinBAlexsonSERudlingMPPARalpha is a key regulator of hepatic FGF21Biochem Biophys Res Commun2007360437440[PubMed][Google Scholar]
  • 488. BadmanMKKoesterAFlierJSKharitonenkovAMaratos-FlierEFibroblast Growth Factor 21-deficient mice demonstrate impaired adaptation to ketosisEndocrinology200915049314940[PubMed][Google Scholar]
  • 489. LinZTianHLamKSLinSHooRCKonishiMItohNWangYBornsteinSRXuAAdiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in miceCell Metab201317779789et al.[PubMed][Google Scholar]
  • 490. HollandWLAdamsACBrozinickJTBuiHHMiyauchiYKusminskiCMBauerSMWadeMSinghalEChengCCAn FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in miceCell Metab201317790797et al.[PubMed][Google Scholar]
  • 491. ShimadaTFukumotoSFGF23 as a novel therapeutic targetAdv Exp Med Biol2012728158170[PubMed][Google Scholar]
  • 492. TangWJWangLFXuXYZhouYJinWFWangHFGaoJAutocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblastsCalcif Tissue Int201086404410[PubMed][Google Scholar]
  • 493. FaulCAmaralAPOskoueiBHuMCSloanAIsakovaTGutierrezOMAguillon-PradaRLincolnJHareJMFGF23 induces left ventricular hypertrophyJ Clin Invest201112143934408et al.[PubMed][Google Scholar]
  • 494. TouchberryCDGreenTMTchikrizovVMannixJEMaoTFCarneyBWGirgisMVincentRJWetmoreLADawnBFGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophyAm J Physiol Endocrinol Metab2013304E863E873et al.[PubMed][Google Scholar]
  • 495. LiuCDib-HajjSDWaxmanSGFibroblast Growth Factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel rNav1.9a (NaN)J Biol Chem20012761892518933[PubMed][Google Scholar]
  • 496. LiuCJDib-HajjSDRenganathanMCumminsTRWaxmanSGModulation of the cardiac sodium channel Na(v)1.5 by Fibroblast Growth Factor homologous factor 1BJ Biol Chem200327810291036[PubMed][Google Scholar]
  • 497. LaezzaFLampertAKozelMAGerberBRRushAMNerbonneJMWaxmanSGDib-HajjSDOrnitzDMFGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channelsMol Cell Neurosci20094290101[PubMed][Google Scholar]
  • 498. ShavkunovAPanovaNPrasaiAVeselenakRBourneNStoilova-McPhieSLaezzaFBioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complexAssay Drug Dev Technol201210148160[PubMed][Google Scholar]
  • 499. HennesseyJAWeiEQPittGSFibroblast Growth Factor homologous factors modulate cardiac calcium channelsCirc Res2013113381388[PubMed][Google Scholar]
  • 500. DoverKSolinasSD'AngeloEGoldfarbMLong-term inactivation particle for voltage-gated sodium channelsJ Physiol201058836953711[PubMed][Google Scholar]
  • 501. BoschMKCarrasquilloYRansdellJLKanakamedalaAOrnitzDMNerbonneJMIntracellular FGF14 (iFGF14) is required for spontaneous and evoked firing in cerebellar Purkinje neurons and for motor coordination and balanceJ Neurosci. In press[Google Scholar]
  • 502. ShavkunovASWildburgerNCNenovMNJamesTFBuzhdyganTPPanova-ElektronovaNIGreenTAVeselenakRLBourneNLaezzaFThe Fibroblast Growth Factor 14.voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3)J Biol Chem20132881937019385[PubMed][Google Scholar]
  • 503. WildburgerNCLaezzaFControl of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinaseFront Mol Neurosci2012580[PubMed][Google Scholar]
  • 504. AliSShavkunovAPanovaNStoilova-McPhieSLaezzaFModulation of the FGF14:FGF14 homodimer interaction through short peptide fragmentsCNS Neurol Disord Drug Targets20141315591570[PubMed][Google Scholar]
  • 505. Van SwietenJCBrusseEDe GraafBMKriegerEVan De GraafRDe KoningIMaat-KievitALeegwaterPDooijesDOostraBAA mutation in the Fibroblast Growth Factor 14 gene is associated with autosomal dominant cerebellar ataxiaAm J Hum Genet200372191199et al.[PubMed][Google Scholar]
  • 506. BrusseEde KoningIMaat-KievitAOostraBAHeutinkPvan SwietenJCSpinocerebellar ataxia associated with a mutation in the Fibroblast Growth Factor 14 gene (SCA27): a new phenotypeMov Disord200621396401[PubMed][Google Scholar]
  • 507. YangJMeyerMMullerAKBohmFGroseRDauwalderTVerreyFKopfMPartanenJBlochWFibroblast Growth Factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasisJ Cell Biol2010188935952et al.[PubMed][Google Scholar]
  • 508. HayashiTCunninghamDBermingham-McDonoghOLoss of Fgfr3 leads to excess hair cell development in the mouse organ of cortiDev Dyn2007236525533[PubMed][Google Scholar]
  • 509. MoldrichRXMezzeraCHolmesWMGodaSBrookfieldSJRankinAJBarrEKurniawanNDewarDRichardsLJFgfr3 regulates development of the caudal telencephalonDev Dyn201124015861599et al.[PubMed][Google Scholar]
  • 510. VidrichABuzanJMBrodrickBIloCBradleyLFendigKSSturgillTCohnSMFibroblast Growth Factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal developmentAm J Physiol Gastrointest Liver Physiol2009297G168G178[PubMed][Google Scholar]
  • 511. HuangXYangCLuoYJinCWangFMcKeehanWLFGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liverDiabetes20075625012510[PubMed][Google Scholar]
  • 512. HuangXYangCJinCLuoYWangFMcKeehanWLResident hepatocyte Fibroblast Growth Factor receptor 4 limits hepatocarcinogenesisMol Carcinog200948553562[PubMed][Google Scholar]
  • 513. UriarteILatasaMUCarottiSFernandez-BarrenaMGGarcia-IrigoyenOElizaldeMUrtasunRVespasiani-GentilucciUMoriniSde MingoAIleal FGF15 contributes to fibrosis-associated hepatocellular carcinoma developmentInt J Cancer2014et al.. In press. doi: 10.1002/ijc.29287[Google Scholar]
  • 514. TekinMOzturkmen AkayHFitozSBirnbaumSCengizFBSennarogluLIncesuluAYuksel KonukEBHasanefendioglu BayrakASenturkSHomozygous FGF3 mutations result in congenital deafness with inner ear agenesis, microtia, and microdontiaClin Genet200873554565et al.[PubMed][Google Scholar]
  • 515. Gregory-EvansCYMoosajeeMHodgesMDMackayDSGameLVargessonNBloch-ZupanARuschendorfFSantos-PintoLWackensGSNP genome scanning localizes oto-dental syndrome to chromosome 11q13 and microdeletions at this locus implicate FGF3 in dental and inner-ear disease and FADD in ocular colobomaHum Mol Genet20071624822493et al.[PubMed][Google Scholar]
  • 516. AlsmadiOMeyerBFAlkurayaFWakilSAlkayalFAl-SaudHRamzanKAl-SayedMSyndromic congenital sensorineural deafness, microtia and microdontia resulting from a novel homoallelic mutation in Fibroblast Growth Factor 3 (FGF3)Eur J Hum Genet2009171421[PubMed][Google Scholar]
  • 517. SensiACerutiSTrevisiPGualandiFBusiMDonatiINeriMFerliniAMartiniALAMM syndrome with middle ear dysplasia associated with compound heterozygosity for FGF3 mutationsAm J Med Genet A2011>155a10961101[PubMed][Google Scholar]
  • 518. CadieuENeffMWQuignonPWalshKChaseKParkerHGVonholdtBMRhueABoykoAByersACoat variation in the domestic dog is governed by variants in three genesScience2009326150153et al.[PubMed][Google Scholar]
  • 519. DrogemullerCRufenachtSWichertBLeebTMutations within the FGF5 gene are associated with hair length in catsAnim Genet200738218221[PubMed][Google Scholar]
  • 520. KehlerJSDavidVASchafferAABajemaKEizirikERyugoDKHannahSSO'BrienSJMenotti-RaymondMFour independent mutations in the feline Fibroblast Growth Factor 5 gene determine the long-haired phenotype in domestic catsJ Hered200798555566[PubMed][Google Scholar]
  • 521. DierksCMomkeSPhilippUDistlOAllelic heterogeneity of FGF5 mutations causes the long-hair phenotype in dogsAnim Genet201344425431[PubMed][Google Scholar]
  • 522. BrehmJMHagiwaraKTesfaigziYBruseSMarianiTJBhattacharyaSBoutaouiNZinitiJPSoto-QuirosMEAvilaLIdentification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary diseaseThorax20116610851090et al.[PubMed][Google Scholar]
  • 523. TrarbachEBAbreuAPSilveiraLFGarmesHMBaptistaMTTelesMGCostaEMMohammadiMPitteloudNMendoncaBBNonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiencyJ Clin Endocrinol Metab20109534913496et al.[PubMed][Google Scholar]
  • 524. RileyBMMansillaMAMaJDaack-HirschSMaherBSRaffenspergerLMRussoETVieiraARDodeCMohammadiMImpaired FGF signaling contributes to cleft lip and palateProc Natl Acad Sci USA200710445124517et al.[PubMed][Google Scholar]
  • 525. FalardeauJChungWCBeenkenARaivioTPlummerLSidisYJacobson-DickmanEEEliseenkovaAVMaJDwyerADecreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and miceJ Clin Invest200811828222831et al.[PubMed][Google Scholar]
  • 526. ArauzRFSolomonBDPineda-AlvarezDEGropmanALParsonsJARoesslerEMuenkeMA hypomorphic allele in the FGF8 gene contributes to holoprosencephaly and is allelic to gonadotropin-releasing hormone deficiency in humansMol Syndromol201015966[PubMed][Google Scholar]
  • 527. McCabeMJGaston-MassuetCTziaferiVGregoryLCAlatzoglouKSSignoreMPuellesEGerrelliDFarooqiISRazaJNovel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunctionJ Clin Endocrinol Metab201196E1709E1718et al.[PubMed][Google Scholar]
  • 528. Valdes-SocinHRubio AlmanzaMTome Fernandez-LadredaMDebrayFGBoursVBeckersAReproduction, smell, and neurodevelopmental disorders: genetic defects in different hypogonadotropic hypogonadal syndromesFront Endocrinol (Lausanne)20145109[PubMed][Google Scholar]
  • 529. ChungCLLuCWChengYSLinCYSunHSLinYMAssociation of aberrant expression of sex-determining gene Fibroblast Growth Factor 9 with Sertoli cell-only syndromeFertil Steril201310015471554.e1541-1544[PubMed][Google Scholar]
  • 530. EntesarianMDahlqvistJShashiVStanleyCSFalahatBReardonWDahlNFGF10 missense mutations in aplasia of lacrimal and salivary glands (ALSG)Eur J Hum Genet200715379382[PubMed][Google Scholar]
  • 531. RohmannEBrunnerHGKayseriliHUygunerONurnbergGLewEDDobbieAEswarakumarVPUzumcuAUlubil-EmerogluMMutations in different components of FGF signaling in LADD syndromeNat Genet200638414417et al.[PubMed][Google Scholar]
  • 532. HsiEChenKCChangWSYuMLLiangCLJuoSHA functional polymorphism at the FGF10 gene is associated with extreme myopiaInvest Ophthalmol Vis Sci20135432653271[PubMed][Google Scholar]
  • 533. MilunskyJMZhaoGMaherTAColbyREvermanDBLADD syndrome is caused by FGF10 mutationsClin Genet200669349354[PubMed][Google Scholar]
  • 534. EntesarianMMatssonHKlarJBergendalBOlsonLArakakiRHayashiYOhuchiHFalahatBBolstadAIMutations in the gene encoding Fibroblast Growth Factor 10 are associated with aplasia of lacrimal and salivary glandsNat Genet200537125127et al.[PubMed][Google Scholar]
  • 535. HennesseyJAMarcouCAWangCWeiEQWangCTesterDJTorchioMDagradiFCrottiLSchwartzPJFGF12 is a candidate Brugada syndrome locusHeart Rhythm20131018861894et al.[PubMed][Google Scholar]
  • 536. GeczJBakerEDonnellyAMingJEMcDonald-McGinnDMSpinnerNBZackaiEHSutherlandGRMulleyJCFibroblast Growth Factor homologous factor 2 (FHF2): gene structure, expression and mapping to the Borjeson-Forssman-Lehmann syndrome region in Xq26 delineated by a duplication breakpoint in a BFLS-like patientHum Genet19991045663[PubMed][Google Scholar]
  • 537. DeStefanoGMFantauzzoKAPetukhovaLKurbanMTadin-StrappsMLevyBWarburtonDCirulliETHanYSunXPosition effect on FGF13 associated with X-linked congenital generalized hypertrichosisProc Natl Acad Sci USA201311077907795et al.[PubMed][Google Scholar]
  • 538. DalskiAAticiJKreuzFRHellenbroichYSchwingerEZuhlkeCMutation analysis in the Fibroblast Growth Factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxiasEur J Hum Genet200513118120[PubMed][Google Scholar]
  • 539. Coebergh JAvan de PutteDESnoeckINRuivenkampCvan HaeringenASmitLMA new variable phenotype in spinocerebellar ataxia 27 (SCA 27) caused by a deletion in the FGF14 geneEur J Paediatr Neurol201418413415[PubMed][Google Scholar]
  • 540. JamsheerAZemojtelTKolanczykMStrickerSHechtJKrawitzPDoelkenSCGlazarRSochaMMundlosSWhole exome sequencing identifies FGF16 nonsense mutations as the cause of X-linked recessive metacarpal 4/5 fusionJ Med Genet201350579584[PubMed][Google Scholar]
  • 541. LaurellTNilssonDHofmeisterWLindstrandAAhituvNVandermeerJAmilonAAnnerenGArnerMPetterssonMIdentification of three novel FGF16 mutations in X-linked recessive fusion of the fourth and fifth metacarpals and possible correlation with heart diseaseMol Genet Genomic Med20142402411et al.[PubMed][Google Scholar]
  • 542. MiraouiHDwyerAASykiotisGPPlummerLChungWFengBBeenkenAClarkeJPersTHDworzynskiPMutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadismAm J Hum Genet201392725743et al.[PubMed][Google Scholar]
  • 543. van der WaltJMNoureddineMAKittappaRHauserMAScottWKMcKayRZhangFStajichJMFujiwaraKScottBLFibroblast Growth Factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson diseaseAm J Hum Genet20047411211127et al.[PubMed][Google Scholar]
  • 544. ItohNOhtaHRoles of FGF20 in dopaminergic neurons and Parkinson's diseaseFront Mol Neurosci2013615[PubMed][Google Scholar]
  • 545. LemaitreHMattayVSSambataroFVerchinskiBStraubRECallicottJHKittappaRHydeTMLipskaBKKleinmanJEGenetic variation in FGF20 modulates hippocampal biologyJ Neurosci20103059925997et al.[PubMed][Google Scholar]
  • 546. ChuAYWorkalemahuTPaynterNPRoseLMGiulianiniFTanakaTNgwaJSQiQCurhanGCRimmEBNovel locus including FGF21 is associated with dietary macronutrient intakeHum Mol Genet20132218951902et al.[PubMed][Google Scholar]
  • 547. TanakaTNgwaJSvan RooijFJZillikensMCWojczynskiMKFrazier-WoodACHoustonDKKanoniSLemaitreRNLuanJGenome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intakeAm J Clin Nutr20139713951402et al.[PubMed][Google Scholar]
  • 548. ZhangMZengLWangYJAnZMYingBWAssociations of Fibroblast Growth Factor 21 gene 3' untranslated region single-nucleotide polymorphisms with metabolic syndrome, obesity, and diabetes in a Han Chinese populationDNA Cell Biol201231547552[PubMed][Google Scholar]
  • 549. Benet-PagesAOrlikPStromTMLorenz-DepiereuxBAn FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemiaHum Mol Genet200514385390[PubMed][Google Scholar]
  • 550. MasiLGozziniAFranchiACampanacciDAmedeiAFalchettiAFranceschelliFMarcucciGTaniniACapannaRA novel recessive mutation of Fibroblast Growth Factor-23 in tumoral calcinosisJ Bone Joint Surg Am20099111901198et al.[PubMed][Google Scholar]
  • 551. MasiLFranceschelliFLeonciniGGozziniARiganteDLa TorreFMatucci-CerinicMBrandiMLFalciniFCan Fibroblast Growth Factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease?Clin Exp Rheumatol201331149153[PubMed][Google Scholar]
  • 552. FalciniFRiganteDMasiLCovinoMFranceschelliFLeonciniGTarantinoGMatucci CerinicMBrandiMLFibroblast Growth Factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalitiesItal J Pediatr20133969[PubMed][Google Scholar]
  • 553. ChefetzIHellerRGalli-TsinopoulouARichardGWollnikBIndelmanMKoerberFTopazOBergmanRSprecherEA novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcificationHum Genet2005118261266et al.[PubMed][Google Scholar]
  • 554. ArayaKFukumotoSBackenrothRTakeuchiYNakayamaKItoNYoshiiNYamazakiYYamashitaTSilverJA novel mutation in Fibroblast Growth Factor (FGF)23 gene as a cause of tumoral calcinosisJ Clin Endocrinol Metab20059055235527et al.[PubMed][Google Scholar]
  • 555. GarringerHJMalekpourMEsteghamatFMortazaviSMDavisSIFarrowEGYuXArkingDEDietzHCWhiteKEMolecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosisAm J Physiol Endocrinol Metab2008295E929E937[PubMed][Google Scholar]
  • 556. MuenkeMSchellUHehrARobinNHLoskenHWSchinzelAPulleynLJRutlandPReardonWMalcolmSA common mutation in the Fibroblast Growth Factor receptor 1 gene in Pfeiffer syndromeNat Genet19948269274et al.[PubMed][Google Scholar]
  • 557. RoscioliTFlanaganSKumarPMaselJGattasMHylandVJGlassIAClinical findings in a patient with FGFR1 P252R mutation and comparison with the literatureAm J Med Genet2000932228[PubMed][Google Scholar]
  • 558. DodeCLevilliersJDupontJMDe PaepeALe DuNSoussi-YanicostasNCoimbraRSDelmaghaniSCompain-NouailleSBaverelFLoss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndromeNat Genet200333463465et al.[PubMed][Google Scholar]
  • 559. PitteloudNAciernoJSJrMeysingAUDwyerAAHayesFJCrowleyWFJrReversible kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the Fibroblast Growth Factor receptor 1 geneJ Clin Endocrinol Metab20059013171322[PubMed][Google Scholar]
  • 560. SimonisNMigeotteILambertNPerazzoloCde SilvaDCDimitrovBHeinrichsCJanssensSKerrBMortierGFGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactylyJ Med Genet201350585592et al.[PubMed][Google Scholar]
  • 561. KoikaVVarnavasPValavaniHSidisYPlummerLDwyerAQuintonRKanaka-GantenbeinCPitteloudNSertedakiAComparative functional analysis of two Fibroblast Growth Factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH)Gene2012516146151et al.[PubMed][Google Scholar]
  • 562. PitteloudNQuintonRPearceSRaivioTAciernoJDwyerAPlummerLHughesVSeminaraSChengYZDigenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadismJ Clin Invest2007117457463et al.[PubMed][Google Scholar]
  • 563. ZhouYXXuXChenLLiCBrodieSGDengCXA Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial suturesHum Mol Genet2000920012008[PubMed][Google Scholar]
  • 564. PitteloudNAciernoJSJrMeysingAEliseenkovaAVMaJIbrahimiOAMetzgerDLHayesFJDwyerAAHughesVAMutations in Fibroblast Growth Factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadismProc Natl Acad Sci USA200610362816286et al.[PubMed][Google Scholar]
  • 565. VillanuevaCJacobson-DickmanEXuCManouvrierSDwyerAASykiotisGPBeenkenALiuYTommiskaJHuYCongenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutationsGenet Med2014et al.. In press. doi: 10.1038/gim.2014.166[Google Scholar]
  • 566. WangXLWangDDGuJQZhangNShanZYA female patient with normosmic idiopathic hypogonadotropic hypogonadism carrying a novel mutation in FGFR1Genet Mol Res20141394729476[PubMed][Google Scholar]
  • 567. RutlandPPulleynLJReardonWBaraitserMHaywardRJonesBMalcolmSWinterRMOldridgeMSlaneySFIdentical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypesNat Genet19959173176et al.[PubMed][Google Scholar]
  • 568. SchellUHehrAFeldmanGJRobinNHZackaiEHde Die-SmuldersCViskochilDHStewartJMWolffGOhashiHMutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndromeHum Mol Genet19954323328et al.[PubMed][Google Scholar]
  • 569. JabsEWLiXScottAFMeyersGChenWEcclesMMaoJCharnasLRJacksonCEJayeMJackson-Weiss and Crouzon syndromes are allelic with mutations in Fibroblast Growth Factor receptor 2Nat Genet19948275279[PubMed][Google Scholar]
  • 570. ParkWJMeyersGALiXThedaCDayDOrlowSJJonesMCJabsEWNovel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variabilityHum Mol Genet1995412291233[PubMed][Google Scholar]
  • 571. ReardonWWinterRMRutlandPPulleynLJJonesBMMalcolmSMutations in the Fibroblast Growth Factor receptor 2 gene cause Crouzon syndromeNat Genet1994898103[PubMed][Google Scholar]
  • 572. OldridgeMWilkieAOSlaneySFPooleMDPulleynLJRutlandPHockleyADWakeMJGoldinJHWinterRMMutations in the third immunoglobulin domain of the Fibroblast Growth Factor receptor-2 gene in Crouzon syndromeHum Mol Genet1995410771082et al.[PubMed][Google Scholar]
  • 573. SteinbergerDMullikenJBMullerUCrouzon syndrome: previously unrecognized deletion, duplication, and point mutation within FGFR2 geneHum Mutat19968386390[PubMed][Google Scholar]
  • 574. PaznekasWACunninghamMLHowardTDKorfBRLipsonMHGrixAWFeingoldMGoldbergRBorochowitzZAleckKGenetic heterogeneity of Saethre-Chotzen-Syndrome, due to twist and Fgfr mutationsAm J Hum Genet19986213701380et al.[PubMed][Google Scholar]
  • 575. OldridgeMZackaiEHMcDonald-McGinnDMIsekiSMorriss-KayGMTwiggSRJohnsonDWallSAJiangWThedaCDe novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndromeAm J Hum Genet199964446461et al.[PubMed][Google Scholar]
  • 576. WilkieAOMSlaneySFOldridgeMPooleMDAshworthGJHockleyADHaywardRDDavidDJPulleynLJRutlandPApert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndromeNat Genet19959165172et al.[PubMed][Google Scholar]
  • 577. MerrillAESarukhanovAKrejciPIdoniBCamachoNEstradaKDLyonsKMDeixlerHRobinsonHChitayatDBent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signalingAm J Hum Genet201290550557et al.[PubMed][Google Scholar]
  • 578. JohnsonDWallSAMannSWilkieAOA novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction leading to craniosynostosis?Eur J Hum Genet20008571577[PubMed][Google Scholar]
  • 579. ParkWJThedaCMaestriNEMeyersGAFryburgJSDufresneCCohenMMJrJabsEWAnalysis of phenotypic features and FGFR2 mutations in Apert syndromeAm J Hum Genet199557321328[PubMed][Google Scholar]
  • 580. Foldynova-TrantirkovaSWilcoxWRKrejciPSixteen years and counting: the current understanding of Fibroblast Growth Factor receptor 3 (FGFR3) signaling in skeletal dysplasiasHum Mutat2012332941[PubMed][Google Scholar]
  • 581. HortonWAHallJGHechtJTAchondroplasiaLancet2007370162172[PubMed][Google Scholar]
  • 582. ChenLLiCQiaoWXuXDengCA Ser(365)–>Cys mutation of Fibroblast Growth Factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasiaHum Mol Genet200110457465[PubMed][Google Scholar]
  • 583. WinterpachtAHilbertKStelzerCSchweikardtTDeckerHSegererHSprangerJZabelBA novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasiaPhysiol Genomics20002912[PubMed][Google Scholar]
  • 584. LiCChenLIwataTKitagawaMFuXYDengCXA Lys644Glu substitution in Fibroblast Growth Factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitorsHum Mol Genet199983544[PubMed][Google Scholar]
  • 585. ChenLAdarRYangXMonsonegoEOLiCHauschkaPVYayonADengCXGly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesisJ Clin Invest199910415171525[PubMed][Google Scholar]
  • 586. BrodieSGKitohHLachmanRSNolascoLMMekikianPBWilcoxWRPlatyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutationsAm J Med Genet199984476480[PubMed][Google Scholar]
  • 587. BellusGABamshadMJPrzylepaKADorstJLeeRRHurkoOJabsEWCurryCJWilcoxWRLachmanRSSevere achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in Fibroblast Growth Factor receptor 3Am J Med Genet1999855365et al.[PubMed][Google Scholar]
  • 588. MatsuiYYasuiNKimuraTTsumakiNKawabataHOchiTGenotype phenotype correlation in achondroplasia and hypochondroplasiaJ Bone Joint Surg Br19988010521056[PubMed][Google Scholar]
  • 589. WebsterMKD'AvisPYRobertsonSCDonoghueDJProfound ligand-independent kinase activation of Fibroblast Growth Factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type IIMol Cell Biol19961640814087[PubMed][Google Scholar]
  • 590. WebsterMKDonoghueDJConstitutive activation of Fibroblast Growth Factor receptor 3 by the transmembrane domain point mutation found in achondroplasiaEMBO J199615520527[PubMed][Google Scholar]
  • 591. TavorminaPLShiangRThompsonLMZhuYWilkinDJLachmanRSWilcoxWRRimoinDLCohnDHWasmuthJJThanatophoric dysplasia (types I and II) caused by distinct mutations in Fibroblast Growth Factor receptor 3Nat Genet19959321328[PubMed][Google Scholar]
  • 592. MeyersGAOrlowSJMunroIRPrzylepaKAJabsEWFibroblast Growth Factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricansNat Genet199511462464[PubMed][Google Scholar]
  • 593. BellusGAMcIntoshISmithEAAylesworthASKaitilaIHortonWAGreenhawGAHechtJTFrancomanoCAA recurrent mutation in the tyrosine kinase domain of Fibroblast Growth Factor receptor 3 causes hypochondroplasiaNat Genet199510357359[PubMed][Google Scholar]
  • 594. ShiangRThompsonLMZhuY-ZChurchDMFielderTJBocianMWinokurSTWasmuthJJMutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasiaCell199478335342[PubMed][Google Scholar]
  • 595. MininaEKreschelCNaskiMCOrnitzDMVortkampAInteraction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiationDev Cell20023439449[PubMed][Google Scholar]
  • 596. MuenkeMGrippKWMcDonald-McGinnDMGaudenzKWhitakerLABartlettSPMarkowitzRIRobinNHNwokoroNMulvihillJJA unique point mutation in the Fibroblast Growth Factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndromeAm J Hum Genet199760555564et al.[PubMed][Google Scholar]
  • 597. GrippKWMcDonald-McGinnDMGaudenzKWhitakerLABartlettSPGlatPMCassilethLBMayroRZackaiEHMuenkeMIdentification of a genetic cause for isolated unilateral coronal synostosis: a unique mutation in the Fibroblast Growth Factor receptor 3J Pediatr1998132714716[PubMed][Google Scholar]
  • 598. LajeunieEEl GhouzziVLe MerrerMMunnichABonaventureJRenierDSex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutationJ Med Genet199936913[PubMed][Google Scholar]
  • 599. GrahamJMJrBraddockSRMortierGRLachmanRVan DopCJabsEWSyndrome of coronal craniosynostosis with brachydactyly and carpal/tarsal coalition due to Pro250Arg mutation in FGFR3 geneAm J Med Genet199877322329[PubMed][Google Scholar]
  • 600. MoloneyDMWallSAAshworthGJOldridgeMGlassIAFrancomanoCAMuenkeMWilkieAOPrevalence of Pro250Arg mutation of Fibroblast Growth Factor receptor 3 in coronal craniosynostosisLancet199734910591062[PubMed][Google Scholar]
  • 601. GollaALichmerPvon GernetSWinterpachtAFairleyJMurkenJSchuffenhauerSPhenotypic expression of the Fibroblast Growth Factor receptor 3 (FGFR3) mutation P250R in a large craniosynostosis familyJ Med Genet199734683684[PubMed][Google Scholar]
  • 602. SchindlerSFriedrichMWagenerHLorenzBPreisingMNHeterozygous P250L mutation of Fibroblast Growth Factor receptor 3 in a case of isolated craniosynostosisJ Med Genet200239764766[PubMed][Google Scholar]
  • 603. SuNSunQLiCLuXQiHChenSYangJDuXZhaoLHeQGain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesisHum Mol Genet20101911991210et al.[PubMed][Google Scholar]
  • 604. PannierSCouloignerVMessaddeqNElmaleh-BergesMMunnichARomandRLegeai-MalletLActivating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasiaBiochim Biophys Acta20091792140147[PubMed][Google Scholar]
  • 605. MansourSLTwiggSRFreelandRMWallSALiCWilkieAOHearing loss in a mouse model of Muenke syndromeHum Mol Genet2009184350[PubMed][Google Scholar]
  • 606. MansourSLLiCUrnessLDGenetic rescue of Muenke syndrome model hearing loss reveals prolonged FGF-dependent plasticity in cochlear supporting cell fatesGenes Dev20132723202331[PubMed][Google Scholar]
  • 607. WilkesDRutlandPPulleynLJReardonWMossCEllisJPWinterRMMalcolmSA recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricansJ Med Genet199633744748[PubMed][Google Scholar]
  • 608. SahlinPTarnowPMartinssonTStenmanGGermline mutation in the FGFR3 gene in a TWIST1-negative family with saethre-chotzen syndrome and breast cancerGenes Chromosomes Cancer200948285288[PubMed][Google Scholar]
  • 609. ToydemirRMBrassingtonAEBayrak-ToydemirPKrakowiakPAJordeLBWhitbyFGLongoNViskochilDHCareyJCBamshadMJA novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndromeAm J Hum Genet200679935941[PubMed][Google Scholar]
  • 610. MakrythanasisPTemtamySAglanMSOtaifyGAHamamyHAntonarakisSEA novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly and arachnodactylyHum Mutat201435959963[PubMed][Google Scholar]
  • 611. IwataTChenLLiCOvchinnikovDABehringerRRFrancomanoCADengCXA neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryosHum Mol Genet2000916031613[PubMed][Google Scholar]
  • 612. SaitoAHiguchiINakagawaMSaitoMUchidaYInoseMKasaiTNiiyamaTFukunagaHArimuraKAn overexpression of Fibroblast Growth Factor (FGF) and FGF receptor 4 in a severe clinical phenotype of facioscapulohumeral muscular dystrophyMuscle Nerve200023490497et al.[PubMed][Google Scholar]
  • 613. RezvaniMWildeJVittPMailaparambilBGrychtolRKruegerMHeinzmannAAssociation of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distressDis Markers201335633640[PubMed][Google Scholar]
  • 614. ChenQLiWJWanYYYuCDLiWGFibroblast Growth Factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese populationGenet Mol Res201211548555[PubMed][Google Scholar]
  • 615. RieckmannTZhuangLFluckCETruebBCharacterization of the first FGFRL1 mutation identified in a craniosynostosis patientBiochim Biophys Acta20091792112121[PubMed][Google Scholar]
  • 616. EngbersHvan der SmagtJJvan‘t SlotRVermeeschJRHochstenbachRPootMWolf-Hirschhorn syndrome facial dysmorphic features in a patient with a terminal 4p16.3 deletion telomeric to the WHSCR and WHSCR 2 regionsEur J Hum Genet200917129132[PubMed][Google Scholar]
  • 617. CatelaCBilbao-CortesDSlonimskyEKratsiosPRosenthalNTe WelscherPMultiple congenital malformations of Wolf-Hirschhorn syndrome are recapitulated in Fgfrl1 null miceDis Model Mech20092283294[PubMed][Google Scholar]
  • 618. WangQGreenRPZhaoGOrnitzDMDifferential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domainsDevelopment200112838673876[PubMed][Google Scholar]
  • 619. JonesBByersHWatsonJSNewmanWGIdentification of a novel familial FGF16 mutation in metacarpal 4–5 fusionClin Dysmorphol2014239597[PubMed][Google Scholar]
  • 620. RazzaqueMSThe FGF23-Klotho axis: endocrine regulation of phosphate homeostasisNat Rev Endocrinol20095611619[PubMed][Google Scholar]
  • 621. ShimadaTMizutaniSMutoTYoneyaTHinoRTakedaSTakeuchiYFujitaTFukumotoSYamashitaTCloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProc Natl Acad Sci USA20019865006505[PubMed][Google Scholar]
  • 622. MisceoDFannemelMBaroyTRobertoRTvedtBJaegerTBrynVStrommePFrengenESCA27 caused by a chromosome translocation: further delineation of the phenotypeNeurogenetics200910371374[PubMed][Google Scholar]
  • 623. ShimojimaKOkumuraANatsumeJAibaKKurahashiHKubotaTYokochiKYamamotoTSpinocerebellar ataxias type 27 derived from a disruption of the Fibroblast Growth Factor 14 gene with mimicking phenotype of paroxysmal non-kinesigenic dyskinesiaBrain Dev201234230233[PubMed][Google Scholar]
  • 624. LaezzaFGerberBRLouJYKozelMAHartmanHCraigAMOrnitzDMNerbonneJMThe FGF14(F145S) mutation disrupts the interaction of FGF14 with voltage-gated Na+ channels and impairs neuronal excitabilityJ Neurosci2007271203312044[PubMed][Google Scholar]
  • 625. WhiteKECabralJMDavisSIFishburnTEvansWEIchikawaSFieldsJYuXShawNJMcLellanNJMutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongationAm J Hum Genet200576361367et al.[PubMed][Google Scholar]
  • 626. IbrahimiOAZhangFEliseenkovaAVLinhardtRJMohammadiMProline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinityHum Mol Genet2004136978[PubMed][Google Scholar]
  • 627. LajeunieEMaHWBonaventureJMunnichALeMerrerMFGFR2 mutations in Pfeiffer syndromeNat Genet19959108[PubMed][Google Scholar]
  • 628. MeyersGADayDGoldbergRDaentlDLPrzylepaKAAbramsLJGrahamJMJrFeingoldMMoeschlerJBRawnsleyEFGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicingAm J Hum Genet199658491498et al.[PubMed][Google Scholar]
  • 629. Martinez-AbadiasNMotchSMPankratzTLWangYAldridgeKJabsEWRichtsmeierJTTissue-specific responses to aberrant FGF signaling in complex head phenotypesDev Dyn2013242C1[Google Scholar]
  • 630. FenwickALBowdinSCKlattREWilkieAOA deletion of FGFR2 creating a chimeric IIIb/IIIc exon in a child with Apert syndromeBMC Med Genet201112122[PubMed][Google Scholar]
  • 631. AndersonJBurnsHDEnriquez-HarrisPWilkieAOMHeathJKApert syndrome mutations in Fibroblast Growth Factor receptor 2 exhibit increased affinity for FGF ligandHum Mol Genet1998714751483[PubMed][Google Scholar]
  • 632. YuKHerrABWaksmanGOrnitzDMLoss of Fibroblast Growth Factor receptor 2 ligand-binding specificity in Apert syndromeProc Natl Acad Sci USA2000971453614541[PubMed][Google Scholar]
  • 633. HajihosseiniMKWilsonSDe MoerloozeLDicksonCA splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypesProc Natl Acad Sci USA20019838553860[PubMed][Google Scholar]
  • 634. IbrahimiOAEliseenkovaAVPlotnikovANYuKOrnitzDMMohammadiMStructural basis for Fibroblast Growth Factor receptor 2 activation in Apert syndromeProc Natl Acad Sci USA200155[Google Scholar]
  • 635. YuKOrnitzDMUncoupling Fibroblast Growth Factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypesProc Natl Acad Sci USA20019836413643[PubMed][Google Scholar]
  • 636. HajihosseiniMKDuarteRPegrumJDonjacourALana-ElolaERiceDPSharpeJDicksonCEvidence that Fgf10 contributes to the skeletal and visceral defects of an Apert syndrome mouse modelDev Dyn2009238376385[PubMed][Google Scholar]
  • 637. HolmesGBasilicoCMesodermal expression of Fgfr2(S252W) is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndromeDev Biol2012368283293[PubMed][Google Scholar]
  • 638. MoritaJNakamuraMKobayashiYDengCXFunatoNMoriyamaKSoluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse modelDev Dyn2014243560567[PubMed][Google Scholar]
  • 639. NebenCLIdoniBSalvaJETuzonCTRiceJCKrakowDMerrillAEHum Mol Genet20142356595671. Bent bone dysplasia syndrome reveals nucleolar activity for FGFR2 in ribosomal DNA transcription.[PubMed]
  • 640. LewEDBaeJHRohmannEWollnikBSchlessingerJStructural basis for reduced FGFR2 activity in LADD syndrome: implications for FGFR autoinhibition and activationProc Natl Acad Sci USA20071041980219807[PubMed][Google Scholar]
  • 641. ShamsIRohmannEEswarakumarVPLewEDYuzawaSWollnikBSchlessingerJLaxILacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the Fibroblast Growth Factor 10 (FGF10)-FGF receptor 2 signaling pathwayMol Cell Biol20072769036912[PubMed][Google Scholar]
  • 642. RousseauFBonaventureJLegeai-MalletLPeletARozetJMMaroteauxPLe MerrerMMunnichAMutations in the gene encoding Fibroblast Growth Factor receptor-3 in achondroplasiaNature1994371252254[PubMed][Google Scholar]
  • 643. BonaventureJRousseauFLegeai-MalletLLe MerrerMMunnichAMaroteauxPCommon mutations in the Fibroblast Growth Factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfismAm J Med Genet199663148154[PubMed][Google Scholar]
  • 644. AgochukwuNBSolomonBDMuenkeMHearing loss in syndromic craniosynostoses: introduction and consideration of mechanismsAm J Audiol201423135141[PubMed][Google Scholar]
  • 645. BeeverJESmitMAMeyersSNHadfieldTSBottemaCAlbretsenJCockettNEA single-base change in the tyrosine kinase II domain of ovine FGFR3 causes hereditary chondrodysplasia in sheepAnim Genet2006376671[PubMed][Google Scholar]
  • 646. SmithLBDallyMRSainzRDRodrigueKLOberbauerAMEnhanced skeletal growth of sheep heterozygous for an inactivated Fibroblast Growth Factor receptor 3J Anim Sci20068429422949[PubMed][Google Scholar]
  • 647. EzzatSZhengLFlorezJCStefanNMayrTHliangMMJablonskiKHardenMStancakovaALaaksoMThe cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetesCell Metab201317929940et al.[PubMed][Google Scholar]
  • 648. BirrerMJJohnsonMEHaoKWongKKParkDCBellAWelchWRBerkowitzRSMokSCWhole genome oligonucleotide-based array comparative genomic hybridization analysis identified Fibroblast Growth Factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasJ Clin Oncol20072522812287[PubMed][Google Scholar]
  • 649. ShariatSFYoussefRFGuptaAChadeDCKarakiewiczPIIsbarnHJeldresCSagalowskyAIAshfaqRLotanYAssociation of angiogenesis related markers with bladder cancer outcomes and other molecular markersJ Urol201018317441750[PubMed][Google Scholar]
  • 650. CuevasRKorzeniewskiNTolstovYHohenfellnerMDuensingSFGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57Cancer Res20137314001410[PubMed][Google Scholar]
  • 651. ReedJAMcNuttNSAlbinoAPDifferential expression of basic Fibroblast Growth Factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progressionAm J Pathol1994144329336[PubMed][Google Scholar]
  • 652. UenoKInoueYKawaguchiTHosoeSKawaharaMIncreased serum levels of basic Fibroblast Growth Factor in lung cancer patients: relevance to response of therapy and prognosisLung Cancer200131213219[PubMed][Google Scholar]
  • 653. UematsuSHigashiTNousoKKariyamaKNakamuraSSuzukiMNakatsukasaHKobayashiYHanafusaTTsujiTAltered expression of vascular endothelial growth factor, Fibroblast Growth Factor-2 and endostatin in patients with hepatocellular carcinomaJ Gastroenterol Hepatol200520583588et al.[PubMed][Google Scholar]
  • 654. GruelNLucchesiCRaynalVRodriguesMJPierronGGoudefroyeRCottuPReyalFSastre-GarauXFourquetALobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinomaEur J Cancer20104623992407et al.[PubMed][Google Scholar]
  • 655. TheilletCLeRoyXdeLapeyriereOGrosgeorgesJAdnaneJRaynaudSDSimony-LafontaineJGoldfarbMEscotCBirnbaumDAmplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomasOncogene19894915922[PubMed][Google Scholar]
  • 656. AllerstorferSSonvillaGFischerHSpiegl-KreineckerSGauglhoferCSetinekUCzechTMarosiCBuchroithnerJPichlerJFGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activitiesOncogene20082741804190et al.[PubMed][Google Scholar]
  • 657. RopiquetFGiriDKwabi-AddoBMansukhaniAIttmannMIncreased expression of Fibroblast Growth Factor 6 in human prostatic intraepithelial neoplasia and prostate cancerCancer Res20006042454250[PubMed][Google Scholar]
  • 658. YamayoshiTNagayasuTMatsumotoKAboTHishikawaYKojiTExpression of keratinocyte growth factor/Fibroblast Growth Factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosisJ Pathol2004204110118[PubMed][Google Scholar]
  • 659. ZammitCCoopeRGommJJShoushaSJohnstonCLCoombesRCFibroblast Growth Factor 8 is expressed at higher levels in lactating human breast and in breast cancerBr J Cancer20028610971103[PubMed][Google Scholar]
  • 660. GauglhoferCSagmeisterSSchrottmaierWFischerCRodgarkia-DaraCMohrTStattnerSBichlerCKandiolerDWrbaFUp-regulation of the Fibroblast Growth Factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesisHepatology201153854864et al.[PubMed][Google Scholar]
  • 661. GnanapragasamVJRobinsonMCMarshCRobsonCNHamdyFCLeungHYFGF8 isoform b expression in human prostate cancerBr J Cancer20038814321438[PubMed][Google Scholar]
  • 662. MarshSKBansalGSZammitCBarnardRCoopeRRoberts-ClarkeDGommJJCoombesRCJohnstonCLIncreased expression of Fibroblast Growth Factor 8 in human breast cancerOncogene19991810531060[PubMed][Google Scholar]
  • 663. LiuRHuangSLeiYZhangTWangKLiuBNiceECXiangRXieKLiJFGF8 promotes colorectal cancer growth and metastasis by activating YAP1Oncotarget20146935952et al.[PubMed][Google Scholar]
  • 664. Abdel-RahmanWMKalininaJShomanSEissaSOllikainenMElomaaOEliseenkovaAVButzowRMohammadiMPeltomakiPSomatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-cateninHum Mutat200829390397[PubMed][Google Scholar]
  • 665. ChenTMShihYHTsengJTLaiMCWuCHLiYHTsaiSJSunHSOverexpression of FGF9 in colon cancer cells is mediated by hypoxia-induced translational activationNucleic Acids Res20144229322944[PubMed][Google Scholar]
  • 666. AraiDHegabAESoejimaKKurodaAIshiokaKYasudaHNaokiKShizukoKHamamotoJYinYCharacterization of the cell of origin and propagation potential of the Fibroblast Growth Factor 9-induced mouse model of lung adenocarcinomaJ Pathol2015235593605et al.[PubMed][Google Scholar]
  • 667. TheodorouVBoerMWeigeltBJonkersJvan der ValkMHilkensJFgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomasOncogene20042360476055[PubMed][Google Scholar]
  • 668. MemarzadehSXinLMulhollandDJMansukhaniAWuHTeitellMAWitteONEnhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptorCancer Cell200712572585[PubMed][Google Scholar]
  • 669. MiuraSMitsuhashiNShimizuHKimuraFYoshidomeHOtsukaMKatoAShidaTOkamuraDMiyazakiMFibroblast Growth Factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinomaBMC Cancer20121256[PubMed][Google Scholar]
  • 670. FengSDakhovaOCreightonCJIttmannMMThe endocrine Fibroblast Growth Factor FGF19 promotes prostate cancer progressionCancer Res20137325512562[PubMed][Google Scholar]
  • 671. BasuMMukhopadhyaySChatterjeeURoySSFGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathwayJ Biol Chem201428914151428[PubMed][Google Scholar]
  • 672. PolnaszekNKwabi-AddoBWangJIttmannMFGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasiaProstate2004601824[PubMed][Google Scholar]
  • 673. KimHJKimKHLeeJOhJJCheongHSWongELYangBSByunSSMyungSCSingle nucleotide polymorphisms in Fibroblast Growth Factor 23 gene, FGF23, are associated with prostate cancer riskBJU Int2013114303310[PubMed][Google Scholar]
  • 674. WeissJSosMLSeidelDPeiferMZanderTHeuckmannJMUllrichRTMenonRMaierSSoltermannAFrequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerSci Transl Med2010262ra93et al.[Google Scholar]
  • 675. LimSMKimHRShimHSSooRAChoBCRole of FGF receptors as an emerging therapeutic target in lung squamous cell carcinomaFuture Oncol20139377386[PubMed][Google Scholar]
  • 676. LehnenNCvon MassenhausenAKalthoffHZhouHGlowkaTSchutteUHollerTRiesnerKBoehmDMerkelbach-BruseSFibroblast Growth Factor receptor 1 gene amplification in pancreatic ductal adenocarcinomaHistopathology201363157166et al.[PubMed][Google Scholar]
  • 677. YangFGaoYGengJQuDHanQQiJChenGElevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancerInt J Clin Exp Pathol2013628462854[PubMed][Google Scholar]
  • 678. TurnerNPearsonASharpeRLambrosMGeyerFLopez-GarciaMANatrajanRMarchioCIornsEMackayAFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerCancer Res20107020852094et al.[PubMed][Google Scholar]
  • 679. GrandEKGrandFHChaseAJRossFMCorcoranMMOscierDGCrossNCIdentification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndromeGenes Chromosomes Cancer2004407883[PubMed][Google Scholar]
  • 680. KornmannMIshiwataTMatsudaKLopezMEFukahiKAsanoGBegerHGKorcMIIIc isoform of Fibroblast Growth Factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cellsGastroenterology2002123301313[PubMed][Google Scholar]
  • 681. XiaoSNalaboluSRAsterJCMaJAbruzzoLJaffeESStoneRWeissmanSMHudsonTJFletcherJAFGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndromeNat Genet1998188487[PubMed][Google Scholar]
  • 682. YoungRJLimAMAngelCCollinsMDebSCorryJWiesenfeldDKleidSSigstonELyonsBFrequency of Fibroblast Growth Factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcomeOral Oncol201349576581et al.[PubMed][Google Scholar]
  • 683. JonesDTHutterBJagerNKorshunovAKoolMWarnatzHJZichnerTLambertSRRyzhovaMQuangDARecurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytomaNat Genet201345927932et al.[PubMed][Google Scholar]
  • 684. JacksonCCMedeirosLJMirandaRN8p11 myeloproliferative syndrome: a reviewHum Pathol201041461476[PubMed][Google Scholar]
  • 685. SinghDChanJMZoppoliPNiolaFSullivanRCastanoALiuEMReichelJPorratiPPellegattaSTransforming fusions of FGFR and TACC genes in human glioblastomaScience201233712311235et al.[PubMed][Google Scholar]
  • 686. LiuJGuzmanMAPezanowskiDPatelDHauptmanJKeislingMHouSJPapenhausenPRPascasioJMPunnettHHFOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcomaMod Pathol20112413271335et al.[PubMed][Google Scholar]
  • 687. PopoviciCZhangBGregoireMJJonveauxPLafage-PochitaloffMBirnbaumDPebusqueMJThe t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to Fibroblast Growth Factor receptor 1Blood19999313811389[PubMed][Google Scholar]
  • 688. GervaisCDanoLPerrussonNHeliasCJeandidierEGaloisyACIttelAHerbrechtRBilgerKMauvieuxLA translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasmLeukemia20132711861188[PubMed][Google Scholar]
  • 689. NakamuraYItoYWakimotoNKakegawaEUchidaYBesshoMA novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocationBlood Cancer J20144e265[PubMed][Google Scholar]
  • 690. LiFZhaiYPTangYMWangLPWanPJIdentification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndromeGenes Chromosomes Cancer201251890897[PubMed][Google Scholar]
  • 691. WasagBLiermanEMeeusPCoolsJVandenberghePThe kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)Haematologica201196922926[PubMed][Google Scholar]
  • 692. ReiterASohalJKulkarniSChaseAMacdonaldDHAguiarRCGoncalvesCHernandezJMJenningsBAGoldmanJMConsistent fusion of ZNF198 to the Fibroblast Growth Factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndromeBlood19989217351742et al.[PubMed][Google Scholar]
  • 693. JangJHShinKHParkJGMutations in Fibroblast Growth Factor receptor 2 and Fibroblast Growth Factor receptor 3 genes associated with human gastric and colorectal cancersCancer Res20016135413543[PubMed][Google Scholar]
  • 694. KuniiKDavisLGorensteinJHatchHYashiroMDi BaccoAElbiCLutterbachBFGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survivalCancer Res20086823402348[PubMed][Google Scholar]
  • 695. SuXZhanPGavinePRMorganSWomackCNiXShenDBangYJImSAHo KimWFGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studyBr J Cancer2014110967975et al.[PubMed][Google Scholar]
  • 696. MatsumotoKAraoTHamaguchiTShimadaYKatoKOdaITaniguchiHKoizumiFYanagiharaKSasakiHFGFR2 gene amplification and clinicopathological features in gastric cancerBr J Cancer2012106727732et al.[PubMed][Google Scholar]
  • 697. TurnerNLambrosMBHorlingsHMPearsonASharpeRNatrajanRGeyerFCvan KouwenhoveMKreikeBMackayAIntegrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene20102920132023et al.[PubMed][Google Scholar]
  • 698. DuttASalvesenHBChenTHRamosAHOnofrioRCHattonCNicolettiRWincklerWGrewalRHannaMDrug-sensitive FGFR2 mutations in endometrial carcinomaProc Natl Acad Sci USA200810587138717et al.[PubMed][Google Scholar]
  • 699. AraiYTotokiYHosodaFShirotaTHamaNNakamuraHOjimaHFurutaKShimadaKOkusakaTFibroblast Growth Factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology20145914271434et al.[PubMed][Google Scholar]
  • 700. BoradMJChampionMDEganJBLiangWSFonsecaRBryceAHMcCulloughAEBarrettMTHuntKPatelMDIntegrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinomaPLoS Genet201410e1004135et al.[PubMed][Google Scholar]
  • 701. WuYMSuFKalyana-SundaramSKhazanovNAteeqBCaoXLonigroRJVatsPWangRLinSFIdentification of targetable FGFR gene fusions in diverse cancersCancer Discov20133636647et al.[PubMed][Google Scholar]
  • 702. GrahamRPBarr FritcherEGPestovaESchulzJSitailoLAVasmatzisGMurphySJMcWilliamsRRHartSNHallingKCFibroblast Growth Factor receptor 2 translocations in intrahepatic cholangiocarcinomaHum Pathol20144516301638et al.[PubMed][Google Scholar]
  • 703. Al-AhmadieHAIyerGJanakiramanMLinOHeguyATickooSKFineSWGopalanAChenYBBalarASomatic mutation of Fibroblast Growth Factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinomaJ Pathol2011224270279et al.[PubMed][Google Scholar]
  • 704. HernandezSTollABaselgaERibeAAzua-RomeoJPujolRMRealFXFibroblast Growth Factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumorsJ Invest Dermatol200712716641666[PubMed][Google Scholar]
  • 705. LogieADunois-LardeCRostyCLevrelOBlancheMRibeiroAGascJMJorcanoJWernerSSastre-GarauXActivating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humansHum Mol Genet20051411531160et al.[PubMed][Google Scholar]
  • 706. ChesiMBrentsLAFlySABaisCRobbianiDFMesriEKuehlWMBergsagelPLActivated Fibroblast Growth Factor receptor 3 is an oncogene that contributes to tumor progression in multiple myelomaBlood200197729736[PubMed][Google Scholar]
  • 707. ZammitCBarnardRGommJCoopeRShoushaSCoombesCJohnstonCAltered intracellular localization of Fibroblast Growth Factor receptor 3 in human breast cancerJ Pathol20011942734[PubMed][Google Scholar]
  • 708. WilliamsSVHurstCDKnowlesMAOncogenic FGFR3 gene fusions in bladder cancerHum Mol Genet201322795803[PubMed][Google Scholar]
  • 709. MajewskiIJMittempergherLDavidsonNMBosmaAWillemsSMHorlingsHMde RinkIGregerLHooijerGKPetersDIdentification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencingJ Pathol2013230270276et al.[PubMed][Google Scholar]
  • 710. RicheldaRRonchettiDBaldiniLCroLViggianoLMarzellaRRocchiMOtsukiTLombardiLMaioloATA novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 geneBlood19979040624070et al.[PubMed][Google Scholar]
  • 711. ChesiMNardiniEBrentsLASchrockERiedTKuehlWMBergsagelPLFrequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of Fibroblast Growth Factor receptor 3Nat Genet199716260264[PubMed][Google Scholar]
  • 712. YagasakiFWakaoDYokoyamaYUchidaYMurohashiIKayanoHTaniwakiMMatsudaABesshoMFusion of ETV6 to Fibroblast Growth Factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocationCancer Res20016183718374[PubMed][Google Scholar]
  • 713. TomlinsonDCKnowlesMASpeirsVMechanisms of FGFR3 actions in endocrine resistant breast cancerInt J Cancer201213028572866[PubMed][Google Scholar]
  • 714. SonvillaGAllerstorferSHeinzleCStattnerSKarnerJKlimpfingerMWrbaFFischerHGauglhoferCSpiegl-KreineckerSFibroblast Growth Factor receptor 3-IIIc mediates colorectal cancer growth and migrationBr J Cancer201010211451156et al.[PubMed][Google Scholar]
  • 715. TaylorJGTCheukATTsangPSChungJYSongYKDesaiKYuYChenQRShahKYoungbloodVIdentification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted modelsJ Clin Invest200911933953407et al.[PubMed][Google Scholar]
  • 716. HoASKannanKRoyDMMorrisLGGanlyIKatabiNRamaswamiDWalshLAEngSHuseJTThe mutational landscape of adenoid cystic carcinomaNat Genet201345791798et al.[PubMed][Google Scholar]
  • 717. ThussbasCNahrigJStreitSBangeJKrinerMKatesRUlmKKiechleMHoeflerHUllrichAFGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancerJ Clin Oncol20062437473755et al.[PubMed][Google Scholar]
  • 718. ZaidTMYeungTLThompsonMSLeungCSHardingTCoNNSchmandtRSKwanSYRodriguez-AguayCLopez-BeresteinGIdentification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerClin Cancer Res201319809820et al.[PubMed][Google Scholar]
  • 719. GauglhoferCPaurJSchrottmaierWCWingelhoferBHuberDNaegelenIPirkerCMohrTHeinzleCHolzmannKFibroblast Growth Factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinomaCarcinogenesis20143523312338et al.[PubMed][Google Scholar]
  • 720. AcevedoVDIttmannMSpencerDMPaths of FGFR-driven tumorigenesisCell Cycle20098580588[PubMed][Google Scholar]
  • 721. KatohMNakagamaHFGF receptors: cancer biology and therapeuticsMed Res Rev201434280300[PubMed][Google Scholar]
  • 722. BrunelloEBrunelliMBoginaGCalioAManfrinENottegarAVergineMMolinoABriaEMassariFFGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinomaJ Exp Clin Cancer Res201231103et al.[PubMed][Google Scholar]
  • 723. DuttARamosAHHammermanPSMermelCChoJSharifniaTChandeATanakaKEStranskyNGreulichHInhibitor-sensitive FGFR1 amplification in human non-small cell lung cancerPLoS One20116e20351et al.[PubMed][Google Scholar]
  • 724. EdwardsJKrishnaNSWittonCJBartlettJMGene amplifications associated with the development of hormone-resistant prostate cancerClin Cancer Res2003952715281[PubMed][Google Scholar]
  • 725. FischbachARoglerAErberRStoehrRPoulsomRHeidenreichASchneevoigtBSHaukeSHartmannAKnuechelRFibroblast Growth Factor Receptor (FGFR) amplifications are rare events in bladder cancerHistopathology2014et al.. doi: 10.1111/his.12473[Google Scholar]
  • 726. BritoLPRibeiroTCAlmeidaMQJorgeAASoaresICLatronicoACMendoncaBBFragosoMCLerarioAMThe role of Fibroblast Growth Factor receptor 4 overexpression and gene amplification as prognostic markers in pediatric and adult adrenocortical tumorsEndocr Relat Cancer201219L11L13[PubMed][Google Scholar]
  • 727. JaakkolaSSalmikangasPNylundSPartanenJArmstrongEPyrhonenSLehtovirtaPNevanlinnaHAmplification of fgfr4 gene in human breast and gynecological cancersInt J Cancer199354378382[PubMed][Google Scholar]
  • 728. WangRWangLLiYHuHShenLShenXPanYYeTZhangYLuoXFGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancerClin Cancer Res20142041074114et al.[PubMed][Google Scholar]
  • 729. ParkerBCAnnalaMJCogdellDEGranbergKJSunYJiPLiXGuminJZhengHHuLThe tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastomaJ Clin Invest2013123855865et al.[PubMed][Google Scholar]
  • 730. StillIHVincePCowellJKThe third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell linesGenomics199958165170[PubMed][Google Scholar]
  • 731. KalffASpencerAThe t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesBlood Cancer J20122e89[PubMed][Google Scholar]
  • 732. ChesiMNardiniELimRSSmithKDKuehlWMBergsagelPLThe t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcriptsBlood19989230253034[PubMed][Google Scholar]
  • 733. KeatsJJReimanTMaxwellCATaylorBJLarrattLMMantMJBelchARPilarskiLMIn multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood200310115201529[PubMed][Google Scholar]
  • 734. SantraMZhanFTianEBarlogieBShaughnessyJJrA subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcriptBlood200310123742376[PubMed][Google Scholar]
  • 735. PollockPMGartsideMGDejezaLCPowellMAMallonMADaviesHMohammadiMFutrealPAStrattonMRTrentJMFrequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene20072671587162et al.[PubMed][Google Scholar]
  • 736. CappellenDDe OliveiraCRicolDde MedinaSBourdinJSastre-GarauXChopinDThieryJPRadvanyiFFrequent activating mutations of FGFR3 in human bladder and cervix carcinomasNat Genet1999231820[PubMed][Google Scholar]
  • 737. YeYShiYZhouYDuCWangCZhanHZhengBCaoXSunMHFuHThe Fibroblast Growth Factor receptor-4 Arg388 allele is associated with gastric cancer progressionAnn Surg Oncol20101733543361[PubMed][Google Scholar]
  • 738. LaederichMBHortonWAFGFR3 targeting strategies for achondroplasiaExpert Rev Mol Med201214e11[PubMed][Google Scholar]
  • 739. KanazawaHTanakaHInoueMYamanakaYNambaNSeinoYEfficacy of growth hormone therapy for patients with skeletal dysplasiaJ Bone Miner Metab200321307310[PubMed][Google Scholar]
  • 740. BocciardiRGiordaRButtgereitJGimelliSDiviziaMTBeriSGarofaloSTavellaSLeroneMZuffardiOOverexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocationHum Mutat200728724731et al.[PubMed][Google Scholar]
  • 741. YasodaAKomatsuYChushoHMiyazawaTOzasaAMiuraMKuriharaTRogiTTanakaSSudaMOverexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathwayNat Med2004108086et al.[PubMed][Google Scholar]
  • 742. LorgetFKaciNPengJBenoist-LasselinCMugnieryEOppeneerTWendtDJBellSMBullensSBuntingSEvaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasiaAm J Hum Genet20129111081114et al.[PubMed][Google Scholar]
  • 743. YasodaAKitamuraHFujiiTKondoEMuraoNMiuraMKanamotoNKomatsuYAraiHNakaoKSystemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasiasEndocrinology200915031383144[PubMed][Google Scholar]
  • 744. GarciaSDiratBTognacciTRochetNMouskaXBonnafousSPatourauxSTranAGualPLe Marchand-BrustelYPostnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in miceSci Transl Med20135203ra124et al.[Google Scholar]
  • 745. Martinez-TorrecuadradaJCifuentesGLopez-SerraPSaenzPMartinezACasalJITargeting the extracellular domain of Fibroblast Growth Factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferationClin Cancer Res20051162806290[PubMed][Google Scholar]
  • 746. QingJDuXChenYChanPLiHWuPMarstersSStawickiSTienJTotpalKAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceJ Clin Invest200911912161229et al.[PubMed][Google Scholar]
  • 747. HadariYSchlessingerJFGFR3-targeted mAb therapy for bladder cancer and multiple myelomaJ Clin Invest200911910771079[PubMed][Google Scholar]
  • 748. YamashitaAMoriokaMKishiHKimuraTYaharaYOkadaMFujitaKSawaiHIkegawaSTsumakiNStatin treatment rescues FGFR3 skeletal dysplasia phenotypesNature2014513507511[PubMed][Google Scholar]
  • 749. LinCCMeloFAGhoshRSuenKMStaggLJKirkpatrickJAroldSTAhmedZLadburyJEInhibition of basal FGF receptor signaling by Dimeric Grb2Cell201214915141524[PubMed][Google Scholar]
  • 750. TimsahZAhmedZLinCCMeloFAStaggLJLeonardPGJeyabalPBerroutJO'NeilRGBogdanovMCompetition between Grb2 and Plcgamma1 for FGFR2 regulates basal phospholipase activity and invasionNat Struct Mol Biol201421180188et al.[PubMed][Google Scholar]
  • 751. ZakrzewskaMHaugstenEMNadratowska-WesolowskaBOppeltAHausottBJinYOtlewskiJWescheJWiedlochaAERK-Mediated phosphorylation of Fibroblast Growth Factor receptor 1 on Ser777 inhibits signalingSci Signal20136ra11[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.